QUARTERLY REPORT
Q2 2021 — Form 10-Q
Q2 2021PDF · 111 pages1.6 MB
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2021
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number 001-33708
Philip Morris International Inc.
(Exact name of registrant as specified in its charter)
Virginia 13-3435103
(State or other jurisdiction of
incorporation or organization) (I.R.S. Employer
Identification No.)
120 Park Avenue New York New York 10017
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (917) 663-2000
Former name, former address and former fiscal year, if changed since last report
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, no par value PM New York Stock Exchange
2.900% Notes due 2021 PM21A New York Stock Exchange
2.625% Notes due 2022 PM22A New York Stock Exchange
2.375% Notes due 2022 PM22B New York Stock Exchange
2.500% Notes due 2022 PM22 New York Stock Exchange
2.500% Notes due 2022 PM22C New York Stock Exchange
2.625% Notes due 2023 PM23 New York Stock Exchange
2.125% Notes due 2023 PM23B New York Stock Exchange
3.600% Notes due 2023 PM23A New York Stock Exchange
2.875% Notes due 2024 PM24 New York Stock Exchange
2.875% Notes due 2024 PM24C New York Stock Exchange
0.625% Notes due 2024 PM24B New York Stock Exchange
3.250% Notes due 2024 PM24A New York Stock Exchange
2.750% Notes due 2025 PM25 New York Stock Exchange
3.375% Notes due 2025 PM25A New York Stock Exchange
2.750% Notes due 2026 PM26A New York Stock Exchange
-- 1 of 111 --
Title of each class Trading Symbol(s) Name of each exchange on which registered
2.875% Notes due 2026 PM26 New York Stock Exchange
0.125% Notes due 2026 PM26B New York Stock Exchange
3.125% Notes due 2027 PM27 New York Stock Exchange
3.125% Notes due 2028 PM28 New York Stock Exchange
2.875% Notes due 2029 PM29 New York Stock Exchange
3.375% Notes due 2029 PM29A New York Stock Exchange
0.800% Notes due 2031 PM31 New York Stock Exchange
3.125% Notes due 2033 PM33 New York Stock Exchange
2.000% Notes due 2036 PM36 New York Stock Exchange
1.875% Notes due 2037 PM37A New York Stock Exchange
6.375% Notes due 2038 PM38 New York Stock Exchange
1.450% Notes due 2039 PM39 New York Stock Exchange
4.375% Notes due 2041 PM41 New York Stock Exchange
4.500% Notes due 2042 PM42 New York Stock Exchange
3.875% Notes due 2042 PM42A New York Stock Exchange
4.125% Notes due 2043 PM43 New York Stock Exchange
4.875% Notes due 2043 PM43A New York Stock Exchange
4.250% Notes due 2044 PM44 New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405
of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such
files). Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or
an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth
company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☑ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
At July 22, 2021, there were 1,558,540,992 shares outstanding of the registrant’s common stock, no par value per share.
1
-- 2 of 111 --
Table of Contents
PHILIP MORRIS INTERNATIONAL INC.
TABLE OF CONTENTS
Page No.
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited)
Condensed Consolidated Statements of Earnings for the
Six Months Ended June 30, 2021 and 2020 3
Three Months Ended June 30, 2021 and 2020 4
Condensed Consolidated Statements of Comprehensive Earnings for the
Six Months Ended June 30, 2021 and 2020 5
Three Months Ended June 30, 2021 and 2020 6
Condensed Consolidated Balance Sheets at
June 30, 2021 and December 31, 2020 7 – 8
Condensed Consolidated Statements of Cash Flows for the
Six Months Ended June 30, 2021 and 2020 9 – 10
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity for the
Six Months Ended June 30, 2021 and 2020 11
Three Months Ended June 30, 2021 and 2020 12
Notes to Condensed Consolidated Financial Statements 13 – 45
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 46 – 99
Item 4. Controls and Procedures 100
PART II - OTHER INFORMATION
Item 1. Legal Proceedings 101
Item 1A. Risk Factors 101
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 102
Item 6. Exhibits 103
Signature 104
In this report, “PMI,” “we,” “us” and “our” refer to Philip Morris International Inc. and its subsidiaries.
Trademarks and service marks in this report are the registered property of, or licensed by, the subsidiaries of Philip Morris International Inc. and are
italicized.
2
-- 3 of 111 --
Table of Contents
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements.
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings
(in millions of dollars, except per share data)
(Unaudited)
For the Six Months Ended June 30,
2021 2020
Revenues including excise taxes $ 39,776 $ 36,072
Excise taxes on products 24,597 22,268
Net revenues (Note 8) 15,179 13,804
Cost of sales 4,627 4,581
Gross profit 10,552 9,223
Marketing, administration and research costs (Note 16) 3,942 3,666
Amortization of intangibles 37 37
Operating income 6,573 5,520
Interest expense, net 328 291
Pension and other employee benefit costs (Note 3) 55 45
Earnings before income taxes 6,190 5,184
Provision for income taxes 1,343 1,124
Equity investments and securities (income)/loss, net (46) 24
Net earnings $ 4,893 $ 4,036
Net earnings attributable to noncontrolling interests 303 263
Net earnings attributable to PMI $ 4,590 $ 3,773
Per share data (Note 6):
Basic earnings per share $ 2.94 $ 2.42
Diluted earnings per share $ 2.93 $ 2.42
See notes to condensed consolidated financial statements.
3
-- 4 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings
(in millions of dollars, except per share data)
(Unaudited)
For the Three Months Ended June
30,
2021 2020
Revenues including excise taxes $ 20,421 $ 17,819
Excise taxes on products 12,827 11,168
Net revenues (Note 8) 7,594 6,651
Cost of sales 2,353 2,179
Gross profit 5,241 4,472
Marketing, administration and research costs (Note 16) 2,093 1,722
Amortization of intangibles 19 19
Operating income 3,129 2,731
Interest expense, net 161 162
Pension and other employee benefit costs (Note 3) 27 22
Earnings before income taxes 2,941 2,547
Provision for income taxes 646 528
Equity investments and securities (income)/loss, net (3) (30)
Net earnings 2,298 2,049
Net earnings attributable to noncontrolling interests 126 102
Net earnings attributable to PMI $ 2,172 $ 1,947
Per share data (Note 6):
Basic earnings per share $ 1.39 $ 1.25
Diluted earnings per share $ 1.39 $ 1.25
See notes to condensed consolidated financial statements.
4
-- 5 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Earnings
(in millions of dollars)
(Unaudited)
For the Six Months Ended June 30,
2021 2020
Net earnings $ 4,893 $ 4,036
Other comprehensive earnings (losses), net of income taxes:
Change in currency translation adjustments:
Unrealized gains (losses), net of income taxes of $(25) in 2021 and $(40) in 2020 227 (785)
Change in net loss and prior service cost:
Net gains (losses) and prior service costs, net of income taxes of $(5) in 2021 and $0 in 2020 20 —
Amortization of net losses, prior service costs and net transition costs, net of income taxes of
$(36) in 2021 and $(34) in 2020 162 149
Change in fair value of derivatives accounted for as hedges:
Gains (losses) recognized, net of income taxes of $(12) in 2021 and $1 in 2020 77 (6)
(Gains) losses transferred to earnings, net of income taxes of $0 in 2021 and $2 in 2020 2 (15)
Total other comprehensive earnings (losses) 488 (657)
Total comprehensive earnings 5,381 3,379
Less comprehensive earnings attributable to:
Noncontrolling interests 275 252
Comprehensive earnings attributable to PMI $ 5,106 $ 3,127
See notes to condensed consolidated financial statements.
5
-- 6 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Earnings
(in millions of dollars)
(Unaudited)
For the Three Months Ended June 30,
2021 2020
Net earnings $ 2,298 $ 2,049
Other comprehensive earnings (losses), net of income taxes:
Change in currency translation adjustments:
Unrealized gains (losses), net of income taxes of $60 in 2021 and $56 in 2020 4 797
Change in net loss and prior service cost:
Net gains (losses) and prior service costs, net of income taxes of $(5) in 2021 and $0 in 2020 20 —
Amortization of net losses, prior service costs and net transition costs, net of income taxes of
$(18) in 2021 and $(17) in 2020 81 75
Change in fair value of derivatives accounted for as hedges:
Gains (losses) recognized, net of income taxes of $2 in 2021 and $6 in 2020 1 (32)
(Gains) losses transferred to earnings, net of income taxes of $0 in 2021 and $1 in 2020 (19) (6)
Total other comprehensive earnings (losses) 87 834
Total comprehensive earnings 2,385 2,883
Less comprehensive earnings attributable to:
Noncontrolling interests 132 171
Comprehensive earnings attributable to PMI $ 2,253 $ 2,712
See notes to condensed consolidated financial statements.
6
-- 7 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in millions of dollars)
(Unaudited)
June 30,
2021 December 31,
2020
ASSETS
Cash and cash equivalents $ 4,915 $ 7,280
Trade receivables (less allowances of $57 in 2021 and $23 in 2020) 3,536 2,905
Other receivables (less allowances of $37 in 2021 and $38 in 2020) 909 856
Inventories:
Leaf tobacco 1,918 2,063
Other raw materials 1,950 1,712
Finished product 4,822 5,816
8,690 9,591
Other current assets 693 860
Total current assets 18,743 21,492
Property, plant and equipment, at cost 14,615 14,909
Less: accumulated depreciation 8,640 8,544
5,975 6,365
Goodwill (Note 4) 5,842 5,964
Other intangible assets, net (Note 4) 1,958 2,019
Equity investments (Note 12) 4,633 4,798
Deferred income taxes 1,112 1,410
Other assets (less allowances of $22 in 2021 and $22 in 2020) 2,423 2,767
TOTAL ASSETS $ 40,686 $ 44,815
See notes to condensed consolidated financial statements.
Continued
7
-- 8 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Balance Sheets (Continued)
(in millions of dollars, except share data)
(Unaudited)
June 30,
2021 December 31,
2020
LIABILITIES
Short-term borrowings (Note 10) $ 136 $ 244
Current portion of long-term debt (Note 10) 1,608 3,124
Accounts payable 2,630 2,780
Accrued liabilities:
Marketing and selling 722 782
Taxes, except income taxes 5,244 6,403
Employment costs 1,016 1,189
Dividends payable 1,889 1,880
Other 1,859 2,122
Income taxes 780 1,091
Total current liabilities 15,884 19,615
Long-term debt (Note 10) 27,414 28,168
Deferred income taxes 505 684
Employment costs 4,054 4,470
Income taxes and other liabilities 2,029 2,509
Total liabilities 49,886 55,446
Contingencies (Note 8)
STOCKHOLDERS’ (DEFICIT) EQUITY
Common stock, no par value
(2,109,316,331 shares issued in 2021 and 2020) — —
Additional paid-in capital 2,143 2,105
Earnings reinvested in the business 32,465 31,638
Accumulated other comprehensive losses (10,665) (11,181)
23,943 22,562
Less: cost of repurchased stock
(550,736,681 and 551,942,600 shares in 2021 and 2020, respectively) 35,056 35,129
Total PMI stockholders’ deficit (11,113) (12,567)
Noncontrolling interests 1,913 1,936
Total stockholders’ deficit (9,200) (10,631)
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY $ 40,686 $ 44,815
See notes to condensed consolidated financial statements.
8
-- 9 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(in millions of dollars)
(Unaudited)
For the Six Months Ended June 30,
2021 2020
CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES
Net earnings $ 4,893 $ 4,036
Adjustments to reconcile net earnings to operating cash flows:
Depreciation and amortization 484 470
Deferred income tax (benefit) provision 2 (94)
Asset impairment and exit costs, net of cash paid (Note 16) (26) (2)
Cash effects of changes in:
Receivables, net (627) (338)
Inventories 767 (20)
Accounts payable (16) (164)
Accrued liabilities and other current assets (940) (780)
Income taxes (459) (233)
Pension plan contributions (197) (52)
Other 184 213
Net cash provided by operating activities 4,065 3,036
CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES
Capital expenditures (307) (310)
Purchases of businesses, net of acquired cash (Note 17) (27) —
Equity investments — (3)
Net investment hedges 147 174
Other 59 5
Net cash used in investing activities (128) (134)
See notes to condensed consolidated financial statements.
Continued
9
-- 10 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Continued)
(in millions of dollars)
(Unaudited)
For the Six Months Ended June 30,
2021 2020
CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES
Short-term borrowing activity by original maturity:
Net issuances (repayments) - maturities of 90 days or less $ (108) $ (75)
Issuances - maturities longer than 90 days — 45
Long-term debt proceeds — 2,230
Long-term debt repaid (1,979) (3,641)
Dividends paid (3,752) (3,658)
Payments to noncontrolling interests and Other (284) (404)
Net cash used in financing activities (6,123) (5,503)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (179) (57)
Cash, cash equivalents and restricted cash :
Increase (Decrease) (2,365) (2,658)
Balance at beginning of period 7,285 6,865
Balance at end of period $ 4,920 $ 4,207
The amounts for cash and cash equivalents shown above include restricted cash of $5 million and $7 million as of June 30, 2021 and 2020, respectively, and $5 million
and $4 million as of December 31, 2020 and 2019, respectively, which were included in other current assets in the condensed consolidated balance sheets.
See notes to condensed consolidated financial statements.
(1)
(1)
10
-- 11 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity
For the Six Months Ended June 30, 2021 and 2020
(in millions of dollars, except per share amounts)
(Unaudited)
PMI Stockholders’ (Deficit) Equity
Common
Stock
Additional
Paid-in
Capital
Earnings
Reinvested in
the
Business
Accumulated
Other
Comprehensive Losses
Cost of
Repurchased
Stock Noncontrolling
Interests Total
Balances, January 1, 2020 $ — $ 2,019 $ 30,987 $ (9,363) $ (35,220) $ 1,978 $ (9,599)
Net earnings 3,773 263 4,036
Other comprehensive earnings
(losses), net of income taxes (646) (11) (657)
Issuance of stock awards 9 85 94
Dividends declared ($2.34 per
share) (3,657) (3,657)
Payments to noncontrolling
interests (339) (339)
Other 16 (14) 2
Balances, June 30, 2020 $ — $ 2,044 $ 31,103 $ (10,009) $ (35,135) $ 1,877 $ (10,120)
Balances, January 1, 2021 $ — $ 2,105 $ 31,638 $ (11,181) $ (35,129) $ 1,936 $ (10,631)
Net earnings 4,590 303 4,893
Other comprehensive earnings
(losses), net of income taxes 516 (28) 488
Issuance of stock awards 38 73 111
Dividends declared ($2.40 per
share) (3,763) (3,763)
Payments to noncontrolling
interests (298) (298)
Balances, June 30, 2021 $ — $ 2,143 $ 32,465 $ (10,665) $ (35,056) $ 1,913 $ (9,200)
See notes to condensed consolidated financial statements.
11
-- 12 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity
For the Three Months Ended June 30, 2021 and 2020
(in millions of dollars, except per share amounts)
(Unaudited)
PMI Stockholders’ (Deficit) Equity
Common
Stock
Additional
Paid-in
Capital
Earnings
Reinvested in
the
Business
Accumulated
Other
Comprehensive Losses
Cost of
Repurchased
Stock Noncontrolling
Interests Total
Balances, April 1, 2020 $ — $ 1,992 $ 30,984 $ (10,774) $ (35,146) $ 1,881 $ (11,063)
Net earnings 1,947 102 2,049
Other comprehensive earnings
(losses), net of income taxes 765 69 834
Issuance of stock awards 34 11 45
Dividends declared ($1.17 per
share) (1,828) (1,828)
Payments to noncontrolling interests (157) (157)
Other 18 (18) —
Balances, June 30, 2020 $ — $ 2,044 $ 31,103 $ (10,009) $ (35,135) $ 1,877 $ (10,120)
Balances, April 1, 2021 $ — $ 2,080 $ 32,178 $ (10,746) $ (35,060) $ 1,974 $ (9,574)
Net earnings 2,172 126 2,298
Other comprehensive earnings
(losses), net of income taxes 81 6 87
Issuance of stock awards 63 4 67
Dividends declared ($1.20 per
share) (1,885) (1,885)
Payments to noncontrolling interests (193) (193)
Balances, June 30, 2021 $ — $ 2,143 $ 32,465 $ (10,665) $ (35,056) $ 1,913 $ (9,200)
See notes to condensed consolidated financial statements.
12
-- 13 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 1. Background and Basis of Presentation:
Background
Philip Morris International Inc. is a holding company incorporated in Virginia, U.S.A. (also referred to herein as the U.S., the United States or the United
States of America), whose subsidiaries and affiliates and their licensees are engaged in the manufacture and sale of cigarettes and other nicotine-containing
products, including reduced-risk products, in markets outside of the United States of America. In addition, PMI ships versions of its Platform 1 device and
its consumables authorized by the U.S. Food and Drug Administration ("FDA") to Altria Group, Inc., for sale in the United States under license.
Throughout these financial statements, the term "PMI" refers to Philip Morris International Inc. and its subsidiaries.
Reduced-risk products ("RRPs") is the term PMI uses to refer to products that present, are likely to present, or have the potential to present less risk of
harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific
assessment and commercialization.
"Platform 1" is the term PMI uses to refer to PMI’s reduced-risk product that uses a precisely controlled heating device into which a specially designed and
proprietary tobacco unit is inserted and heated to generate an aerosol.
Basis of Presentation
The interim condensed consolidated financial statements of PMI are unaudited. These interim condensed consolidated financial statements have been
prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and such principles are applied on a
consistent basis. It is the opinion of PMI’s management that all adjustments necessary for a fair statement of the interim results presented have been
reflected therein. All such adjustments were of a normal recurring nature. Net revenues and net earnings attributable to PMI for any interim period are not
necessarily indicative of results that may be expected for the entire year.
Certain prior years' amounts have been reclassified to conform with the current year's presentation. The changes did not have a material impact on PMI's
consolidated financial position, results of operations or cash flows in any of the periods presented.
These statements should be read in conjunction with the audited consolidated financial statements and related notes, which appear in PMI’s Annual Report
on Form 10-K for the year ended December 31, 2020.
13
-- 14 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 2. Stock Plans:
In May 2017, PMI’s shareholders approved the Philip Morris International Inc. 2017 Performance Incentive Plan (the “2017 Plan”). Under the 2017 Plan,
PMI may grant to eligible employees restricted shares and restricted share units, performance-based cash incentive awards and performance-based equity
awards. Up to 25 million shares of PMI’s common stock may be issued under the 2017 Plan. At June 30, 2021, shares available for grant under the 2017
Plan were 14,867,021.
In May 2017, PMI’s shareholders also approved the Philip Morris International Inc. 2017 Stock Compensation Plan for Non-Employee Directors (the
“2017 Non-Employee Directors Plan”). A non-employee director is defined as a member of the PMI Board of Directors who is not a full-time employee of
PMI or of any corporation in which PMI owns, directly or indirectly, stock possessing at least 50% of the total combined voting power of all classes of
stock entitled to vote in the election of directors in such corporation. Up to 1 million shares of PMI common stock may be awarded under the 2017 Non-
Employee Directors Plan. At June 30, 2021, shares available for grant under the plan were 914,413.
Restricted share unit (RSU) awards
During the six months ended June 30, 2021 and 2020, shares granted to eligible employees and the weighted-average grant date fair value per share related
to RSU awards were as follows:
Number of
Shares
Granted
Weighted-Average Grant
Date Fair Value Per RSU
Award Granted
2021 1,981,480 $ 81.91
2020 1,692,650 $ 85.91
Compensation expense related to RSU awards was as follows:
Compensation Expense Related to RSU Awards
(in millions) For the Six Months Ended June 30, For the Three Months Ended June 30,
2021 $ 73 $ 33
2020 $ 68 $ 29
As of June 30, 2021, PMI had $211 million of total unrecognized compensation cost related to non-vested RSU awards. The cost is recognized over the
original restriction period of the awards, which is typically three years after the date of the award, or upon death, disability or reaching the age of 58.
During the six months ended June 30, 2021, 1,106,129 RSU awards vested. The grant date fair value of all the vested awards was approximately $108
million. The total fair value of RSU awards that vested during the six months ended June 30, 2021 was approximately $96 million.
Performance share unit (PSU) awards
During the six months ended June 30, 2021 and 2020, PMI granted PSU awards to certain executives. The PSU awards require the achievement of certain
performance factors, which are predetermined at the time of grant, typically over a three-year performance cycle. The performance metrics for such PSU's
granted during the six months ended June 30, 2021 and 2020 consisted of PMI's Total Shareholder Return ("TSR") relative to a predetermined peer group
and on an absolute basis (40% weight), PMI’s currency-neutral compound annual adjusted diluted earnings per share growth rate (30% weight), and PMI’s
performance against specific measures of PMI’s transformation, defined as net revenues from PMI's RRPs and any other non-combustible products as a
percentage of PMI's total net revenues in the last year of the performance cycle (30% weight).
The aggregate of the weighted performance factors for the three metrics in each such PSU award determines the percentage of PSUs that will vest at the
end of the three-year performance cycle. The minimum percentage of such PSUs that can vest is zero, with a target percentage of 100 and a maximum
percentage of 200. Each such vested PSU entitles the participant to one share
14
-- 15 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
of common stock. An aggregate weighted PSU performance factor of 100 will result in the targeted number of PSUs being vested. At the end of the
performance cycle, participants are entitled to an amount equivalent to the accumulated dividends paid on common stock during the performance cycle for
the number of shares earned.
During the six months ended June 30, 2021 and 2020, shares granted to eligible employee and the grant date fair value per share related to PSU awards
were as follows:
Number of Shares
Granted
Grant Date
Fair Value Subject to Other
Performance Factors
Grant Date
Fair Value Subject to TSR
Performance Factor
(Per Share) (Per Share)
2021 574,410 $ 81.86 $ 106.93
2020 671,220 $ 86.04 $ 80.36
The grant date fair value of the PSU awards subject to the other performance factors was determined by using the average of the high and low market price
of PMI’s stock at the date of the grant. The grant date fair value of the PSU market based awards subject to the TSR performance factor was determined by
using the Monte Carlo simulation model. The following assumptions were used to determine the grant date fair value of the PSU awards subject to the TSR
performance factor:
2021 2020
Risk-free interest rate 0.2 % 1.4 %
Expected volatility 31.7 % 23.5 %
Based on the U.S. Treasury yield curve.
Determined using the observed historical volatility.
Compensation expense related to PSU awards was as follows:
Compensation Expense Related to PSU Awards
(in millions) For the Six Months Ended June 30, For the Three Months Ended June 30,
2021 $ 46 $ 34
2020 $ 32 $ 9
As of June 30, 2021, PMI had $71 million of total unrecognized compensation cost related to non-vested PSU awards. The cost is recognized over the
performance cycle of the awards, or upon death, disability or reaching the age of 58.
During the six months ended June 30, 2021, 189,839 PSU awards vested. The grant date fair value of all the vested awards was approximately $21 million.
The total fair value of PSU awards that vested during the six months ended June 30, 2021 was approximately $16 million.
Note 3. Benefit Plans:
Pension coverage for employees of PMI’s subsidiaries is provided, to the extent deemed appropriate, through separate plans, many of which are governed
by local statutory requirements. In addition, PMI provides health care and other benefits to substantially all U.S. retired employees and certain non-U.S.
retired employees. In general, health care benefits for non-U.S. retired employees are covered through local government plans.
(a)
(b)
(a)
(b)
15
-- 16 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Pension and other employee benefit costs per the condensed consolidated statements of earnings consisted of the following:
For the Six Months Ended June 30, For the Three Months Ended June
30,
(in millions) 2021 2020 2021 2020
Net pension costs (income) $ (2) $ (8) $ (1) $ (4)
Net postemployment costs 53 49 25 24
Net postretirement costs 4 4 3 2
Total pension and other employee benefit costs $ 55 $ 45 $ 27 $ 22
Pension Plans
Components of Net Periodic Benefit Cost
Net periodic pension cost consisted of the following:
Pension
For the Six Months Ended June 30, For the Three Months Ended June
30,
(in millions) 2021 2020 2021 2020
Service cost $ 147 $ 130 $ 72 $ 65
Interest cost 25 35 12 18
Expected return on plan assets (186) (173) (91) (87)
Amortization:
Net loss 158 129 78 64
Prior service cost 1 1 — 1
Net periodic pension cost $ 145 $ 122 $ 71 $ 61
Primarily non-U.S. based defined benefit retirement plans.
Employer Contributions
PMI makes, and plans to make, contributions, to the extent that they are tax deductible and to meet specific funding requirements of its funded pension
plans. Employer contributions of $197 million were made to the pension plans during the six months ended June 30, 2021. Currently, PMI anticipates
making additional contributions during the remainder of 2021 of approximately $78 million to its pension plans, based on current tax and benefit laws.
However, this estimate is subject to change as a result of changes in tax and other benefit laws, as well as asset performance significantly above or below
the assumed long-term rate of return on pension assets, or changes in interest and currency rates.
Note 4. Goodwill and Other Intangible Assets, net:
The movements in goodwill were as follows:
(in millions) European
Union Eastern Europe Middle East &
Africa South &
Southeast Asia East Asia &
Australia
Latin
America &
Canada Total
Balances, December 31, 2020 $ 1,434 $ 317 $ 86 $ 2,915 $ 559 $ 653 $ 5,964
Changes due to:
Acquisitions 29 — — — — — 29
Currency (30) (8) 2 (86) (17) (12) (151)
Balances, June 30, 2021 $ 1,433 $ 309 $ 88 $ 2,829 $ 542 $ 641 $ 5,842
At June 30, 2021, goodwill primarily reflects PMI’s acquisitions in Colombia, Greece, Indonesia, Mexico, Pakistan and Serbia, as well as the business
combination in the Philippines.
(1)
(1)
16
-- 17 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The increase in goodwill from acquisitions was due to the preliminary purchase price allocation of AG Snus Aktieselskab ("AG Snus"), a Danish based
company, and it's Swedish subsidiary Tobacco House of Sweden AB, fully owned by AG Snus. For further details, see Note 17. Acquisitions.
Details of other intangible assets were as follows:
June 30, 2021 December 31, 2020
(in millions)
Weighted-Average
Remaining Useful
Life Gross Carrying
Amount Accumulated
Amortization Net Gross Carrying
Amount Accumulated
Amortization Net
Non-amortizable intangible assets $ 1,261 $ 1,261 $ 1,289 $ 1,289
Amortizable intangible assets:
Trademarks 12 years 1,233 $ 621 612 1,233 $ 594 639
Distribution networks 7 years 113 79 34 115 78 37
Other* 8 years 105 54 51 104 50 54
Total other intangible assets $ 2,712 $ 754 $ 1,958 $ 2,741 $ 722 $ 2,019
* Primarily includes intellectual property rights
Non-amortizable intangible assets substantially consist of trademarks from PMI’s acquisitions in Indonesia and Mexico. The decrease since December 31,
2020 was due to currency movements of ($28 million).
The decrease in the gross carrying amount of amortizable intangible assets from December 31, 2020, was mainly due to currency movements of ($8
million), partially offset by the preliminary purchase price allocation of AG Snus trademarks in the amount of $7 million. For further details, see Note 17.
Acquisitions.
The change in the accumulated amortization from December 31, 2020, was mainly due to the 2021 amortization of $37 million, partially offset by currency
movements of ($5 million).
Amortization expense for each of the next five years is estimated to be $75 million or less, assuming no additional transactions occur that require the
amortization of intangible assets.
During the second quarter of 2021, PMI completed its annual review of goodwill and non-amortizable intangible assets for potential impairment, and no
impairment charges were required as a result of this review.
17
-- 18 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 5. Financial Instruments:
Overview
PMI operates in markets outside of the United States of America, with manufacturing and sales facilities in various locations around the world. PMI utilizes
certain financial instruments to manage foreign currency and interest rate exposures. Derivative financial instruments are used by PMI principally to reduce
exposures to market risks resulting from fluctuations in foreign currency exchange and interest rates by creating offsetting exposures. PMI is not a party to
leveraged derivatives and, by policy, does not use derivative financial instruments for speculative purposes. Substantially all of PMI's derivative financial
instruments are subject to master netting arrangements, whereby the right to offset occurs in the event of default by a participating party. While these
contracts contain the enforceable right to offset through close-out netting rights, PMI elects to present them on a gross basis in the consolidated balance
sheets. Collateral associated with these arrangements is in the form of cash and is unrestricted. Financial instruments qualifying for hedge accounting must
maintain a specified level of effectiveness between the hedging instrument and the item being hedged, both at inception and throughout the hedged period.
PMI formally documents the nature and relationships between the hedging instruments and hedged items, as well as its risk-management objectives,
strategies for undertaking the various hedge transactions and method of assessing hedge effectiveness. Additionally, for hedges of forecasted transactions,
the significant characteristics and expected terms of the forecasted transaction must be specifically identified, and it must be probable that each forecasted
transaction will occur. If it were deemed probable that the forecasted transaction would not occur, the gain or loss would be recognized in earnings.
PMI uses deliverable and non-deliverable forward foreign exchange contracts, foreign currency swaps and foreign currency options, collectively referred to
as foreign exchange contracts ("foreign exchange contracts"), and interest rate contracts to mitigate its exposure to changes in exchange and interest rates
from third-party and intercompany actual and forecasted transactions. Both foreign exchange contracts and interest rate contracts are collectively referred to
as derivative contracts ("derivative contracts"). The primary currencies to which PMI is exposed include the Euro, Indonesian rupiah, Japanese yen,
Mexican peso, Philippine peso, Russian ruble and Swiss franc. At June 30, 2021, PMI had contracts with aggregate notional amounts of $22.7 billion of
which $3.5 billion related to cash flow hedges, $7.6 billion related to hedges of net investments in foreign operations and $11.6 billion related to other
derivatives that primarily offset currency exposures on intercompany financing.
18
-- 19 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The fair value of PMI’s derivative contracts included in the condensed consolidated balance sheets as of June 30, 2021 and December 31, 2020, were as
follows:
Derivative Assets Derivative Liabilities
Fair Value Fair Value
At At At At
(in millions) Balance Sheet
Classification June 30, 2021 December 31,
2020 Balance Sheet
Classification June 30, 2021 December 31,
2020
Derivative contracts designated as
hedging instruments Other current
assets $ 187 $ 130 Other accrued
liabilities $ 92 $ 241
Other assets — 6 Income taxes and
other liabilities 424 605
Derivative contracts not designated
as hedging instruments Other current
assets 104 46 Other accrued
liabilities 28 207
Other assets — — Income taxes and
other liabilities 38 57
Total gross amount derivatives
contracts presented in the
condensed consolidated balance
sheets $ 291 $ 182 $ 582 $ 1,110
Gross amounts not offset in the
condensed consolidated balance
sheets
Finance instruments (140) (156) (140) (156)
Cash collateral received/pledged (126) (23) (425) (892)
Net amount $ 25 $ 3 $ 17 $ 62
PMI assesses the fair value of its foreign exchange contracts and interest rate contracts using standard valuation models that use, as their basis, readily
observable market inputs. The fair value of PMI’s foreign exchange forward contracts, foreign currency swaps and interest rate contracts is determined by
using the prevailing foreign exchange spot rates and interest rate differentials, and the respective maturity dates of the instruments. The fair value of PMI’s
currency options is determined by using a Black-Scholes methodology based on foreign exchange spot rates and interest rate differentials, currency
volatilities and maturity dates. PMI’s derivative contracts have been classified within Level 2 at June 30, 2021 and December 31, 2020.
19
-- 20 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
For the six months ended June 30, 2021 and 2020, PMI's derivative contracts impacted the condensed consolidated statements of earnings and
comprehensive earnings as follows:
(pre-tax, in millions) For the Six Months Ended June 30,
Amount of Gain/(Loss)
Recognized in Other
Comprehensive
Earnings/(Losses) on
Derivatives
Statement of Earnings
Classification of
Gain/(Loss)
on Derivatives
Amount of Gain/(Loss)
Reclassified from Other
Comprehensive
Earnings/(Losses) into
Earnings Amount of Gain/(Loss)
Recognized in Earnings
2021 2020 2021 2020 2021 2020
Derivative contracts designated as
hedging instruments:
Cash flow hedges $ 89 $ (7)
Net revenues $ 17 $ 4
Cost of sales — 7
Marketing,
administration and
research costs (12) 11
Interest expense, net (7) (5)
Net investment hedges 192 269 Interest expense, net $ 82 $ 104
Derivative contracts not designated as
hedging instruments: Interest expense, net 25 48
Marketing,
administration and
research costs 196 (63)
Total $ 281 $ 262 $ (2) $ 17 $ 303 $ 89
Amount of gains (losses) on hedges of net investments principally related to changes in exchange and interest rates between the Euro and U.S. dollar
Represent the gains for amounts excluded from the effectiveness testing
The gains (losses) from these contracts attributable to changes in foreign currency exchange rates substantially offset the (losses) and gains generated by the underlying
intercompany and third-party loans being hedged
(a) (b)
(c)
(a)
(b)
(c)
20
-- 21 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
For the three months ended June 30, 2021 and 2020, PMI's derivative contracts impacted the condensed consolidated statements of earnings and
comprehensive earnings as follows:
(pre-tax, in millions) For the Three Months Ended June 30,
Amount of Gain/(Loss)
Recognized in Other
Comprehensive
Earnings/(Losses) on
Derivatives
Statement of Earnings
Classification of
Gain/(Loss)
on Derivatives
Amount of Gain/(Loss)
Reclassified from Other
Comprehensive
Earnings/(Losses) into
Earnings Amount of Gain/(Loss)
Recognized in Earnings
2021 2020 2021 2020 2021 2020
Derivative contracts designated as
hedging instruments:
Cash flow hedges $ (1) $ (38)
Net revenues $ 17 $ 1
Cost of sales — 3
Marketing,
administration and
research costs 6 6
Interest expense, net (4) (3)
Net investment hedges (126) (138) Interest expense, net $ 40 $ 48
Derivative contracts not designated as
hedging instruments: Interest expense, net 14 14
Marketing,
administration and
research costs (91) (92)
Total $ (127) $ (176) $ 19 $ 7 $ (37) $ (30)
Amount of gains (losses) on hedges of net investments principally related to changes in exchange and interest rates between the Euro and U.S. dollar
Represent the gains for amounts excluded from the effectiveness testing
The gains (losses) from these contracts attributable to changes in foreign currency exchange rates substantially offset the (losses) and gains generated by the underlying
intercompany and third-party loans being hedged
Cash Flow Hedges
PMI has entered into derivative contracts to hedge the foreign currency exchange and interest rate risks related to certain forecasted transactions. Gains and
losses associated with qualifying cash flow hedge contracts are deferred as components of accumulated other comprehensive losses until the underlying
hedged transactions are reported in PMI’s condensed consolidated statements of earnings. As of June 30, 2021, PMI has hedged forecasted transactions for
periods not exceeding the next twelve months with the exception of one derivative contract that expires in May 2024. The impact of these hedges is
primarily included in operating cash flows on PMI’s condensed consolidated statements of cash flows.
Hedges of Net Investments in Foreign Operations
PMI designates derivative contracts and certain foreign currency denominated debt instruments as net investment hedges, primarily of its Euro net assets.
For the six months ended June 30, 2021 and 2020, the amount of pre-tax gain/(loss) related to these debt instruments, that was reported as a component of
accumulated other comprehensive losses within currency translation adjustments, was $110 million and $(103) million, respectively. For the three months
ended June 30, 2021 and 2020, the amount of pre-tax gain/(loss) related to these debt instruments, that was reported as a component of accumulated other
comprehensive losses within currency translation adjustments, was $(71) million and $(98) million, respectively. The premiums paid for, and settlements
of, net investment hedges are included in investing cash flows on PMI’s condensed consolidated statements of cash flows.
(a) (b)
(c)
(a)
(b)
(c)
21
-- 22 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Other Derivatives
PMI has entered into derivative contracts to hedge the foreign currency exchange and interest rate risks related to intercompany loans between certain
subsidiaries, and third-party loans. While effective as economic hedges, no hedge accounting is applied for these contracts; therefore, the gains (losses)
relating to these contracts are reported in PMI’s condensed consolidated statements of earnings.
Qualifying Hedging Activities Reported in Accumulated Other Comprehensive Losses
Derivative gains or losses reported in accumulated other comprehensive losses are a result of qualifying hedging activity. Transfers of these gains or losses
to earnings are offset by the corresponding gains or losses on the underlying hedged item. Hedging activity affected accumulated other comprehensive
losses, net of income taxes, as follows:
(in millions) For the Six Months Ended June 30, For the Three Months Ended June 30,
2021 2020 2021 2020
Gain/(loss) as beginning of period $ (85) $ 3 $ 12 $ 20
Derivative (gains)/losses transferred to earnings 2 (15) (19) (6)
Change in fair value 77 (6) 1 (32)
Gain/(loss) as of June 30, $ (6) $ (18) $ (6) $ (18)
At June 30, 2021, PMI expects $26 million of derivative gains that are included in accumulated other comprehensive losses to be reclassified to the
condensed consolidated statement of earnings within the next 12 months. These gains are expected to be substantially offset by the statement of earnings
impact of the respective hedged transactions.
Contingent Features
PMI’s derivative instruments do not contain contingent features.
Credit Exposure and Credit Risk
PMI is exposed to credit loss in the event of non-performance by counterparties. While PMI does not anticipate non-performance, its risk is limited to the
fair value of the financial instruments less any cash collateral received or pledged. PMI actively monitors its exposure to credit risk through the use of
credit approvals and credit limits and by selecting and continuously monitoring a diverse group of major international banks and financial institutions as
counterparties.
Note 6. Earnings Per Share:
Basic and diluted earnings per share (“EPS”) were calculated using the following:
(in millions) For the Six Months Ended June 30, For the Three Months Ended June
30,
2021 2020 2021 2020
Net earnings attributable to PMI $ 4,590 $ 3,773 $ 2,172 $ 1,947
Less distributed and undistributed earnings attributable to share-based payment
awards 14 10 6 5
Net earnings for basic and diluted EPS $ 4,576 $ 3,763 $ 2,166 $ 1,942
Weighted-average shares for basic EPS 1,558 1,557 1,558 1,558
Plus contingently issuable performance stock units (PSUs) 2 — 2 —
Weighted-average shares for diluted EPS 1,560 1,557 1,560 1,558
Unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents are participating securities and therefore are
included in PMI’s earnings per share calculation pursuant to the two-class method.
22
-- 23 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
For the 2021 and 2020 computations, there were no antidilutive stock awards.
Note 7. Segment Reporting:
PMI’s subsidiaries and affiliates are engaged in the manufacture and sale of cigarettes and other nicotine-containing products, including RRPs, in markets
outside of the United States of America. In addition, PMI ships versions of its Platform 1 device and its consumables authorized by the FDA to Altria
Group, Inc. for sale in the United States under license. Operating segments for PMI are organized by geographic region and managed by segment managers
who are responsible for the operating and financial results of the regions inclusive of all product categories sold in the region. PMI’s operating segments are
the European Union; Eastern Europe; Middle East & Africa; South & Southeast Asia; East Asia & Australia; and Latin America & Canada. PMI records
net revenues and operating income to its segments based upon the geographic area in which the customer resides. Revenues from shipments of Platform 1
devices, heated tobacco units and accessories to Altria Group, Inc. for sale under license in the United States are included in net revenues of the Latin
America & Canada segment.
In July 2021, the Latin America & Canada operating segment was renamed as the Americas operating segment.
PMI’s chief operating decision maker evaluates segment performance and allocates resources based on regional operating income, which includes results
from all product categories sold in each region.
PMI disaggregates its net revenue from contracts with customers by both geographic location and product category for each of PMI's six operating
segments, as PMI believes this best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors.
Segment data were as follows:
(in millions) For the Six Months Ended June 30, For the Three Months Ended June
30,
2021 2020 2021 2020
Net revenues:
European Union $ 6,058 $ 5,010 $ 3,149 $ 2,475
Eastern Europe 1,691 1,571 895 783
Middle East & Africa 1,361 1,580 560 704
South & Southeast Asia 2,219 2,140 1,046 889
East Asia & Australia 2,986 2,687 1,514 1,432
Latin America & Canada 864 816 430 368
Net revenues $ 15,179 $ 13,804 $ 7,594 $ 6,651
Operating income:
European Union $ 3,131 $ 2,336 $ 1,641 $ 1,178
Eastern Europe 575 365 314 266
Middle East & Africa 351 558 16 237
South & Southeast Asia 860 888 331 289
East Asia & Australia 1,410 1,155 715 669
Latin America & Canada 246 218 112 92
Operating income $ 6,573 $ 5,520 $ 3,129 $ 2,731
23
-- 24 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
PMI's net revenues by product category were as follows:
(in millions) For the Six Months Ended June 30, For the Three Months Ended June 30,
2021 2020 2021 2020
Net revenues:
Combustible products:
European Union $ 4,113 $ 3,855 $ 2,162 $ 1,945
Eastern Europe 1,047 1,045 555 522
Middle East & Africa 1,307 1,528 527 696
South & Southeast Asia 2,216 2,140 1,045 889
East Asia & Australia 1,259 1,272 611 630
Latin America & Canada 840 803 418 363
Total combustible products $ 10,781 $ 10,643 $ 5,318 $ 5,045
Reduced-risk products:
European Union $ 1,945 $ 1,155 $ 987 $ 530
Eastern Europe 644 526 340 261
Middle East & Africa 54 52 33 8
South & Southeast Asia 3 — 1 —
East Asia & Australia 1,727 1,415 903 802
Latin America & Canada 24 13 12 5
Total reduced-risk products $ 4,398 $ 3,161 $ 2,276 $ 1,606
Total PMI net revenues $ 15,179 $ 13,804 $ 7,594 $ 6,651
Note: Sum of product categories or Regions might not foot to total PMI due to roundings.
Items affecting the comparability of results from operations were as follows:
• Asset impairment and exit costs - See Note 16. Asset Impairment and Exit Costs for a breakdown of these costs by segment for the six months and
three months ended June 30, 2021 and 2020.
• Saudi Arabia customs assessments - See Note 8. Contingencies for the details of the $246 million reduction in net revenues of combustible products
included in the Middle East & Africa segment for the six months and three months ended June 30, 2021.
Net revenues related to combustible products refer to the operating revenues generated from the sale of these products, including shipping and handling
charges billed to customers, net of sales and promotion incentives, and excise taxes. These net revenue amounts consist of the sale of PMI's cigarettes and
other tobacco products combined. Other tobacco products primarily include roll-your-own and make-your-own cigarettes, pipe tobacco, cigars and
cigarillos and do not include reduced-risk products.
Net revenues related to reduced-risk products refer to the operating revenues generated from the sale of these products, including shipping and handling
charges billed to customers, net of sales and promotion incentives, and excise taxes. These net revenue amounts consist of the sale of PMI's heated tobacco
units, heat-not-burn devices and related accessories, and other nicotine-containing products, which primarily include PMI's e-vapor products.
24
-- 25 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 8. Contingencies:
Tobacco-Related Litigation
Legal proceedings covering a wide range of matters are pending or threatened against us, and/or our subsidiaries, and/or our indemnitees in various
jurisdictions. Our indemnitees include distributors, licensees, and others that have been named as parties in certain cases and that we have agreed to defend,
as well as to pay costs and some or all of judgments, if any, that may be entered against them. Pursuant to the terms of the Distribution Agreement between
Altria Group, Inc. (“Altria”) and PMI, PMI will indemnify Altria and Philip Morris USA Inc. (“PM USA”), a U.S. tobacco subsidiary of Altria, for tobacco
product claims based in substantial part on products manufactured by PMI or contract manufactured for PMI by PM USA, and PM USA will indemnify
PMI for tobacco product claims based in substantial part on products manufactured by PM USA, excluding tobacco products contract manufactured for
PMI.
It is possible that there could be adverse developments in pending cases against us and our subsidiaries. An unfavorable outcome or settlement of pending
tobacco-related litigation could encourage the commencement of additional litigation.
Damages claimed in some of the tobacco-related litigation are significant and, in certain cases in Brazil, Canada and Nigeria, range into the billions of U.S.
dollars. The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrate that the
monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome. Much of the tobacco-related litigation is in its early stages,
and litigation is subject to uncertainty. However, as discussed below, we have to date been largely successful in defending tobacco-related litigation.
We and our subsidiaries record provisions in the consolidated financial statements for pending litigation when we determine that an unfavorable outcome is
probable and the amount of the loss can be reasonably estimated. At the present time, except as stated otherwise in this Note 8. Contingencies, while it is
reasonably possible that an unfavorable outcome in a case may occur, after assessing the information available to it (i) management has not concluded that
it is probable that a loss has been incurred in any of the pending tobacco-related cases; (ii) management is unable to estimate the possible loss or range of
loss for any of the pending tobacco-related cases; and (iii) accordingly, no estimated loss has been accrued in the consolidated financial statements for
unfavorable outcomes in these cases, if any. Legal defense costs are expensed as incurred.
It is possible that our consolidated results of operations, cash flows or financial position could be materially affected in a particular fiscal quarter or fiscal
year by an unfavorable outcome or settlement of certain pending litigation. Nevertheless, although litigation is subject to uncertainty, we and each of our
subsidiaries named as a defendant believe, and each has been so advised by counsel handling the respective cases, that we have valid defenses to the
litigation pending against us, as well as valid bases for appeal of adverse verdicts. All such cases are, and will continue to be, vigorously defended.
However, we and our subsidiaries may enter into settlement discussions in particular cases if we believe it is in our best interests to do so.
CCAA Proceedings and Stay of Tobacco-Related Cases Pending in Canada
As a result of the Court of Appeal of Quebec’s decision in both the Létourneau and Blais cases described below, our subsidiary, Rothmans, Benson &
Hedges Inc. (“RBH”), and the other defendants, JTI Macdonald Corp., and Imperial Tobacco Canada Limited, sought protection in the Ontario Superior
Court of Justice under the Companies’ Creditors Arrangement Act (“CCAA”) on March 22, March 8, and March 12, 2019, respectively. CCAA is a
Canadian federal law that permits a Canadian business to restructure its affairs while carrying on its business in the ordinary course. The initial CCAA
order made by the Ontario Superior Court on March 22, 2019, authorizes RBH to pay all expenses incurred in carrying on its business in the ordinary
course after the CCAA filing, including obligations to employees, vendors, and suppliers. As further described in Item 8, Note 20. Deconsolidation of RBH
of PMI's Annual Report on Form 10-K for the year ended December 31, 2020, RBH's financial results have been deconsolidated from our consolidated
financial statements since March 22, 2019. As part of the CCAA proceedings, there is currently a comprehensive stay up to and including September 30,
2021, of all tobacco-related litigation pending in Canada against RBH and the other defendants, including PMI and our indemnitees (PM USA and Altria),
namely, the smoking and health class actions filed in various Canadian provinces and health care cost recovery actions. These proceedings are presented
below under the caption “Stayed Litigation — Canada.” Ernst & Young Inc. has been appointed as monitor of RBH in the CCAA proceedings. In
accordance with the CCAA process, as the parties work towards a plan of arrangement or compromise in a confidential mediation, it is anticipated that the
court will set additional hearings and further extend the stay of proceedings. On April 17, 2019, the Ontario Superior Court ruled that RBH and the other
defendants will not be allowed to file an application to the Supreme Court of Canada for leave to appeal the Court of Appeal’s decision in the Létourneau
and the Blais cases so long as the comprehensive stay of all tobacco-related litigation in Canada remains in effect and that the time period to file the
application would be extended by the stay period. While RBH believes that the findings of liability and damages in both Létourneau and the Blais cases
were incorrect, the CCAA proceedings will provide a forum for
25
-- 26 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
RBH to seek resolution through a plan of arrangement or compromise of all tobacco-related litigation pending in Canada. It is not possible to predict the
resolution of the underlying legal proceedings or the length of the CCAA process.
Stayed Litigation — Canada
Smoking and Health Litigation — Canada
In the first class action pending in Canada, Conseil Québécois Sur Le Tabac Et La Santé and Jean-Yves Blais v. Imperial Tobacco Ltd., Rothmans,
Benson & Hedges Inc. and JTI-Macdonald Corp., Quebec Superior Court, Canada, filed in November 1998, RBH and other Canadian cigarette
manufacturers (Imperial Tobacco Canada Ltd. and JTI-Macdonald Corp.) are defendants. The plaintiffs, an anti-smoking organization and an individual
smoker, sought compensatory and punitive damages for each member of the class who suffers allegedly from certain smoking-related diseases. The class
was certified in 2005. The trial court issued its judgment on May 27, 2015. The trial court found RBH and two other Canadian manufacturers liable and
found that the class members’ compensatory damages totaled approximately CAD 15.5 billion, including pre-judgment interest (approximately $12.3
billion). The trial court awarded compensatory damages on a joint and several liability basis, allocating 20% to our subsidiary (approximately CAD 3.1
billion, including pre-judgment interest (approximately $2.5 billion)). In addition, the trial court awarded CAD 90,000 (approximately $71,600) in punitive
damages, allocating CAD 30,000 (approximately $23,900) to RBH. The trial court estimated the disease class at 99,957 members. RBH appealed to the
Court of Appeal of Quebec. In October 2015, the Court of Appeal ordered RBH to furnish security totaling CAD 226 million (approximately $180 million)
to cover both the Létourneau and Blais cases, which RBH has paid in installments through March 2017. The Court of Appeal ordered Imperial Tobacco
Canada Ltd. to furnish security totaling CAD 758 million (approximately $603 million) in installments through June 2017. JTI Macdonald Corp. was not
required to furnish security in accordance with plaintiffs’ motion. The Court of Appeal ordered that the security is payable upon a final judgment of the
Court of Appeal affirming the trial court’s judgment or upon further order of the Court of Appeal.
On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court’s findings of liability and the compensatory and punitive damages
award while reducing the total amount of compensatory damages to approximately CAD 13.5 billion including interest (approximately $10.7 billion) due to
the trial court’s error in the calculation of interest. The compensatory damages award is on a joint and several basis with an allocation of 20% to RBH
(approximately CAD 2.7 billion, including pre-judgment interest (approximately $2.1 billion)). The Court of Appeal upheld the trial court’s findings that
defendants violated the Civil Code of Quebec, the Quebec Charter of Human Rights and Freedoms, and the Quebec Consumer Protection Act by failing to
warn adequately of the dangers of smoking and by conspiring to prevent consumers from learning of the dangers of smoking. The Court of Appeal further
held that the plaintiffs either need not prove, or had adequately proven, that these faults were a cause of the class members’ injuries. In accordance with the
judgment, defendants were required to deposit their respective portions of the damages awarded in both the Létourneau case described below and the Blais
case, approximately CAD 1.1 billion (approximately $875 million), into trust accounts within 60 days. RBH’s share of the deposit was approximately CAD
257 million (approximately $194 million). PMI recorded a pre-tax charge of $194 million in its consolidated results, representing $142 million net of tax,
as tobacco litigation-related expense, in the first quarter of 2019. The charge reflects PMI’s assessment of the portion of the judgment that represents
probable and estimable loss prior to the deconsolidation of RBH and corresponds to the trust account deposit required by the judgment.
In the second class action pending in Canada, Cecilia Létourneau v. Imperial Tobacco Ltd., Rothmans, Benson & Hedges Inc. and JTI-Macdonald Corp.,
Quebec Superior Court, Canada, filed in September 1998, RBH and other Canadian cigarette manufacturers (Imperial Tobacco Canada Ltd. and JTI-
Macdonald Corp.) are defendants. The plaintiff, an individual smoker, sought compensatory and punitive damages for each member of the class who is
deemed addicted to smoking. The class was certified in 2005. The trial court issued its judgment on May 27, 2015. The trial court found RBH and two
other Canadian manufacturers liable and awarded a total of CAD 131 million (approximately $104 million) in punitive damages, allocating CAD 46
million (approximately $37 million) to RBH. The trial court estimated the size of the addiction class at 918,000 members but declined to award
compensatory damages to the addiction class because the evidence did not establish the claims with sufficient accuracy. The trial court found that a claims
process to allocate the awarded punitive damages to individual class members would be too expensive and difficult to administer. On March 1, 2019, the
Court of Appeal issued a decision largely affirming the trial court’s findings of liability and the total amount of punitive damages awarded allocating CAD
57 million including interest (approximately $45 million) to RBH. See the Blais description above and Item 8, Note 20. Deconsolidation of RBH in PMI's
Annual Report on Form 10-K for the year ended December 31, 2020 for further detail concerning the security order pertaining to both Létourneau and
Blais cases and the impact of the decision on PMI’s financial statements.
26
-- 27 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
RBH and PMI believe the findings of liability and damages in both Létourneau and the Blais cases were incorrect and in contravention of applicable law on
several grounds including the following: (i) defendants had no obligation to warn class members who knew, or should have known, of the risks of smoking;
(ii) defendants cannot be liable to class members who would have smoked regardless of what warnings were given; and (iii) defendants cannot be liable to
all class members given the individual differences between class members.
In the third class action pending in Canada, Kunta v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Winnipeg, Canada, filed
June 12, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker,
alleges her own addiction to tobacco products and chronic obstructive pulmonary disease (“COPD”), severe asthma, and mild reversible lung disease
resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers,
their estates, dependents and family members, as well as restitution of profits, and reimbursement of government health care costs allegedly caused by
tobacco products.
In the fourth class action pending in Canada, Adams v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Saskatchewan, Canada, filed
July 10, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker,
alleges her own addiction to tobacco products and COPD resulting from the use of tobacco products. She is seeking compensatory and punitive damages on
behalf of a proposed class comprised of all smokers who have smoked a minimum of 25,000 cigarettes and have allegedly suffered, or suffer, from COPD,
emphysema, heart disease, or cancer, as well as restitution of profits.
In the fifth class action pending in Canada, Semple v. Canadian Tobacco Manufacturers' Council, et al., The Supreme Court (trial court), Nova Scotia,
Canada, filed June 18, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an
individual smoker, alleges his own addiction to tobacco products and COPD resulting from the use of tobacco products. He is seeking compensatory and
punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, as well as restitution of profits,
and reimbursement of government health care costs allegedly caused by tobacco products.
In the sixth class action pending in Canada, Dorion v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Alberta, Canada, filed
June 15, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker,
alleges her own addiction to tobacco products and chronic bronchitis and severe sinus infections resulting from the use of tobacco products. She is seeking
compensatory and punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, restitution of
profits, and reimbursement of government health care costs allegedly caused by tobacco products. To date, we, our subsidiaries, and our indemnitees have
not been properly served with the complaint.
In the seventh class action pending in Canada, McDermid v. Imperial Tobacco Canada Limited, et al., Supreme Court, British Columbia, Canada, filed
June 25, 2010, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker,
alleges his own addiction to tobacco products and heart disease resulting from the use of tobacco products. He is seeking compensatory and punitive
damages on behalf of a proposed class comprised of all smokers who were alive on June 12, 2007, and who suffered from heart disease allegedly caused by
smoking, their estates, dependents and family members, plus disgorgement of revenues earned by the defendants from January 1, 1954, to the date the
claim was filed.
In the eighth class action pending in Canada, Bourassa v. Imperial Tobacco Canada Limited, et al., Supreme Court, British Columbia, Canada, filed
June 25, 2010, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, the heir to a deceased
smoker, alleges that the decedent was addicted to tobacco products and suffered from emphysema resulting from the use of tobacco products. She is
seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who were alive on June 12, 2007, and who suffered
from chronic respiratory diseases allegedly caused by smoking, their estates, dependents and family members, plus disgorgement of revenues earned by the
defendants from January 1, 1954, to the date the claim was filed. In December 2014, plaintiff filed an amended statement of claim.
In the ninth class action pending in Canada, Suzanne Jacklin v. Canadian Tobacco Manufacturers' Council, et al., Ontario Superior Court of Justice, filed
June 20, 2012, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker,
alleges her own addiction to tobacco products and COPD resulting from the use of tobacco products. She is seeking compensatory and punitive damages on
behalf of a proposed class comprised
27
-- 28 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
of all smokers who have smoked a minimum of 25,000 cigarettes and have allegedly suffered, or suffer, from COPD, heart disease, or cancer, as well as
restitution of profits.
Health Care Cost Recovery Litigation — Canada
In the first health care cost recovery case pending in Canada, Her Majesty the Queen in Right of British Columbia v. Imperial Tobacco Limited, et al.,
Supreme Court, British Columbia, Vancouver Registry, Canada, filed January 24, 2001, we, RBH, our indemnitee (PM USA), and other members of the
industry are defendants. The plaintiff, the government of the province of British Columbia, brought a claim based upon legislation enacted by the province
authorizing the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, resulting
from a “tobacco related wrong.”
In the second health care cost recovery case filed in Canada, Her Majesty the Queen in Right of New Brunswick v. Rothmans Inc., et al., Court of Queen's
Bench of New Brunswick, Trial Court, New Brunswick, Fredericton, Canada, filed March 13, 2008, we, RBH, our indemnitees (PM USA and Altria), and
other members of the industry are defendants. The claim was filed by the government of the province of New Brunswick based on legislation enacted in the
province. This legislation is similar to the law introduced in British Columbia that authorizes the government to file a direct action against cigarette
manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the third health care cost recovery case filed in Canada, Her Majesty the Queen in Right of Ontario v. Rothmans Inc., et al., Ontario Superior Court of
Justice, Toronto, Canada, filed September 29, 2009, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants.
The claim was filed by the government of the province of Ontario based on legislation enacted in the province. This legislation is similar to the laws
introduced in British Columbia and New Brunswick that authorize the government to file a direct action against cigarette manufacturers to recover the
health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the fourth health care cost recovery case filed in Canada, Attorney General of Newfoundland and Labrador v. Rothmans Inc., et al., Supreme Court of
Newfoundland and Labrador, St. Johns, Canada, filed February 8, 2011, we, RBH, our indemnitees (PM USA and Altria), and other members of the
industry are defendants. The claim was filed by the government of the province of Newfoundland and Labrador based on legislation enacted in the province
that is similar to the laws introduced in British Columbia, New Brunswick and Ontario. The legislation authorizes the government to file a direct action
against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the fifth health care cost recovery case filed in Canada, Attorney General of Quebec v. Imperial Tobacco Limited, et al., Superior Court of Quebec,
Canada, filed June 8, 2012, we, RBH, our indemnitee (PM USA), and other members of the industry are defendants. The claim was filed by the
government of the province of Quebec based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces.
The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will
incur, as a result of a “tobacco related wrong.”
In the sixth health care cost recovery case filed in Canada, Her Majesty in Right of Alberta v. Altria Group, Inc., et al., Supreme Court of Queen's Bench
Alberta, Canada, filed June 8, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was
filed by the government of the province of Alberta based on legislation enacted in the province that is similar to the laws enacted in several other Canadian
provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred,
and will incur, as a result of a “tobacco related wrong.”
In the seventh health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Manitoba v. Rothmans, Benson & Hedges,
Inc., et al., The Queen's Bench, Winnipeg Judicial Centre, Canada, filed May 31, 2012, we, RBH, our indemnitees (PM USA and Altria), and other
members of the industry are defendants. The claim was filed by the government of the province of Manitoba based on legislation enacted in the province
that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette
manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the eighth health care cost recovery case filed in Canada, The Government of Saskatchewan v. Rothmans, Benson & Hedges Inc., et al., Queen's Bench,
Judicial Centre of Saskatchewan, Canada, filed June 8, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are
defendants. The claim was filed by the government of the province of Saskatchewan based on legislation enacted in the province that is similar to the laws
enacted in several other Canadian
28
-- 29 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred,
and will incur, as a result of a “tobacco related wrong.”
In the ninth health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Prince Edward Island v. Rothmans, Benson &
Hedges Inc., et al., Supreme Court of Prince Edward Island (General Section), Canada, filed September 10, 2012, we, RBH, our indemnitees (PM USA
and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Prince Edward Island based on
legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file
a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the tenth health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Nova Scotia v. Rothmans, Benson & Hedges
Inc., et al., Supreme Court of Nova Scotia, Canada, filed January 2, 2015, we, RBH, our indemnitees (PM USA and Altria), and other members of the
industry are defendants. The claim was filed by the government of the province of Nova Scotia based on legislation enacted in the province that is similar
to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to
recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
__________
The table below lists the number of tobacco-related cases pertaining to combustible products pending against us and/or our subsidiaries or indemnitees as
of July 23, 2021, July 24, 2020 and July 23, 2019:¹
Type of Case
Number of Cases
Pending as of July 23,
2021
Number of Cases
Pending as of July 24,
2020
Number of Cases
Pending as of July 23,
2019
Individual Smoking and Health Cases 44 44 52
Smoking and Health Class Actions 9 10 10
Health Care Cost Recovery Actions 17 17 17
Label-Related Class Actions — — 1
Individual Label-Related Cases 4 5 6
Public Civil Actions 2 2 2
Since 1995, when the first tobacco-related litigation was filed against a PMI entity, 515 Smoking and Health, Label-Related, Health Care Cost Recovery,
and Public Civil Actions in which we and/or one of our subsidiaries and/or indemnitees were a defendant have been terminated in our favor. Fourteen cases
have had decisions in favor of plaintiffs. Ten of these cases have subsequently reached final resolution in our favor and four remain on appeal.
The table below lists the verdict and significant post-trial developments in the four pending cases where a verdict was returned in favor of the plaintiff:
______
¹ Includes cases pending in Canada.
29
-- 30 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Date
Location of
Court/Name of
Plaintiff Type of
Case Verdict Post-Trial
Developments
May 27, 2015 Canada/Conseil Québécois Sur
Le Tabac Et La Santé and Jean-
Yves Blais
Class Action On May 27, 2015, the Superior
Court of the District of
Montreal, Province of Quebec
ruled in favor of the Blais class
on liability and found the class
members’ compensatory
damages totaled approximately
CAD 15.5 billion
(approximately $12.3 billion),
including pre-judgment interest.
The trial court awarded
compensatory damages on a
joint and several liability basis,
allocating 20% to our subsidiary
(approximately CAD 3.1 billion
including pre-judgment interest
(approximately $2.5 billion)).
The trial court awarded CAD
90,000 (approximately $71,600)
in punitive damages, allocating
CAD 30,000 (approximately
$23,900) to our subsidiary. The
trial court ordered defendants to
pay CAD 1 billion
(approximately $796 million) of
the compensatory damage
award, CAD 200 million
(approximately $159 million) of
which is our subsidiary’s
portion, into a trust within 60
days.
In June 2015, RBH commenced the
appellate process with the Court of
Appeal of Quebec. On March 1, 2019,
the Court of Appeal issued a decision
largely affirming the trial court's
decision. (See “Stayed Litigation —
Canada” for further detail.)
30
-- 31 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Date
Location of
Court/Name of
Plaintiff Type of
Case Verdict Post-Trial
Developments
May 27, 2015 Canada/Cecilia Létourneau Class Action On May 27, 2015, the Superior
Court of the District of
Montreal, Province of Quebec
ruled in favor of the Létourneau
class on liability and awarded a
total of CAD 131 million
(approximately $104 million) in
punitive damages, allocating
CAD 46 million (approximately
$37 million) to RBH. The trial
court ordered defendants to pay
the full punitive damage award
into a trust within 60 days. The
court did not order the payment
of compensatory damages.
In June 2015, RBH commenced the
appellate process with the Court of
Appeal of Quebec. On March 1, 2019,
the Court of Appeal issued a decision
largely affirming the trial court's
decision. (See “Stayed Litigation —
Canada” for further detail.)
Date
Location of
Court/Name of
Plaintiff Type of
Case Verdict Post-Trial
Developments
August 5, 2016 Argentina/Hugo Lespada Individual
Action On August 5, 2016, the Civil
Court No. 14 - Mar del Plata,
issued a verdict in favor of
plaintiff, an individual smoker,
and awarded him ARS 110,000
(approximately $1,141), plus
interest, in compensatory and
moral damages. The trial court
found that our subsidiary failed
to warn plaintiff of the risk of
becoming addicted to cigarettes.
On August 23, 2016, our subsidiary filed
its notice of appeal. On October 31,
2017, the Civil and Commercial Court of
Appeals of Mar del Plata ruled that
plaintiff's claim was barred by the statute
of limitations and it reversed the trial
court's decision. On November 28, 2017,
plaintiff filed an extraordinary appeal of
the reversal of the trial court's decision to
the Supreme Court of the Province of
Buenos Aires. On April 19, 2021, the
Supreme Court of the Province of
Buenos Aires rejected plaintiff's
extraordinary appeal. On May 17, 2021
plaintiff filed a federal extraordinary
appeal to the Federal Supreme Court. On
June 16, 2021 our subsidiary filed its
reply to the federal extraordinary appeal.
31
-- 32 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Date
Location of
Court/Name of
Plaintiff Type of
Case Verdict Post-Trial
Developments
June 17, 2021 Argentina/Claudia Milano Individual
Action On June 17, 2021, the Civil
Court No. 9 - Mar del Plata,
issued a verdict in favor of
plaintiff, an individual smoker,
and awarded her smoking
cessation treatments, ARS
150,000 (approximately
$1,556), in compensatory and
moral damages, and ARS
4,000,000 (approximately
$41,500) in punitive damages,
plus interest and costs. The trial
court found that our subsidiary
failed to warn plaintiff of the
risk of becoming addicted to
cigarettes.
On July 2, 2021, our subsidiary filed its
notice of appeal. In addition, plaintiff
filed an appeal challenging the dismissal
of the claim for psychological damages.
As required by local law, our subsidiary
will have to deposit the damages
awarded, plus interest and costs, in total
ARS 6,114,428 (approximately $63,438),
into a court escrow account. Our
subsidiary plans to challenge the amount
determined by the court. If our
subsidiary ultimately prevails on appeal,
the deposited amounts will be returned to
our subsidiary.
Pending claims related to tobacco products generally fall within the following categories:
Smoking and Health Litigation: These cases primarily allege personal injury and are brought by individual plaintiffs or on behalf of a class or purported
class of individual plaintiffs. Plaintiffs' allegations of liability in these cases are based on various theories of recovery, including negligence, gross
negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, breach of express and implied warranties, violations of deceptive trade
practice laws and consumer protection statutes. Plaintiffs in these cases seek various forms of relief, including compensatory and other damages, and
injunctive and equitable relief. Defenses raised in these cases include licit activity, failure to state a claim, lack of defect, lack of proximate cause,
assumption of the risk, contributory negligence, and statute of limitations.
As of July 23, 2021, there were a number of smoking and health cases pending against us, our subsidiaries or indemnitees, as follows:
• 44 cases brought by individual plaintiffs in Argentina (31), Brazil (3), Canada (2), Chile (2), China (1), Italy (1), the Philippines (1), Turkey (1)
and Scotland (1), as well as 1 case brought by an individual plaintiff in the United States District Court for the District of Oregon in May 2021.
The provisions of the 2008 Share Distribution Agreement between PMI and Altria provide for indemnities to PMI for certain liabilities concerning
tobacco products as described above under the caption "Tobacco-Related Litigation," compared with 44 such cases on July 24, 2020, and 52 cases
on July 23, 2019; and
• 9 cases brought on behalf of classes of individual plaintiffs in Canada, compared with 10 such cases on July 24, 2020 and 10 such cases on
July 23, 2019.
The class actions pending in Canada are described above under the caption “Smoking and Health Litigation — Canada.”
Health Care Cost Recovery Litigation: These cases, brought by governmental and non-governmental plaintiffs, seek reimbursement of health care cost
expenditures allegedly caused by tobacco products. Plaintiffs' allegations of liability in these cases are based on various theories of recovery including
unjust enrichment, negligence, negligent design, strict liability, breach of express and implied warranties, violation of a voluntary undertaking or special
duty, fraud, negligent misrepresentation, conspiracy, public nuisance, defective product, failure to warn, sale of cigarettes to minors, and claims under
statutes governing
32
-- 33 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
competition and deceptive trade practices. Plaintiffs in these cases seek various forms of relief including compensatory and other damages, and injunctive
and equitable relief. Defenses raised in these cases include lack of proximate cause, remoteness of injury, failure to state a claim, adequate remedy at law,
“unclean hands” (namely, that plaintiffs cannot obtain equitable relief because they participated in, and benefited from, the sale of cigarettes), and statute of
limitations.
As of July 23, 2021, there were 17 health care cost recovery cases pending against us, our subsidiaries or indemnitees in Brazil (1), Canada (10), Korea (1)
and Nigeria (5), compared with 17 such cases on July 24, 2020 and 17 such cases on July 23, 2019.
The health care cost recovery actions pending in Canada are described above under the caption “Health Care Cost Recovery Litigation — Canada.”
In the health care cost recovery case in Brazil, The Attorney General of Brazil v. Souza Cruz Ltda., et al., Federal Trial Court, Porto Alegre, Rio Grande do
Sul, Brazil, filed May 21, 2019, we, our subsidiaries, and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of
treating alleged smoking-related diseases in certain prior years, payment of anticipated costs of treating future alleged smoking-related diseases, and moral
damages. Defendants filed answers to the complaint in May 2020.
In the first health care cost recovery case in Nigeria, The Attorney General of Lagos State v. British American Tobacco (Nigeria) Limited, et al., High Court
of Lagos State, Lagos, Nigeria, filed March 13, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of
treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20
years, various forms of injunctive relief, plus punitive damages. We are in the process of making challenges to service and the court's jurisdiction.
Currently, the case is stayed in the trial court pending the appeals of certain co-defendants relating to service objections.
In the second health care cost recovery case in Nigeria, The Attorney General of Kano State v. British American Tobacco (Nigeria) Limited, et al., High
Court of Kano State, Kano, Nigeria, filed May 9, 2007, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of
treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20
years, various forms of injunctive relief, plus punitive damages. We are in the process of challenging the court's jurisdiction. Currently, the case is stayed in
the trial court pending the appeals of certain co-defendants relating to service objections.
In the third health care cost recovery case in Nigeria, The Attorney General of Gombe State v. British American Tobacco (Nigeria) Limited, et al., High
Court of Gombe State, Gombe, Nigeria, filed October 17, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the
cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next
20 years, various forms of injunctive relief, plus punitive damages. In February 2011, the court ruled that the plaintiff had not complied with the procedural
steps necessary to serve us. As a result of this ruling, plaintiff must re-serve its claim. We have not yet been re-served.
In the fourth health care cost recovery case in Nigeria, The Attorney General of Oyo State, et al., v. British American Tobacco (Nigeria) Limited, et al.,
High Court of Oyo State, Ibadan, Nigeria, filed May 25, 2007, we and other members of the industry are defendants. Plaintiffs seek reimbursement for the
cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next
20 years, various forms of injunctive relief, plus punitive damages. We challenged service as improper. In June 2010, the court ruled that plaintiffs did not
have leave to serve the writ of summons on the defendants and that they must re-serve the writ. We have not yet been re-served.
In the fifth health care cost recovery case in Nigeria, The Attorney General of Ogun State v. British American Tobacco (Nigeria) Limited, et al., High Court
of Ogun State, Abeokuta, Nigeria, filed February 26, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost
of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20
years, various forms of injunctive relief, plus punitive damages. In May 2010, the trial court rejected our objections to the court's jurisdiction. We have
appealed. Currently, the case is stayed in the trial court pending the appeals of certain co-defendants relating to service objections.
In the health care cost recovery case in Korea, the National Health Insurance Service v. KT&G, et. al., filed April 14, 2014, our subsidiary and other
Korean manufacturers are defendants. Plaintiff alleges that defendants concealed the health hazards of smoking, marketed to youth, added ingredients to
make their products more harmful and addictive, and misled consumers into believing that Lights cigarettes are safer than regular cigarettes. The National
Health Insurance Service seeks to recover
33
-- 34 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
damages allegedly incurred in treating 3,484 patients with small cell lung cancer, squamous cell lung cancer, and squamous cell laryngeal cancer from 2003
to 2012. The trial court dismissed the case in its entirety on November 20, 2020. Plaintiff appealed.
Label-Related Cases: These cases, now brought only by individual plaintiffs, allege that the use of the descriptor “Lights” or other alleged
misrepresentations or omissions of labeling information constitute fraudulent and misleading conduct. Plaintiffs' allegations of liability in these cases are
based on various theories of recovery including misrepresentation, deception, and breach of consumer protection laws. Plaintiffs seek various forms of
relief including restitution, injunctive relief, and compensatory and other damages. Defenses raised include lack of causation, lack of reliance, assumption
of the risk, and statute of limitations.
As of July 23, 2021, there were 4 label-related cases brought by individual plaintiffs in Italy (1) and Chile (3) pending against our subsidiaries, compared
with 5 such cases on July 24, 2020, and 6 such cases on July 23, 2019.
Public Civil Actions: Claims have been filed either by an individual, or a public or private entity, seeking to protect collective or individual rights, such as
the right to health, the right to information or the right to safety. Plaintiffs' allegations of liability in these cases are based on various theories of recovery
including product defect, concealment, and misrepresentation. Plaintiffs in these cases seek various forms of relief including injunctive relief such as
banning cigarettes, descriptors, smoking in certain places and advertising, as well as implementing communication campaigns and reimbursement of
medical expenses incurred by public or private institutions.
As of July 23, 2021, there were 2 public civil actions pending against our subsidiaries in Argentina (1) and Venezuela (1), compared with 2 such cases on
July 24, 2020, and 2 such cases on July 23, 2019.
In the public civil action in Argentina, Asociación Argentina de Derecho de Danos v. Massalin Particulares S.A., et al., Civil Court of Buenos Aires,
Argentina, filed February 26, 2007, our subsidiary and another member of the industry are defendants. The plaintiff, a consumer association, seeks the
establishment of a relief fund for reimbursement of medical costs associated with diseases allegedly caused by smoking. Our subsidiary filed its answer in
September 2007. In March 2010, the case file was transferred to the Federal Court on Administrative Matters after the Civil Court granted plaintiff's
request to add the national government as a co-plaintiff in the case. The trial court dismissed the case on May 14, 2021.
In the public civil action in Venezuela, Federation of Consumers and Users Associations (“FEVACU”), et al. v. National Assembly of Venezuela and the
Venezuelan Ministry of Health, Constitutional Chamber of the Venezuelan Supreme Court, filed April 29, 2008, we were not named as a defendant, but the
plaintiffs published a notice pursuant to court order, notifying all interested parties to appear in the case. In January 2009, our subsidiary appeared in the
case in response to this notice. The plaintiffs purport to represent the right to health of the citizens of Venezuela and claim that the government failed to
protect adequately its citizens' right to health. The claim asks the court to order the government to enact stricter regulations on the manufacture and sale of
tobacco products. In addition, the plaintiffs ask the court to order companies involved in the tobacco industry to allocate a percentage of their “sales or
benefits” to establish a fund to pay for the health care costs of treating smoking-related diseases. In October 2008, the court ruled that plaintiffs have
standing to file the claim and that the claim meets the threshold admissibility requirements. In December 2012, the court admitted our subsidiary and BAT's
subsidiary as interested third parties. In February 2013, our subsidiary answered the complaint.
Reduced-Risk Products
In Colombia, an individual filed a purported class action, Ana Ferrero Rebolledo v. Philip Morris Colombia S.A., et al., in April 2019, against our
subsidiaries with the Civil Court of Bogota related to the marketing of our Platform 1 product. Plaintiff alleged that our subsidiaries advertise the product in
contravention of law and in a manner that misleads consumers by portraying the product in a positive light, and further asserts that the Platform 1 vapor
contains many toxic compounds, creates a high level of dependence, and has damaging second-hand effects. Plaintiff sought injunctive relief and damages
on her behalf and on a behalf of two classes (class 1 - all Platform 1 consumers in Colombia who seek damages for the purchase price of the product and
personal injuries related to the alleged addiction, and class 2 - all residents of the neighborhood where the advertising allegedly took place who seek
damages for exposure to the alleged illegal advertising). Our subsidiaries answered the complaint in January 2020, and in February 2020, plaintiff filed an
amended complaint. The amended complaint modifies the relief sought on behalf of the named plaintiff and on behalf of a single class (all consumers of
Platform 1 products in Colombia who seek damages for the product purchase price and personal injuries related to the use of an allegedly harmful product.)
In June 2021, our subsidiaries answered the amended complaint.
34
-- 35 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Other Litigation
The Department of Special Investigations of the government of Thailand ("DSI") conducted an investigation into alleged underpayment by our subsidiary,
Philip Morris (Thailand) Limited ("PM Thailand"), of customs duties and excise taxes relating to imports from the Philippines covering the period 2003-
2007. On January 18, 2016, the Public Prosecutor filed charges against our subsidiary and seven former and current employees in the Bangkok Criminal
Court alleging that PM Thailand and the individual defendants jointly and with the intention to defraud the Thai government, under-declared import prices
of cigarettes to avoid full payment of taxes and duties in connection with import entries of cigarettes from the Philippines during the period of July 2003 to
June 2006. The government is seeking a fine of approximately THB 80.8 billion (approximately $2.5 billion). In May 2017, Thailand enacted a new
customs act. The new act, which took effect in November 2017, substantially limits the amount of fines that Thailand could seek in these proceedings. PM
Thailand believes that its declared import prices are in compliance with the Customs Valuation Agreement of the World Trade Organization and Thai law,
and that the allegations of the Public Prosecutor are inconsistent with several decisions already taken by Thai Customs and other Thai governmental
agencies. Trial in the case began in November 2017, and concluded in September 2019. In November 2019, the trial court found our subsidiary guilty of
under-declaration of the prices and imposed a fine of approximately THB 1.2 billion (approximately $36 million). The trial court dismissed all charges
against the individual defendants. In December 2019, as required by the Thai law, our subsidiary paid the fine. This payment is included in other assets on
the condensed consolidated balance sheets and negatively impacted net cash provided by operating activities in the condensed consolidated statements of
cash flows in the period of payment. Our subsidiary filed an appeal of the trial court's decision. In addition, the Public Prosecutor filed an appeal of the trial
court's decision challenging the dismissal of charges against the individual defendants and the amount of the fine imposed. If our subsidiary ultimately
prevails on appeal, then Thailand will be required to return this payment to our subsidiary.
The DSI also conducted an investigation into alleged underpayment by PM Thailand of customs duties and excise taxes relating to imports from Indonesia
covering the period 2000-2003. On January 26, 2017, the Public Prosecutor filed charges against PM Thailand and its former Thai employee in the
Bangkok Criminal Court alleging that PM Thailand and its former employee jointly and with the intention to defraud the Thai government under-declared
import prices of cigarettes to avoid full payment of taxes and duties in connection with import entries during the period from January 2002 to July 2003.
The government is seeking a fine of approximately THB 19.8 billion (approximately $602 million). In May 2017, Thailand enacted a new customs act. The
new act, which took effect in November 2017, substantially limits the amount of fines that Thailand could seek in these proceedings. PM Thailand believes
that its declared import prices are in compliance with the Customs Valuation Agreement of the World Trade Organization and Thai law, and that the
allegations of the Public Prosecutor are inconsistent with several decisions already taken by Thai Customs and a Thai court. Trial in the case began in
November 2018 and concluded in December 2019. In March 2020, the trial court found our subsidiary guilty of under-declaration of the prices and
imposed a fine of approximately THB 130 million (approximately $4 million). The trial court dismissed all charges against the individual defendant. In
April 2020, as required by Thai law, our subsidiary paid the fine. This payment is included in other assets on the condensed consolidated balance sheets and
negatively impacted net cash provided by operating activities in the condensed consolidated statements of cash flows in the period of payment. Our
subsidiary filed an appeal of the trial court's decision. In addition, the Public Prosecutor filed an appeal of the trial court's decision challenging the dismissal
of charges against the individual defendant and the amount of the fine imposed. If our subsidiary ultimately prevails on appeal, then Thailand will be
required to return this payment to our subsidiary.
The South Korean Board of Audit and Inspection (“BAI”) conducted an audit of certain Korean government agencies and the tobacco industry into whether
inventory movements ahead of the January 1, 2015 increase of cigarette-related taxes by tobacco companies, including Philip Morris Korea Inc. ("PM
Korea"), our South Korean subsidiary, were in compliance with South Korean tax laws. In November 2016, the tax authorities completed their audit and
assessed allegedly underpaid taxes and penalties. In order to avoid nonpayment financial costs, PM Korea paid approximately KRW 272 billion
(approximately $236 million), of which KRW 100 billion (approximately $87 million) was paid in 2016 and KRW 172 billion (approximately $149
million) was paid in the first quarter of 2017. These paid amounts are included in other assets in the condensed consolidated balance sheets and negatively
impacted net cash provided by operating activities in the condensed consolidated statements of cash flows in the period of payment. PM Korea appealed
the assessments. In January 2020, a trial court ruled that PM Korea did not underpay taxes in the amount of approximately KRW 218 billion
(approximately $189 million). The tax authorities appealed this decision to the appellate court. In September 2020, the appellate court upheld the trial
court's decision. The tax authorities have appealed to the Supreme Court of South Korea. In June 2020, another trial court ruled that PM Korea did not
underpay approximately KRW 54 billion (approximately $46 million) of alleged underpayments. The government agencies appealed this decision. In
January 2021, the appellate court upheld the trial court's decision. The government agencies appealed
35
-- 36 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
to the Supreme Court of South Korea. If the tax authorities and government agencies ultimately lose, then they would be required to return the paid
amounts to PM Korea.
The Moscow Tax Inspectorate for Major Taxpayers (“MTI”) conducted an audit of AO Philip Morris Izhora (“PM Izhora”), our Russian subsidiary, for the
2015-2017 financial years. On July 26, 2019, MTI issued its initial assessment, claiming that intercompany sales of cigarettes between PM Izhora and
another Russian subsidiary prior to excise tax increases and submission by PM Izhora of the maximum retail sales price notifications for cigarettes to the
tax authorities were improper under Russian tax laws and resulted in underpayment of excise taxes and VAT. In August 2019, PM Izhora submitted its
objections disagreeing with MTI’s allegations set forth in the initial assessment and MTI’s methodology for calculating the alleged underpayments. MTI
accepted some of PM Izhora’s arguments, and in September 2019, issued the final tax assessment claiming an underpayment of RUB 24.3 billion
(approximately $374 million), including penalties and interest. In accordance with Russian tax laws, PM Izhora paid the entire amount of MTI’s final
assessment. This amount was neither imposed on, nor concurrent with, the specific revenue-producing transaction, nor was it collected from customers of
our Russian subsidiaries. In the third quarter of 2019, PMI recorded a pre-tax charge of $374 million, in marketing, administration and research costs in the
condensed consolidated statements of earnings, representing $315 million net of an associated income tax benefit of $59 million.
The Saudi Arabia Customs General Authority issued its assessments requiring our distributors to pay additional customs duties in the amount of
approximately 1.5 billion Saudi Riyal, or approximately $396 million, in relation to the fees paid by these distributors under their agreements with our
subsidiary for exclusive rights to distribute our products in Saudi Arabia. In order to challenge these assessments, the distributors posted bank guarantees.
To enable the distributors' challenge, our subsidiary agreed with the banks to bear a portion of the amount the authority may draw on the bank guarantees.
In September and October 2020, respectively, the distributors lost their challenges of the assessments. Both distributors appealed, and in June 2021, the
Customs Appeal Committee in Riyadh notified the distributors of its decisions to largely reject their appeals. On the basis of the above-mentioned
decisions, in June 2021, PMI recorded a pre-tax charge of $246 million in relation to the period of 2014 through 2020 in line with existing and
contemplated arrangements with the distributors. The estimated amounts for 2021 are immaterial. In accordance with U.S. GAAP, the charge was recorded
as a reduction in net revenues on the consolidated statements of earnings for the three months and six months ended June 30, 2021. Despite the unfavorable
decisions, our subsidiary believes that customs duties paid in Saudi Arabia were in compliance with the applicable law and the WTO Customs Valuation
Agreement.
A putative shareholder class action lawsuit, In re Philip Morris International Inc. Securities Litigation, is pending in the United States District Court for the
Southern District of New York, purportedly on behalf of purchasers of Philip Morris International Inc. stock between July 26, 2016 and April 18, 2018.
The lawsuit names Philip Morris International Inc. and certain officers and employees as defendants and includes allegations that the defendants made
false and/or misleading statements and/or failed to disclose information about PMI’s business, operations, financial condition, and prospects, related to
product sales of, and alleged irregularities in clinical studies of, PMI’s Platform 1 product. The lawsuit seeks various forms of relief, including damages. In
November 2018, the court consolidated three putative shareholder class action lawsuits with similar allegations previously filed in the Southern District of
New York (namely, City of Westland Police and Fire Retirement System v. Philip Morris International Inc., et al, Greater Pennsylvania Carpenters’
Pension Fund v. Philip Morris International Inc., et al., and Gilchrist v. Philip Morris International Inc., et al.) into these proceedings. A putative
shareholder class action lawsuit, Rubenstahl v. Philip Morris International Inc., et al., that had been previously filed in December 2017 in the United States
District Court for the District of New Jersey, was voluntarily dismissed by the plaintiff due to similar allegations in these proceedings. On February 4,
2020, the court granted defendants’ motion in its entirety, dismissing all but one of the plaintiffs’ claims with prejudice. The court noted that one of
plaintiffs’ claims (allegations relating to four non-clinical studies of PMI’s Platform 1 product) did not state a viable claim but allowed plaintiffs to replead
that claim by March 3, 2020. On February 18, 2020, the plaintiffs filed a motion for reconsideration of the court's February 4th decision; this motion was
denied on September 21, 2020. On September 28, 2020, plaintiffs filed an amended complaint seeking to replead allegations relating to four non-clinical
studies of PMI's Platform 1 product. We believe that this lawsuit is without merit and will continue to defend it vigorously.
In April 2020, affiliates of British American Tobacco plc (“BAT”) commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v.
Altria Client Services LLC, et al., in the federal court in the Eastern District of Virginia, where PMI's subsidiary, Philip Morris Products S.A., as well as
Altria Group, Inc.'s subsidiaries, are defendants. Plaintiffs seek damages and injunctive relief against the commercialization of the Platform 1 products in
the United States. In April 2020, BAT affiliates filed a complaint against PMI, Philip Morris Products S.A., Altria Group, Inc., and its subsidiaries before
the International Trade Commission ("ITC"). Plaintiffs seek an order to prevent the importation of Platform 1 products into the United States.
36
-- 37 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The ITC evidentiary hearing closed on February 1, 2021. On May 14, 2021, the administrative law judge issued an Initial and Recommended
Determination ("ID/RD") finding that the Platform 1 product infringes two of the three patents asserted by Plaintiffs, recommending that the ITC issue a
Limited Exclusion order against infringing products, and recommending against a cease-and-desist, as well as recommending against a bond pending
Presidential review of the ITC's Final Determination. Defendants and Plaintiffs filed separate Petitions for Review with the ITC of the ID on May 28, 2021;
a decision on those petitions is expected on July 27, 2021. Plaintiffs and Defendants also submitted brief statements of the public interest factors in issue to
the ITC on June 15, 2021. The ITC's Final Determination is expected in mid-September 2021. In June 2020, defendants filed their responses in both
proceedings. In the Eastern District of Virginia case, the defendants also counterclaimed that BAT infringed their patents relating to certain e-vapor
products, seeking damages for, and injunctive relief against, the commercialization of these products by BAT; defendants' claims against BAT are set for
trial on April 4, 2022. Upon petition of Philip Morris Products S.A., the Patent Trial and Appeal Board of the United States Patent and Trademark Office
has instituted review of certain claims pertaining to four of the six patents asserted by BAT affiliates in both proceedings.
In April 2020, BAT’s affiliate commenced patent infringement proceedings, Nicoventures Trading Limited v. PM GmbH, et al., against PMI’s German
subsidiary, Philip Morris GmbH, and Philip Morris Products S.A., in the Regional Court in Munich, Germany. Plaintiffs seek damages and injunctive relief
against the commercialization of the Platform 1 products in Germany.
In July 2020, in response to a challenge in the United Kingdom by PMI’s subsidiary to patents related to the BAT patents in the German proceedings, BAT
affiliates brought a patent infringement action, Nicoventures Trading Limited, et al. v. Philip Morris Products S.A., et al., against Philip Morris Products
S.A. and PMI’s U.K. subsidiary, Philip Morris Limited, in the English High Court, seeking damages and injunctive relief against the commercialization of
the Platform 1 products in the United Kingdom. On March 9, 2021, the court revoked the BAT patents and found that, had the BAT patents not been
revoked as invalid, they would have been infringed. BAT affiliates sought to appeal the court’s judgment and the U.K. Court of Appeal refused BAT's
request to appeal.
In September 2020, BAT’s affiliates commenced patent infringement and unfair competition proceedings, RAI Strategic Holdings, Inc., et al. v. Philip
Morris Products S.A., et al., against Philip Morris Products S.A. and PMI’s Italian subsidiaries, Philip Morris Manufacturing & Technology Bologna S.p.A.
and Philip Morris Italia S.r.l., in the Court of Milan, Italy. Plaintiffs seek damages, as well as injunctive relief against the manufacture in Italy of the
Platform 1 heated tobacco units allegedly infringing the asserted patents and the commercialization of the Platform 1 products in Italy. As part of this
proceeding, in October 2020, BAT’s affiliates filed a request based on one of the two asserted patents seeking preliminary injunctive relief against the
manufacture and commercialization of the Platform 1 products in Italy.
In October 2020, BAT’s affiliates commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Philip Morris Japan, Limited, et al.,
against PMI’s Japanese subsidiary, Philip Morris Japan Limited, and a third-party distributor in the Tokyo District Court. Plaintiffs seek damages and
injunctive relief against the commercialization of the Platform 1 products in Japan.
In November 2020, BAT’s affiliates commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Philip Morris Romania SRL, et al.,
against PMI’s Romanian subsidiaries, Philip Morris Romania S.R.L. and Philip Morris Trading S.R.L., and a third-party distributor in the Court of Law of
Bucharest, Civil Registry. Plaintiffs seek damages and preliminary and permanent injunctive relief against the manufacture and commercialization of the
Platform 1 products in Romania. In February 2021, the court dismissed plaintiffs’ request for a preliminary injunction. In April 2021, the appellate court
denied plaintiffs' appeal, confirming the dismissal of plaintiffs' request for preliminary injunction. Plaintiffs' proceeding requesting damages and a
permanent injunction remains pending before the Court of Law of Bucharest, Civil Registry.
In February 2021, BAT’s affiliate commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Papastratos SA, et al., against PMI’s
Greek subsidiary, Papastratos Cigarettes Manufacturing Company S.A., and Philip Morris Products S.A., in the First Instance Court of Athens. Plaintiff
seeks preliminary injunctive relief against the commercialization of the Platform 1 products in Greece. In July 2021, the court dismissed plaintiffs' request
in its entirety.
In March 2021, BAT’s affiliates commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Philip Morris Korea, Co., Ltd., against
PM Korea in the Seoul Central District Court. Plaintiffs seek damages and injunctive relief against the commercialization of the Platform 1 heated tobacco
units in South Korea.
Other patent challenges by both parties are pending in various jurisdictions.
We believe that the foregoing proceedings by the affiliates of BAT are without merit and will defend them vigorously.
37
-- 38 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
We are also involved in additional litigation arising in the ordinary course of our business. While the outcomes of these proceedings are uncertain,
management does not expect that the ultimate outcomes of other litigation, including any reasonably possible losses in excess of current accruals, will have
a material adverse effect on our consolidated results of operations, cash flows or financial position.
Third-Party Guarantees
On October 17, 2020, Medicago Inc., an equity method investee of Philip Morris Investments B.V. (“PMIBV”), a PMI subsidiary, entered into a
contribution agreement with the Canadian government (the “Contribution Agreement”), whereby the Canadian government agreed to contribute up to CAD
173 million (approximately $131 million on the date of signing) to Medicago Inc., to support its on-going COVID-19 vaccine development and clinical
trials, and for the construction of its Quebec City manufacturing facility (the “Project”). PMIBV and the majority shareholder of Medicago Inc. are also
parties to the Contribution Agreement as guarantors of Medicago Inc.’s obligations thereunder on a joint and several basis (“Co-Guarantors”). The Co-
Guarantors agreed to repay amounts contributed by the Canadian government plus interest, if Medicago Inc. fails to do so, and could be responsible for the
costs of other Medicago’s obligations (such as the achievement of specific milestones of the Project). The maximum amount of these obligations is
currently non-estimable. As of June 30, 2021, PMI has determined that these guarantees did not have a material impact on its condensed consolidated
financial statements.
In connection with the Contribution Agreement, PMIBV and the majority shareholder of Medicago Inc. entered into a guarantors’ agreement that
apportions Co-Guarantors’ obligations and limits those of PMIBV to its then share of holdings in Medicago Inc., which as of June 30, 2021 was
approximately 32%. In July 2021, Medicago Inc. initiated an additional round of equity funding in which PMIBV did not participate. As a result, PMIBV’s
share of holdings in Medicago Inc. was reduced to approximately 25%. The guarantees are in effect through March 31, 2026.
Note 9. Income Taxes:
Income tax provisions for jurisdictions outside the United States of America, as well as state and local income tax provisions, were determined on a
separate company basis, and the related assets and liabilities were recorded in PMI’s condensed consolidated balance sheets.
On March 11, 2021, the American Rescue Plan Act of 2021 ("the Act") was signed into law in the U.S. to provide certain relief as a result of the COVID-
19 pandemic. As of June 30, 2021, PMI has determined that the Act had no significant impact on PMI's effective tax rate.
PMI’s effective tax rates for the six months and three months ended June 30, 2021 were 21.7% and 22.0%, respectively. PMI’s effective tax rates for the six
months and three months ended June 30, 2020 were 21.7% and 20.7%, respectively. The effective tax rate for the six months ended June 30, 2021 was
favorably impacted by the corporate income tax rate reduction in the Philippines (enacted in the first quarter of 2021). The effective tax rate for the six
months ended June 30, 2020 was favorably impacted by the corporate income tax rate reduction in Indonesia (enacted in the second quarter of 2020). PMI
estimates that its full-year 2021 effective tax rate will be around 22%, excluding discrete tax events. Changes in currency exchange rates, earnings mix by
taxing jurisdiction or future regulatory developments may have an impact on the effective tax rates, which PMI monitors each quarter. Significant judgment
is required in determining income tax provisions and in evaluating tax positions.
PMI is regularly examined by tax authorities around the world and is currently under examination in a number of jurisdictions. The U.S. federal statute of
limitations remains open for the years 2017 and onward. Foreign and U.S. state jurisdictions have statutes of limitations generally ranging from three to
five years.
It is reasonably possible that within the next 12 months certain tax examinations will close, which could result in a change in unrecognized tax benefits
along with related interest and penalties. An estimate of any possible change cannot be made at this time.
38
-- 39 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 10. Indebtedness:
Short-term Borrowings:
PMI's short-term borrowings, consisting of bank loans to certain PMI subsidiaries at June 30, 2021 and December 31, 2020, had a carrying value of $136
million and $244 million, respectively. The fair values of PMI’s short-term borrowings, based on current market interest rates, approximate carrying value.
Long-term Debt:
At June 30, 2021 and December 31, 2020, PMI’s long-term debt consisted of the following:
(in millions) June 30, 2021 December 31, 2020
U.S. dollar notes, 0.875% to 6.375% (average interest rate 3.232%), due through 2044 $ 20,134 $ 21,221
Foreign currency obligations:
Euro notes, 0.125% to 3.125% (average interest rate 1.995%), due through 2039 8,082 9,253
Swiss franc notes, 1.625% to 2.000% (average interest rate 1.830%), due through
2024 597 622
Other (average interest rate 3.724%), due through 2025 209 196
Carrying value of long-term debt 29,022 31,292
Less current portion of long-term debt 1,608 3,124
$ 27,414 $ 28,168
Includes mortgage debt in Switzerland as well as $56 million and $37 million in finance leases at June 30, 2021 and December 31, 2020, respectively.
The fair value of PMI’s outstanding long-term debt, which is utilized solely for disclosure purposes, is determined using quotes and market interest rates
currently available to PMI for issuances of debt with similar terms and remaining maturities. At June 30, 2021, the fair value of PMI's outstanding long-
term debt, excluding the aforementioned finance leases, was as follows:
(in millions) June 30, 2021
Level 1 $ 31,789
Level 2 167
For a description of the fair value hierarchy and the three levels of inputs used to measure fair values, see Item 8, Note 2. Summary of Significant
Accounting Policies of PMI's Annual Report on Form 10-K for the year ended December 31, 2020.
Credit Facilities:
On January 29, 2021, PMI entered into an agreement to amend and extend the term of its 364-day revolving credit facility from February 2, 2021, to
February 1, 2022 in the amount of $1.75 billion.
(a)
(a)
39
-- 40 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
At June 30, 2021, PMI's total committed credit facilities were as follows:
(in billions)
Type
Committed
Credit
Facilities
364-day revolving credit, expiring February 1, 2022 $ 1.75
Multi-year revolving credit, expiring October 1, 2022 3.50
Multi-year revolving credit, expiring February 10, 2025 2.00
Total facilities $ 7.25
On January 29, 2021, PMI entered into an agreement, effective February 10, 2021, to amend and extend the term of its $2.0 billion multi-year revolving credit facility, for
an additional year covering the period February 11, 2025 to February 10, 2026, in the amount of $1.86 billion. Effective July 2, 2021, the total facility amount for this
additional year is $1.95 billion.
At June 30, 2021, there were no borrowings under these committed credit facilities, and the entire committed amounts were available for borrowing.
Note 11. Accumulated Other Comprehensive Losses:
PMI’s accumulated other comprehensive losses, net of taxes, consisted of the following:
(Losses) Earnings At At At
(in millions) June 30, 2021 December 31, 2020 June 30, 2020
Currency translation adjustments $ (6,586) $ (6,843) $ (6,311)
Pension and other benefits (4,073) (4,253) (3,680)
Derivatives accounted for as hedges (6) (85) (18)
Total accumulated other comprehensive losses $ (10,665) $ (11,181) $ (10,009)
Reclassifications from Other Comprehensive Earnings
The movements in accumulated other comprehensive losses and the related tax impact, for each of the components above, that are due to current period
activity and reclassifications to the income statement, are shown on the condensed consolidated statements of comprehensive earnings for the six months
and three months ended June 30, 2021 and 2020. For additional information, see Note 3. Benefit Plans for disclosures related to PMI's pension and other
benefits and Note 5. Financial Instruments for disclosures related to derivative financial instruments.
(a)
(a)
40
-- 41 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 12. Related Parties - Equity Investments and Other:
Equity Method Investments:
At June 30, 2021 and December 31, 2020, PMI had total equity method investments of $907 million and $966 million, respectively. Equity method
investments are initially recorded at cost. Under the equity method of accounting, the investment is adjusted for PMI's proportionate share of earnings or
losses, dividends, capital contributions, changes in ownership interests and movements in currency translation adjustments. The carrying value of our
equity method investments at June 30, 2021 and December 31, 2020 exceeded our share of the investees' book value by $773 million and $773 million,
respectively. The difference between the investment carrying value and the amount of underlying equity in net assets, excluding $742 million and $745
million attributable to goodwill as of June 30, 2021 and December 31, 2020, respectively, is being amortized on a straight-line basis over the underlying
assets' estimated useful lives of 10 to 20 years. At June 30, 2021 and December 31, 2020, PMI received year-to-date dividends from equity method
investees of $73 million and $79 million, respectively.
PMI holds a 23% equity interest in Megapolis Distribution BV, the holding company of CJSC TK Megapolis, PMI's distributor in Russia (Eastern Europe
segment).
PMI holds a 49% equity interest in United Arab Emirates-based Emirati Investors-TA (FZC) (“EITA”). PMI holds an approximate 25% economic interest
in Société des Tabacs Algéro-Emiratie (“STAEM”), an Algerian joint venture that is 51% owned by EITA and 49% by the Algerian state-owned enterprise
Management et Développement des Actifs et des Ressources Holding ("MADAR Holding"), which is part of the Middle East & Africa segment,
manufactures and distributes under license some of PMI’s brands.
The initial investments in Megapolis Distribution BV and EITA were recorded at cost and are included in equity investments on the condensed
consolidated balance sheets.
Equity securities:
Following the deconsolidation of RBH on March 22, 2019, PMI recorded the continuing investment in RBH, PMI's wholly owned subsidiary in Canada, at
fair value of $3,280 million at the date of deconsolidation, within equity investments. For further details, see Item 8, Note 20. Deconsolidation of RBH, in
PMI's Annual Report on Form 10-K for the year ended December 31, 2020. Transactions between PMI and RBH are considered to be related party
transactions from the date of deconsolidation and are included in the tables below.
The fair value of PMI’s other equity securities, which have been classified within Level 1, was $242 million at June 30, 2021. Unrealized pre-tax gain
(loss) was not material for the six months and three months ended June 30, 2021.
Other related parties:
United Arab Emirates-based Trans-Emirates Trading and Investments (FZC) ("TTI") holds a 33% non-controlling interest in Philip Morris Misr LLC
("PMM"), an entity incorporated in Egypt which is consolidated in PMI’s financial statements in the Middle East & Africa segment. PMM sells, under
license, PMI brands in Egypt through an exclusive distribution agreement with a local entity that is also controlled by TTI.
Godfrey Phillips India Ltd ("GPI") is one of the non-controlling interest holders in IPM India, which is a 56.3% owned PMI consolidated subsidiary in the
South & Southeast Asia segment. GPI also acts as contract manufacturer and distributor for IPM India. Amounts in the tables below include transactions
between these related parties.
41
-- 42 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Financial activity with the above related parties:
PMI’s net revenues and expenses with the above related parties were as follows:
For the Six Months Ended June 30, For the Three Months Ended June
30,
(in millions) 2021 2020 2021 2020
Net revenues:
Megapolis Group $ 1,038 $ 1,026 $ 555 $ 530
Other 560 523 280 242
Net revenues $ 1,598 $ 1,549 $ 835 $ 772
Expenses:
Other $ 33 $ 27 $ 16 $ 8
Expenses $ 33 $ 27 $ 16 $ 8
Net revenues exclude excise taxes and VAT billed to customers.
PMI’s balance sheet activity with the above related parties was as follows:
(in millions) At June 30, 2021 At December 31, 2020
Receivables:
Megapolis Group $ 521 $ 209
Other 282 156
Receivables $ 803 $ 365
Payables:
Other $ 14 $ 13
Payables $ 14 $ 13
The activities with the above related parties are in the ordinary course of business, and are primarily for distribution, service fees, contract manufacturing
and license agreements. PMI eliminated its respective share of all significant intercompany transactions with the equity method investees.
Note 13. Sale of Accounts Receivable:
To mitigate risk and enhance cash and liquidity management, PMI sells trade receivables to unaffiliated financial institutions. These arrangements allow
PMI to sell, on an ongoing basis, certain trade receivables without recourse. The trade receivables sold are generally short-term in nature and are removed
from the condensed consolidated balance sheets. PMI sells trade receivables under two types of arrangements, servicing and non-servicing. For servicing
arrangements, PMI continues to service the sold trade receivables on an administrative basis and does not act on behalf of the unaffiliated financial
institutions. When applicable, a servicing liability is recorded for the estimated fair value of the servicing. The amounts associated with the servicing
liability were not material as of June 30, 2021 and June 30, 2020. Under the non-servicing arrangements, PMI does not provide any administrative support
or servicing after the trade receivables have been sold to the unaffiliated financial institutions.
Cumulative trade receivables sold, including excise taxes, for the six months ended June 30, 2021 and 2020, were $5.5 billion. PMI’s operating cash flows
were positively impacted by the amount of the trade receivables sold and derecognized from the condensed consolidated balance sheets, which remained
outstanding with the unaffiliated financial institutions. The trade receivables sold that remained outstanding under these arrangements as of June 30, 2021
and June 30, 2020, were $0.7 billion, and $0.6 billion, respectively. The net proceeds received are included in cash provided by operating activities in the
condensed consolidated statements of cash flows. The difference between the carrying amount of the trade receivables sold and the sum of
(a)
(a)
42
-- 43 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
the cash received is recorded as a loss on sale of trade receivables within marketing, administration and research costs in the condensed consolidated
statements of earnings. For the six months and three months ended June 30, 2021 and 2020, the loss on sale of trade receivables was not material.
Note 14. Product Warranty:
PMI's heat-not-burn devices and e-vapor products are subject to standard product warranties generally for a period of 12 months from the date of purchase
or such other periods as required by law. PMI generally provides in cost of sales for the estimated cost of warranty in the period the related revenue is
recognized. PMI assesses the adequacy of its accrued product warranties and adjusts the amounts as necessary based on actual experience and changes in
future estimates. Factors that affect product warranties may vary across markets but typically include device version mix, product failure rates, logistics and
service delivery costs, and warranty policies. PMI accounts for its product warranties within other accrued liabilities. At June 30, 2021 and December 31,
2020, these amounts were as follows:
(in millions) At June 30, 2021 At December 31, 2020
Balance at beginning of period $ 137 $ 140
Changes due to:
Warranties issued 80 242
Settlements (99) (254)
Currency/Other — 9
Balance at end of period $ 118 $ 137
Note 15. Leases:
The components of PMI’s lease cost were as follows for the six months and three months ended June 30, 2021 and 2020:
For the Six Months Ended June 30, For the Three Months Ended June
30,
(in millions) 2021 2020 2021 2020
Operating lease cost $ 126 $ 117 $ 66 $ 57
Short-term lease cost 25 25 15 12
Variable lease cost 14 15 7 7
Total lease cost $ 165 $ 157 $ 88 $ 76
Note 16. Asset Impairment and Exit Costs:
For the six months and three months ended June 30, 2021, PMI recorded total pre-tax asset impairment and exit costs of $127 million and $79 million,
respectively. For the six months and three months ended June 30, 2020, PMI recorded total pre-tax asset impairment and exit costs of $71 million. The total
pre-tax asset impairment and exit costs were included in marketing, administration and research costs on the condensed consolidated statements of
earnings.
South Korea
In the first quarter of 2021, PM Korea commenced the implementation of a new business operating model, which requires the restructuring of its current
distribution agreements. As a result, PMI recorded exit costs of $26 million in the first quarter of 2021 related to contract terminations with certain
distributors; exit costs will continue to be recorded as the agreements are executed. There were no exit costs incurred in the second quarter of 2021 related
to this restructuring of distribution agreements in South Korea. The implementation of the new business operating model is expected to be completed in the
second half of 2021.
43
-- 44 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Organizational Design Optimization
As part of PMI’s transformation to a smoke-free future, PMI seeks to optimize its organizational design, which includes the elimination, relocation and
outsourcing of certain operations center and centralized activities. In January 2020, PMI commenced a multi-phase restructuring project in Switzerland.
PMI initiated the employee consultation procedures, as required under Swiss law, for the impacted employees. In 2020, the consultation procedures for two
phases were completed. Additional phases commenced during the first quarter of 2021. The consultation procedures for these phases were completed in
June 2021, impacting approximately 130 positions. Additionally, since the commencement of this multi-phase restructuring project in 2020, PMI launched
a voluntary separation program in Switzerland for certain eligible employees and announced the outsourcing of certain activities in Argentina, Indonesia,
Poland and the United States. This multi-phase restructuring project is expected to be completed in the second half of 2021 upon finalization of the
voluntary separation program in Switzerland.
For the six months and three months ended June 30, 2021, PMI recorded pre-tax charges of $101 million and $79 million, respectively, and for the six
months and three months ended June 30, 2020, PMI recorded pre-tax charges of $71 million, related to the organizational design optimization. Since
inception of this multi-phase restructuring project in 2020 through June 30, 2021, approximately 950 positions in total were impacted, resulting in
cumulative pre-tax charges of $250 million related to the organizational design optimization program. Of this cumulative pre-tax amount, $242 million
related to separation program charges and $8 million related to asset impairment charges.
The amounts related to the potential pension settlement accounting impact of the restructuring, which could be significant, have not been reflected in 2021
as the full-year thresholds for accounting were not expected to be exceeded as of June 30, 2021.
Asset Impairment and Exit Costs by Segment
PMI recorded the following pre-tax asset impairment and exit costs by segment:
(in millions) For the Six Months Ended June 30, For the Three Months Ended June
30,
2021 2020 2021 2020
Separation programs:
European Union $ 44 $ 24 $ 35 $ 24
Eastern Europe 9 6 7 6
Middle East & Africa 10 8 8 8
South & Southeast Asia 13 10 10 10
East Asia & Australia 20 12 15 12
Latin America & Canada 5 4 4 4
Total separation programs 101 64 79 64
Contract termination charges:
East Asia & Australia 26 — — —
Total contract termination charges 26 — — —
Asset impairment charges:
European Union — 3 — 3
Eastern Europe — 1 — 1
Middle East & Africa — 1 — 1
South & Southeast Asia — 1 — 1
East Asia & Australia — 1 — 1
Latin America & Canada — — — —
Total asset impairment charges — 7 — 7
Asset impairment and exit costs $ 127 $ 71 $ 79 $ 71
Organizational design optimization pre-tax charges in 2021 and 2020 were allocated across all operating segments.
(1)
(1)
(1)
44
-- 45 of 111 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Movement in Exit Cost Liabilities
The movement in exit cost liabilities for the six months ended June 30, 2021 was as follows:
(in millions)
Liability balance, January 1, 2021 $ 180
Charges, net 127
Cash spent (153)
Currency/other (6)
Liability balance, June 30, 2021 $ 148
Future cash payments for exit costs incurred to date are anticipated to be substantially paid by the end of 2022, with approximately $65 million expected to
be paid in the remainder of 2021.
Note 17. Acquisitions:
In May 2021, PMI acquired 100% of AG Snus Aktieselskab ("AG Snus"), a Danish based company, and its Swedish subsidiary Tobacco House of Sweden
AB fully owned by AG Snus, which operates in the oral tobacco (i.e. snus) and modern oral (i.e. nicotine pouches) product categories. The purchase price
was $27 million in cash, net of cash acquired, with additional contingent payments of up to $10 million, primarily relating to product development and
performance targets over a less than two-year period.
Note 18. Subsequent Event:
In July 2021, PMI deposited $1.5 billion of existing cash to a designated account. The account is operated solely for the purpose of funding the anticipated
transaction of Vectura Group plc (“Vectura”), a U.K. based company. On July 9, 2021, PMI announced that it agreed with the board of Vectura on the terms
of an all-cash, recommended offer to acquire Vectura for an enterprise value of GBP 852 million (approximately $1.2 billion, at the then-prevailing
exchange rate). PMI will fund the transaction with existing cash and expects it to close in the second half of 2021, subject to a shareholder vote and
approval by the appropriate regulatory authorities. This restricted cash of $1.5 billion (including a reserve for foreign exchange volatility) will be included
in other current assets in our consolidated balance sheets starting in July 2021 until the closing.
45
-- 46 of 111 --
Table of Contents
Item 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Description of Our Company
We are leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the
benefit of adults who would otherwise continue to smoke, society, the company, its shareholders and its other stakeholders. We are a leading international
tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and
other nicotine-containing products in markets outside the United States. In addition, we ship versions of our Platform 1 device and consumables to Altria
Group, Inc. for sale under license in the United States, where these products have received marketing authorizations from the U.S. Food and Drug
Administration ("FDA") under the premarket tobacco product application ("PMTA") pathway; the FDA has also authorized the marketing of a version of
our Platform 1 device and its consumables as a Modified Risk Tobacco Product ("MRTP"), finding that an exposure modification order for these products
is appropriate to promote the public health. We are building a future on a new category of smoke-free products that, while not risk-free, are a much better
choice than continuing to smoke. We describe the PMTA and MRTP orders in more detail in the "Business Environment" section of this Item 2. Through
multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, we aim to ensure that our smoke-free products
meet adult consumer preferences and rigorous regulatory requirements. Our smoke-free product portfolio includes heat-not-burn and nicotine-containing
vapor products.
We manage our business in six operating segments:
• European Union ("EU");
• Eastern Europe ("EE");
• Middle East & Africa ("ME&A"), which includes our international duty free business;
• South & Southeast Asia ("S&SA");
• East Asia & Australia ("EA&A"); and
• Latin America & Canada ("LA&C"), which includes transactions under license with Altria Group, Inc. for the distribution of our Platform 1
product in the United States.
In July 2021, our Latin America & Canada operating segment was renamed as the Americas operating segment.
Our cigarettes are sold in more than 175 markets, and in many of these markets they hold the number one or number two market share position. We have a
wide range of premium, mid-price and low-price brands. Our portfolio comprises both international and local brands. In addition to the manufacture and
sale of cigarettes, we are engaged in the development and commercialization of reduced-risk products ("RRPs"). RRPs is the term we use to refer to
products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing
smoking.
We use the term net revenues to refer to our operating revenues from the sale of our products, including shipping and handling charges billed to customers,
net of sales and promotion incentives, and excise taxes. Our net revenues and operating income are affected by various factors, including the volume of
products we sell, the price of our products, changes in currency exchange rates and the mix of products we sell. Mix is a term used to refer to the
proportionate value of premium-price brands to mid-price or low-price brands in any given market (product mix). Mix can also refer to the proportion of
shipment volume in more profitable markets versus shipment volume in less profitable markets (geographic mix).
Our cost of sales consists principally of: tobacco leaf, non-tobacco raw materials, labor and manufacturing costs; shipping and handling costs; and the cost
of devices produced by third-party electronics manufacturing service providers. Estimated costs associated with device warranty programs are generally
provided for in cost of sales in the period the related revenues are recognized.
Our marketing, administration and research costs include the costs of marketing and selling our products, other costs generally not related to the
manufacture of our products (including general corporate expenses), and costs incurred to develop new products. The most significant components of our
marketing, administration and research costs are marketing and sales expenses and general and administrative expenses.
46
-- 47 of 111 --
Table of Contents
Philip Morris International Inc. is a legal entity separate and distinct from its direct and indirect subsidiaries. Accordingly, our right, and thus the right of
our creditors and stockholders, to participate in any distribution of the assets or earnings of any subsidiary is subject to the prior rights of creditors of such
subsidiary, except to the extent that claims of our company itself as a creditor may be recognized. As a holding company, our principal sources of funds,
including funds to make payment on our debt securities, are from the receipt of dividends and repayment of debt from our subsidiaries. Our principal
wholly owned and majority-owned subsidiaries currently are not limited by long-term debt or other agreements in their ability to pay cash dividends or to
make other distributions that are otherwise compliant with law.
Executive Summary
The following executive summary provides the business update and significant highlights from the "Discussion and Analysis" that follows.
Consolidated Operating Results for the Six Months Ended June 30, 2021
• Net Revenues - Net revenues of $15.2 billion for the six months ended June 30, 2021 increased by $1.4 billion, or 10.0%, from the comparable 2020
amount. The change in our net revenues from the comparable 2020 amount was driven by the following (variances not to scale with year-to-date
results):
For the six months ended June 30, 2021, net revenues, excluding favorable currency, increased by 5.3%, reflecting: favorable volume/mix, primarily
driven by higher heated tobacco unit volume (notably in the EU, particularly Germany, Italy and Poland, as well as Japan, Russia and Ukraine), partly
offset by lower cigarette volume (mainly in the EU Region, notably Germany, as well as Japan, Kuwait, North Africa, the Philippines and PMI Duty
Free, partially offset by Indonesia and Turkey); and a favorable pricing variance (notably driven by Germany, Japan, North Africa, the Philippines,
Russia and Turkey, partly offset by Indonesia and Poland); partially offset by the unfavorable impact of the Saudi Arabia customs assessments of $246
million, shown in "Other" and further described in the following "Diluted Earnings Per Share" discussion.
This net revenue growth reflects both the recovery of the combustible business in many markets compared to the disrupted second quarter of 2020 due
to the effects of the COVID-19 pandemic, and the continued strength of IQOS, which resulted in growth of our RRP net revenues.
47
-- 48 of 111 --
Table of Contents
Net revenues by product category for the six months ended June 30, 2021 and 2020 are shown below:
• Diluted Earnings Per Share - The changes in our reported diluted earnings per share (“diluted EPS”) for the six months ended June 30, 2021, from
the comparable 2020 amounts, were as follows:
Diluted EPS % Growth
For the six months ended June 30, 2020 $ 2.42
2020 Asset impairment and exit costs 0.04
2020 Fair value adjustment for equity security investments 0.04
2020 Tax items —
Subtotal of 2020 items 0.08
2021 Asset impairment and exit costs (0.07)
2021 Saudi Arabia customs assessments (0.14)
2021 Tax items —
Subtotal of 2021 items (0.21)
Currency 0.15
Interest (0.01)
Change in tax rate 0.03
Operations 0.47
For the six months ended June 30, 2021 $ 2.93 21.1 %
Asset impairment and exit costs – During the six months ended June 30, 2021, we recorded pre-tax asset impairment and exit costs of $127 million,
representing $105 million net of income tax and a diluted EPS charge of $0.07 per share, related to the organizational design optimization plan, primarily in
Switzerland, and the product distribution restructuring in South Korea. During the six months ended June 30, 2020, we recorded pre-tax asset impairment
and exit costs of $71 million, representing $57 million net of income tax and a diluted EPS charge of $0.04, related to the organizational design
optimization plan, primarily in Switzerland. The total pre-tax charges were included in marketing, administration and research costs on the condensed
consolidated statements of earnings. For further details, see Note 16. Asset Impairment and Exit Costs.
Fair Value adjustment for equity security investments – During the six months ended June 30, 2020, we recorded an unfavorable fair value adjustment for
our equity security investments of $62 million after tax (or $0.04 per share decrease in diluted EPS). The fair value adjustment for our equity security
investments was included in equity investments and securities (income)/loss, net ($78 million loss) and provision for income taxes ($16 million benefit) on
the condensed consolidated statements of earnings.
48
-- 49 of 111 --
Table of Contents
Saudi Arabia customs assessments – In June 2021, the Customs Appeal Committee in Riyadh notified our distributors in Saudi Arabia of its decisions to
largely reject their challenges of the Saudi Arabia Customs General Authority assessments as described in Note 8. Contingencies. On the basis of these
decisions and in line with arrangements with the distributors, we recorded a pre-tax charge of $246 million in the second quarter of 2021 (representing
$215 million net of income tax and a diluted EPS charge of $0.14 per share). The pre-tax charge was recorded as a reduction of net revenues on the
condensed consolidated statement of earnings and was included in the Middle East & Africa segment results.
Currency – The favorable impact of $0.15 per share during the reporting period results from the fluctuations of the U.S. dollar, especially against the Euro
and Japanese yen. This favorable currency movement has impacted our profitability across our primary revenue markets and local currency cost bases.
Income taxes – The change in the tax rate that increased our diluted EPS by $0.03 per share in the table above was primarily due to the corporate income
tax rate reduction in the Philippines (enacted in the first quarter of 2021), as well as changes in earnings mix by taxing jurisdiction.
Operations – The increase in diluted EPS of $0.47 from our operations in the table above was due primarily to the following segments:
• European Union: Favorable volume/mix, lower manufacturing costs and favorable pricing, partially offset by higher marketing, administration and
research costs;
• East Asia & Australia: Favorable pricing, lower manufacturing costs and favorable volume/mix, partially offset by higher marketing, administration
and research costs;
• Eastern Europe: Favorable volume/mix, lower manufacturing costs, favorable pricing and lower marketing, administration and research costs;
• Middle East & Africa: Favorable pricing and lower manufacturing costs, partially offset by unfavorable volume/mix; and
• Latin America & Canada: Lower marketing, administration and research costs and favorable pricing;
partially offset by
• South & Southeast Asia: Unfavorable volume/mix and unfavorable pricing.
Consolidated Operating Results for the Three Months Ended June 30, 2021
• Net Revenues - Net revenues of $7.6 billion for the three months ended June 30, 2021 increased by $0.9 billion, or 14.2%, from the comparable 2020
amount. The change in our net revenues from the comparable 2020 amount was driven by the following (variances not to scale with quarterly results):
During the quarter, net revenues, excluding favorable currency, increased by 7.9%, mainly reflecting: favorable volume/mix, primarily driven by
higher heated tobacco unit volume (notably in the EU, particularly Italy and Poland, as well as Japan, Russia and Ukraine) and higher cigarette volume
(mainly in Indonesia, Italy, PMI Duty Free and Spain, partly offset by the GCC, Germany, Japan and the Philippines); and a favorable pricing variance
(notably driven by Germany, Japan,
49
-- 50 of 111 --
Table of Contents
the Philippines, Russia and Turkey, partly offset by Indonesia); partly offset by the unfavorable impact of the Saudi Arabia customs assessments of
$246 million, shown in "Other".
This net revenue growth reflects both the recovery of the combustible business in many markets compared to the disrupted second quarter of 2020 due
to the effects of the COVID-19 pandemic, and the continued strength of IQOS, which resulted in growth of our RRP net revenues.
Net revenues by product category for the three months ended June 30, 2021 and 2020, are shown below:
• Diluted Earnings Per Share - The changes in our reported diluted EPS for the three months ended June 30, 2021, from the comparable 2020 amounts,
were as follows:
Diluted EPS % Growth
For the three months ended June 30, 2020 $ 1.25
2020 Asset impairment and exit costs 0.04
2020 Fair value adjustment for equity security investments —
2020 Tax items —
Subtotal of 2020 items 0.04
2021 Asset impairment and exit costs (0.04)
2021 Saudi Arabia customs assessments (0.14)
2021 Tax items —
Subtotal of 2021 items (0.18)
Currency 0.05
Interest —
Change in tax rate (0.01)
Operations 0.24
For the three months ended June 30, 2021 $ 1.39 11.2 %
Asset impairment and exit costs – In the second quarter of 2021, we recorded pre-tax asset impairment and exit costs of $79 million, representing $67
million net of income tax and a diluted EPS charge of $0.04 per share, related to the organizational design optimization plan, primarily in Switzerland. In
the second quarter of 2020, we recorded pre-tax asset impairment and exit costs of $71 million, representing $57 million net of income tax and a diluted
EPS charge of $0.04 per share, related to the organizational design optimization plan, primarily in Switzerland. The total pre-tax charge was included in
marketing,
50
-- 51 of 111 --
Table of Contents
administration and research costs on the condensed consolidated statements of earnings. For further details, see Note 16. Asset Impairment and Exit Costs.
Saudi Arabia customs assessments – In June 2021, the Customs Appeal Committee in Riyadh notified our distributors in Saudi Arabia of its decisions to
largely reject their challenges of the Saudi Arabia Customs General Authority assessments as described in Note 8. Contingencies. On the basis of these
decisions and in line with arrangements with the distributors, we recorded a pre-tax charge of $246 million in the second quarter of 2021 (representing
$215 million net of income tax and a diluted EPS charge of $0.14 per share). The pre-tax charge was recorded as a reduction of net revenues on the
condensed consolidated statement of earnings and was included in the Middle East & Africa segment results.
Currency – The favorable impact of $0.05 per share during the reporting period results from the fluctuations of the U.S. dollar, especially against the Euro.
This favorable currency movement has impacted our profitability across our primary revenue markets and local currency cost bases.
Income Taxes – The change in the tax rate that decreased our diluted EPS by $0.01 per share in the table above was primarily due to the corporate income
tax rate reduction in Indonesia (enacted in the second quarter of 2020).
Operations – The increase in diluted EPS of $0.24 from our operations in the table above was due primarily to the following segments:
• European Union: Favorable volume/mix, lower manufacturing costs and favorable pricing, partially offset by higher marketing, administration and
research costs;
• Eastern Europe: Favorable volume/mix, favorable pricing and lower manufacturing costs;
• Middle East & Africa: Favorable volume/mix and favorable pricing, partially offset by lower fees for certain distribution rights and higher marketing,
administration and research costs;
• East Asia & Australia: Favorable pricing and lower manufacturing costs, partially offset by higher marketing, administration and research costs and
unfavorable volume/mix;
• South & Southeast Asia: Favorable volume/mix and favorable pricing, partially offset by higher marketing, administration and research costs; and
• Latin America & Canada: Favorable pricing and favorable volume/mix.
For further details, see the “Consolidated Operating Results” and “Operating Results by Business Segment” sections of the following “Discussion and
Analysis.”
COVID-19 Impact on Our Business
COVID-19: Business Continuity Update
Since the onset of the COVID-19 pandemic, PMI has undertaken a number of business continuity measures to mitigate potential disruption to its
operations and route-to-market in order to preserve the availability of products to its customers and adult consumers.
Currently:
• PMI has sufficient access to the inputs for its products and is not facing any significant business continuity issues with respect to key suppliers;
• All of PMI's cigarette and heated tobacco unit manufacturing facilities globally are operational;
• COVID-related restrictions do not have a significant impact on the availability of PMI's products to its customers and adult consumers; and
• PMI has sufficient liquidity resources through cash on hand, the ongoing cash generation of its business, and its access to the commercial paper and
debt markets.
Nonetheless, significant uncertainty remains as the spread of the disease is increasing in a number of markets, resulting in additional restrictions and
increasing risk of disruptions.
51
-- 52 of 111 --
Table of Contents
Discussion and Analysis
Consolidated Operating Results
See pages 91-99 for a discussion of our "Cautionary Factors That May Affect Future Results." Our net revenues and operating income by segment are
shown in the table below:
(in millions) For the Six Months Ended June 30, For the Three Months Ended June
30,
2021 2020 2021 2020
Net revenues:
European Union $ 6,058 $ 5,010 $ 3,149 $ 2,475
Eastern Europe 1,691 1,571 895 783
Middle East & Africa 1,361 1,580 560 704
South & Southeast Asia 2,219 2,140 1,046 889
East Asia & Australia 2,986 2,687 1,514 1,432
Latin America & Canada 864 816 430 368
Net revenues $ 15,179 $ 13,804 $ 7,594 $ 6,651
Operating income:
European Union $ 3,131 $ 2,336 $ 1,641 $ 1,178
Eastern Europe 575 365 314 266
Middle East & Africa 351 558 16 237
South & Southeast Asia 860 888 331 289
East Asia & Australia 1,410 1,155 715 669
Latin America & Canada 246 218 112 92
Operating income $ 6,573 $ 5,520 $ 3,129 $ 2,731
52
-- 53 of 111 --
Table of Contents
Our net revenues by product category are shown in the table below:
PMI Net Revenues by Product Category
(in millions) For the Six Months Ended June 30, For the Three Months Ended June 30,
2021 2020 Change 2021 2020 Change
Combustible Products
European Union $ 4,113 $ 3,855 6.7 % $ 2,162 $ 1,945 11.2 %
Eastern Europe 1,047 1,045 0.1 % 555 522 6.2 %
Middle East & Africa 1,307 1,528 (14.5)% 527 696 (24.2)%
South & Southeast Asia 2,216 2,140 3.5 % 1,045 889 17.5 %
East Asia & Australia 1,259 1,272 (1.0)% 611 630 (3.0)%
Latin America & Canada 840 803 4.6 % 418 363 15.3 %
Total Combustible Products $ 10,781 $ 10,643 1.3 % $ 5,318 $ 5,045 5.4 %
Reduced-Risk Products
European Union $ 1,945 $ 1,155 68.5 % $ 987 $ 530 86.2 %
Eastern Europe 644 526 22.6 % 340 261 30.5 %
Middle East & Africa 54 52 4.0 % 33 8 +100%
South & Southeast Asia 3 — — % 1 — — %
East Asia & Australia 1,727 1,415 22.0 % 903 802 12.6 %
Latin America & Canada 24 13 79.5 % 12 5 +100%
Total Reduced-Risk Products $ 4,398 $ 3,161 39.1 % $ 2,276 $ 1,606 41.7 %
Total PMI Net Revenues $ 15,179 $ 13,804 10.0 % $ 7,594 $ 6,651 14.2 %
Note: Sum of product categories or Regions might not foot to total PMI due to roundings.
Items affecting the comparability of results from operations were as follows:
• Asset impairment and exit costs – See Note 16. Asset Impairment and Exit Costs for a breakdown of these costs by segment for the six months and
three months ended June 30, 2021 and 2020.
• Saudi Arabia customs assessments – See Note 8. Contingencies for the details of the $246 million reduction in net revenues of combustible products
included in the Middle East & Africa segment for the six months and three months ended June 30, 2021.
Net revenues related to combustible products refer to the operating revenues generated from the sale of these products, including shipping and handling
charges billed to customers, net of sales and promotion incentives, and excise taxes. These net revenue amounts consist of the sale of our cigarettes and
other tobacco products combined. Other tobacco products primarily include roll-your-own and make-your-own cigarettes, pipe tobacco, cigars and
cigarillos and do not include reduced-risk products.
Net revenues related to reduced-risk products refer to the operating revenues generated from the sale of these products, including shipping and handling
charges billed to customers, net of sales and promotion incentives, and excise taxes. These net revenue amounts consist of the sale of our heated tobacco
units, heat-not-burn devices and related accessories, and other nicotine-containing products, which primarily include our e-vapor products.
PMI's heat-not-burn products include licensed KT&G heat-not-burn products.
Revenues from shipments of Platform 1 devices, heated tobacco units and accessories to Altria Group, Inc., commencing in the third quarter of 2019, for
sale under license in the United States, are included in Net Revenues of the Latin America & Canada segment.
53
-- 54 of 111 --
Table of Contents
References to "Cost/Other" in the Consolidated Financial Summary table of total PMI and the six operating segments throughout this "Discussion and
Analysis" reflects the currency-neutral variances of: cost of sales (excluding the volume/mix cost component); marketing, administration and research costs
(including asset impairment and exit costs); and amortization of intangibles. “Cost/Other” also includes the currency-neutral net revenue variance,
unrelated to volume/mix and price components, attributable to: fees for certain distribution rights billed to customers in certain markets in the ME&A
Region and the Saudi Arabia customs assessment net revenue adjustment.
Our shipment volume by segment for cigarettes and heated tobacco units is shown in the table below:
PMI Shipment Volume (Million Units)
For the Six Months Ended June 30, For the Three Months Ended June 30,
2021 2020 Change 2021 2020 Change
Cigarettes
European Union 78,273 80,963 (3.3)% 41,504 40,317 2.9 %
Eastern Europe 42,751 45,076 (5.2)% 22,785 23,657 (3.7)%
Middle East & Africa 57,989 57,184 1.4 % 30,347 27,188 11.6 %
South & Southeast Asia 70,209 70,941 (1.0)% 35,321 33,346 5.9 %
East Asia & Australia 22,330 24,370 (8.4)% 10,968 12,071 (9.1)%
Latin America & Canada 30,098 29,843 0.9 % 15,213 14,780 2.9 %
Total Cigarettes 301,650 308,377 (2.2)% 156,138 151,359 3.2 %
Heated Tobacco Units
European Union 13,347 8,888 50.2 % 6,921 4,227 63.7 %
Eastern Europe 12,475 9,492 31.4 % 6,840 5,126 33.4 %
Middle East & Africa 908 655 38.6 % 512 185 +100%
South & Southeast Asia 72 — — % 39 — — %
East Asia & Australia 19,043 16,198 17.6 % 9,904 9,076 9.1 %
Latin America & Canada 245 202 21.3 % 140 94 48.9 %
Total Heated Tobacco Units 46,090 35,435 30.1 % 24,356 18,708 30.2 %
Cigarettes and Heated Tobacco Units
European Union 91,620 89,851 2.0 % 48,425 44,544 8.7 %
Eastern Europe 55,226 54,568 1.2 % 29,625 28,783 2.9 %
Middle East & Africa 58,897 57,839 1.8 % 30,859 27,373 12.7 %
South & Southeast Asia 70,281 70,941 (0.9)% 35,360 33,346 6.0 %
East Asia & Australia 41,373 40,568 2.0 % 20,872 21,147 (1.3)%
Latin America & Canada 30,343 30,045 1.0 % 15,353 14,874 3.2 %
Total Cigarettes and Heated Tobacco Units 347,740 343,812 1.1 % 180,494 170,067 6.1 %
Heated tobacco units ("HTU") is the term we use to refer to heated tobacco consumables, which include our HEETS, HEETS Creations, HEETS
Dimensions, HEETS Marlboro and HEETS FROM MARLBORO (defined collectively as HEETS), Marlboro Dimensions, Marlboro HeatSticks and
Parliament HeatSticks, as well as the KT&G-licensed brands, Fiit and Miix (outside of South Korea).
Market share for HTUs is defined as the total sales volume for HTUs as a percentage of the total estimated sales volume for cigarettes and HTUs.
Shipment volume of heated tobacco units to the United States is included in the heated tobacco unit shipment volume of the Latin America & Canada
segment.
54
-- 55 of 111 --
Table of Contents
References to total international market, defined as worldwide cigarette and heated tobacco unit volume excluding the United States, total industry, total
market and market shares throughout this "Discussion and Analysis" are our estimates for tax-paid products based on the latest available data from a
number of internal and external sources and may, in defined instances, exclude the People's Republic of China and/or our duty free business.
2020 and 2021 estimates for total industry volume and market share in certain geographies reflect limitations on the availability and accuracy of industry
data during pandemic-related restrictions.
In-market sales ("IMS") is defined as sales to the retail channel, depending on the market and distribution model.
North Africa is defined as Algeria, Egypt, Libya, Morocco and Tunisia.
The Gulf Cooperation Council ("GCC") is defined as Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and the United Arab Emirates (UAE).
References to total industry, total market, our shipment volume and our market share performance reflect cigarettes and heated tobacco units, unless
otherwise stated,
From time to time, PMI’s shipment volumes are subject to the impact of distributor inventory movements, and estimated total industry/market volumes are
subject to the impact of inventory movements in various trade channels that include estimated trade inventory movements of PMI’s competitors arising
from market-specific factors that significantly distort reported volume disclosures. Such factors may include changes to the manufacturing supply chain,
shipment methods, consumer demand, timing of excise tax increases or other influences that may affect the timing of sales to customers. In such instances,
in addition to reviewing PMI shipment volumes and certain estimated total industry/market volumes on a reported basis, management reviews these
measures on an adjusted basis that excludes the impact of distributor and/or estimated trade inventory movements. Management also believes that
disclosing PMI shipment volumes and estimated total industry/market volumes in such circumstances on a basis that excludes the impact of distributor
and/or estimated trade inventory movements improves the comparability of performance and trends for these measures over different reporting periods.
55
-- 56 of 111 --
Table of Contents
Key market data regarding total market size, our shipments and market share are shown in the tables below:
For the Six Months Ended June 30,
PMI Shipments (billion units) PMI Market Share (%)
Market Total Market
(billion units) Total Cigarette Heated Tobacco
Unit Total Heated Tobacco
Unit
2021 2020 2021 2020 2021 2020 2021 2020 2021 2020 2021 2020
Total 1,265.1 1,222.6 347.7 343.8 301.7 308.4 46.1 35.4 27.0 27.8 3.5 2.9
European Union
France 17.3 18.2 7.9 8.5 7.8 8.4 0.1 0.1 43.6 44.7 0.6 0.4
Germany 36.0 36.0 14.3 14.5 13.2 13.7 1.1 0.8 39.8 40.4 3.1 2.2
Italy 33.8 32.0 19.5 17.1 15.1 14.6 4.4 2.5 52.9 52.0 11.2 7.5
Poland 23.2 21.5 8.6 8.5 7.3 7.6 1.4 0.9 37.1 39.7 5.9 4.3
Spain 20.1 20.0 6.8 6.4 6.6 6.2 0.2 0.2 31.1 31.1 1.2 1.0
Eastern Europe
Russia 104.2 103.6 33.3 32.9 25.4 26.7 7.9 6.2 31.3 32.6 7.5 6.2
Middle East & Africa
Saudi Arabia 10.7 10.3 4.2 3.8 4.1 3.8 0.1 — 41.8 39.4 0.8 0.1
Turkey 55.8 54.3 24.5 21.8 24.5 21.8 — — 43.9 40.1 — —
South & Southeast Asia
Indonesia 142.7 131.3 40.0 38.5 40.0 38.5 — — 28.0 29.3 — —
Philippines 26.9 29.5 16.7 20.5 16.7 20.5 0.1 — 62.2 69.3 0.3 —
East Asia & Australia
Australia 4.8 5.1 1.5 1.5 1.5 1.5 — — 31.8 29.4 — —
Japan 67.6 70.6 28.0 26.9 11.4 13.1 16.5 13.8 38.7 36.6 23.0 19.7
South Korea 34.9 34.6 7.0 7.4 4.7 5.1 2.3 2.3 20.0 21.4 6.6 6.6
Latin America & Canada
Argentina 17.5 15.7 9.8 10.0 9.8 10.0 — — 56.0 64.0 — —
Mexico 14.8 14.2 9.1 8.8 9.1 8.7 — — 61.4 61.6 0.3 0.2
(1) Market share estimates are calculated using IMS data
Note: % change for Total Market and PMI shipments is computed based on millions of units. "-" indicates volume below 50 million units and market share below 0.1%
(1)
56
-- 57 of 111 --
Table of Contents
For the Three Months Ended June 30,
PMI Shipments (billion units) PMI Market Share (%)
Market Total Market
(billion units) Total Cigarette Heated Tobacco
Unit Total Heated Tobacco
Unit
2021 2020 2021 2020 2021 2020 2021 2020 2021 2020 2021 2020
Total 649.9 607.4 180.5 170.1 156.1 151.4 24.4 18.7 27.3 28.1 3.5 3.0
European Union
France 9.1 9.8 4.1 4.5 4.1 4.4 — — 43.5 44.9 0.6 0.5
Germany 18.6 20.0 7.2 7.8 6.7 7.4 0.5 0.4 38.8 38.9 2.7 2.0
Italy 17.9 16.3 9.9 7.9 7.7 6.8 2.2 1.1 53.1 52.1 11.2 7.7
Poland 12.5 10.6 4.7 4.2 3.9 3.7 0.8 0.5 37.5 39.3 6.3 4.4
Spain 10.5 9.6 4.1 2.7 4.0 2.7 0.1 0.1 31.1 31.3 1.2 1.0
Eastern Europe
Russia 55.1 56.7 17.6 17.9 13.3 14.3 4.3 3.6 31.6 32.7 7.3 6.0
Middle East & Africa
Saudi Arabia 5.3 6.0 2.0 2.7 1.9 2.7 0.1 — 41.5 38.6 0.9 0.2
Turkey 30.5 28.3 13.5 11.7 13.5 11.7 — — 44.3 41.1 — —
South & Southeast Asia
Indonesia 71.7 63.8 20.1 18.0 20.1 18.0 — — 28.1 28.3 — —
Philippines 13.8 14.2 8.6 9.7 8.5 9.7 — — 62.0 68.4 0.3 —
East Asia & Australia
Australia 2.4 2.6 0.7 0.8 0.7 0.8 — — 30.8 30.8 — —
Japan 35.0 35.1 14.2 14.1 5.5 6.3 8.6 7.8 38.3 36.8 22.7 20.2
South Korea 18.1 18.4 3.6 3.8 2.4 2.6 1.2 1.2 20.0 21.1 6.5 6.6
Latin America & Canada
Argentina 8.1 7.7 4.5 4.8 4.5 4.8 — — 56.2 62.0 — —
Mexico 8.0 7.6 5.1 4.7 5.0 4.7 — — 63.0 62.1 0.3 0.2
(1) Market share estimates are calculated using IMS data
Note: % change for Total Market and PMI shipments is computed based on millions of units. "-" indicates volume below 50 million units and market share below 0.1%
Consolidated Operating Results for the Six Months Ended June 30, 2021
The following discussion compares our consolidated operating results for the six months ended June 30, 2021, with the six months ended June 30, 2020.
Our total shipment volume increased by 1.1%, driven by:
• the EU, reflecting higher heated tobacco unit shipment volume across the Region, particularly in Italy and Poland, partly offset by lower cigarette
shipment volume, notably in the Czech Republic, France and Germany, partly offset by Italy and Spain;
• Eastern Europe, reflecting higher heated tobacco unit shipment volume, notably in Russia and Ukraine, partly offset by lower cigarette shipment
volume, mainly in Russia and Ukraine;
• Middle East & Africa, reflecting higher cigarette shipment volume (primarily in Turkey, partly offset by the GCC, North Africa and PMI Duty Free),
as well as higher heated tobacco unit shipment volume (driven notably by the GCC and Lebanon, partly offset by PMI Duty Free);
• East Asia & Australia, reflecting higher heated tobacco unit shipment volume driven by Japan, partly offset by lower cigarette shipment volume,
predominantly in Japan and South Korea; and
(1)
57
-- 58 of 111 --
Table of Contents
• Latin America & Canada, reflecting higher cigarette shipment volume, primarily in Brazil and Mexico, partially offset by Argentina;
partly offset by
• South & Southeast Asia, reflecting lower cigarette shipment volume, primarily in the Philippines, partially offset by Indonesia, Pakistan and Thailand.
Impact of Inventory Movements
The net impact of estimated distributor inventory movements for the first half of the year was immaterial to our total shipment volume performance. Our
total in-market sales volume increased by 0.5%.
Our cigarette shipment volume by brand and heated tobacco units shipment volume are shown in the table below:
PMI Shipment Volume by Brand (Million Units)
Six Months Year-to-Date
2021 2020 Change
Cigarettes
Marlboro 112,148 114,057 (1.7) %
L&M 42,464 45,025 (5.7) %
Chesterfield 27,027 25,507 6.0 %
Philip Morris 20,774 22,569 (7.9) %
Parliament 18,980 16,035 18.4 %
Sampoerna A 17,884 15,802 13.2 %
Dji Sam Soe 11,126 11,972 (7.1) %
Bond Street 9,158 12,041 (23.9) %
Lark 7,781 8,213 (5.3) %
Sampoerna Hijau 4,228 3,043 38.9 %
Others 30,080 34,113 (11.8) %
Total Cigarettes 301,650 308,377 (2.2)%
Heated Tobacco Units 46,090 35,435 30.1 %
Total Cigarettes and Heated Tobacco Units 347,740 343,812 1.1 %
Note: Sampoerna A includes Sampoerna; Philip Morris includes Philip Morris/Dubliss; and Lark includes Lark Harmony.
Our cigarette shipment volume of the following brands increased:
• Chesterfield, mainly due to Brazil, the Philippines and Russia, partly offset by Saudi Arabia;
• Parliament, primarily due to Russia, Saudi Arabia and Turkey, partly offset by Japan;
• Sampoerna A in Indonesia, mainly due to premium A Mild; and
• Sampoerna Hijau in Indonesia.
Our cigarette shipment volume of the following brands decreased:
• Marlboro, mainly due to France, Japan, Kuwait, the Philippines and PMI Duty Free, partly offset by Mexico and Turkey;
• L&M, notably due to Egypt, Germany, Poland and Turkey, partly offset by Spain and Thailand;
• Philip Morris, primarily due to Indonesia, Italy and Russia, partly offset by Japan;
• Dji Sam Soe in Indonesia, mainly due to Dji Sam Soe Magnum Mild;
• Bond Street, mainly due to Russia and Ukraine;
58
-- 59 of 111 --
Table of Contents
• Lark, primarily due to Japan; and
• "Others," notably due to: mid-price Fortune (Philippines), Hope (Philippines) and Sampoerna U (Indonesia); and low-price Jackpot (Philippines);
partly offset by low-price Diana (Italy) and Morven (Pakistan).
The increase in our heated tobacco unit shipment volume was mainly driven by the EU (notably Italy), Eastern Europe (notably Russia and Ukraine) and
Japan.
International Share of Market (excluding China and the United States)
Our total international market share (excluding China and the United States), defined as our cigarette and heated tobacco unit sales volume as a percentage
of total industry cigarette and heated tobacco unit sales volume, decreased by 0.8 points to 27.0%, reflecting:
• Total international market share for cigarettes of 23.5%, down by 1.4 points; and
• Total international market share for heated tobacco units of 3.5%, up by 0.6 points.
Our total international cigarette sales volume as a percentage of total industry cigarette sales volume was down by 1.2 points to 24.6%, mainly reflecting
lower cigarette market share and/or an unfavorable geographic mix impact, notably in Japan, the Philippines and Russia, partly offset by Turkey.
Financial Summary
Financial Summary -
Six Months Ended June 30,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2021 2020 Total Excl.
Curr. Total Cur-
rency Price Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 15,179 $ 13,804 10.0 % 5.3 % $ 1,375 $ 645 $ 432 $ 544 $ (246)
Cost of Sales (4,627) (4,581) (1.0)% 3.8 % (46) (220) — (118) 292
Marketing, Administration and Research
Costs (3,942) (3,666) (7.5)% (4.5)% (276) (110) — — (166)
Amortization of Intangibles (37) (37) — % 2.7 % — (1) — — 1
Operating Income $ 6,573 $ 5,520 19.1 % 13.4 % $ 1,053 $ 314 $ 432 $ 426 $ (119)
Cost/Other variance includes a $246 million reduction in net revenues in 2021 related to the Saudi Arabia customs assessments. For more details, see Note 8.
Contingencies.
Cost/Other variance includes charges in 2021 and 2020 of $127 million and $71 million, respectively, for asset impairment and exit costs.
For the six months ended June 30, 2021, net revenues, excluding favorable currency, increased by 5.3%, mainly reflecting: favorable volume/mix,
primarily driven by higher heated tobacco unit volume (notably in the EU, particularly Germany, Italy and Poland, as well as Japan, Russia and Ukraine),
partly offset by lower cigarette volume (mainly in the EU Region, notably Germany, as well as Japan, Kuwait, North Africa, the Philippines and PMI Duty
Free, partially offset by Indonesia and Turkey); and a favorable pricing variance (notably driven by Germany, Japan, North Africa, the Philippines, Russia
and Turkey, partly offset by Indonesia and Poland); partially offset by the unfavorable impact of the Saudi Arabia customs assessments of $246 million,
shown in "Cost/Other". Excluding the unfavorable impact of the Saudi Arabia customs assessments of $246 million, net revenues increased by 11.7%, or
7.1% excluding favorable currency of $645 million.
The favorable currency in net revenues was due primarily to the Euro, Indonesian rupiah, Japanese yen and Philippine peso, partially offset by the Russian
ruble and Turkish lira.
Net revenues include $4.4 billion in 2021 and $3.2 billion in 2020 related to the sale of RRPs. IQOS devices accounted for approximately 5% of RRP net
revenues for the six months ended June 30, 2021, reflecting longer replacement times and fewer second device purchases for existing users due to
improving battery lives, functionality and reliability; and lower device prices in certain markets as we prepare for the launch of the new IQOS ILUMA
device.
Operating income, excluding favorable currency, increased by 13.4%, primarily reflecting: a favorable pricing variance;
(1)
(2)
(1)
(2)
59
-- 60 of 111 --
Table of Contents
favorable volume/mix, mainly driven by the same factors as for net revenues noted above; and lower manufacturing costs (driven by productivity gains
related to reduced-risk and combustible products); partly offset by the unfavorable impact of the Saudi Arabia customs assessments (as noted above for net
revenues); and higher marketing, administration and research costs, including higher asset impairment and exit costs (mainly related to organizational
design optimization, as well as product distribution restructuring in South Korea).
Interest expense, net, of $328 million increased by $37 million (12.7%).
Our effective tax rate was flat at 21.7%. We estimate that our full-year 2021 effective tax rate will be around 22%, excluding discrete tax events. For further
details, see Note 9. Income Taxes.
Net earnings attributable to PMI of $4.6 billion increased by $817 million or 21.7%. This increase was due primarily to higher operating income as
discussed above. Basic EPS of $2.94 increased by 21.5%. Diluted EPS of $2.93 increased by 21.1%. Excluding a favorable currency impact of $0.15,
diluted EPS increased by 14.9%.
Consolidated Operating Results for the Three Months Ended June 30, 2021
The following discussion compares our consolidated operating results for the three months ended June 30, 2021, with the three months ended June 30,
2020.
Our total shipment volume increased by 6.1%, driven by:
• the EU, reflecting higher heated tobacco unit shipment volume across the Region, notably in Italy, and higher cigarette shipment volume, notably in
Italy and Spain, partly offset by Germany;
• Eastern Europe, reflecting higher heated tobacco unit shipment volume across the Region, primarily in Russia and Ukraine, partly offset by lower
cigarette shipment volume, notably in Russia;
• Middle East & Africa, mainly reflecting higher cigarette shipment volume, primarily in North Africa (particularly Egypt), PMI Duty Free and Turkey,
partly offset by the GCC (predominantly Saudi Arabia);
• South & Southeast Asia, primarily reflecting higher cigarette shipment volume, mainly in Indonesia and Thailand, partly offset by the Philippines; and
• Latin America & Canada, mainly reflecting higher cigarette shipment volume, notably in Mexico, partly offset by Argentina;
partly offset by
• East Asia & Australia, reflecting lower cigarette shipment volume, mainly in Japan, partly offset by higher heated tobacco unit shipment volume,
primarily in Japan.
Our cigarette shipment volume increase in the quarter includes a favorable comparison versus the second quarter of 2020, when pandemic-related
disruption across many key markets was at its peak.
Impact of Inventory Movements
Excluding the net favorable impact of estimated distributor inventory movements of approximately 3.2 billion units, our total in-market sales increased by
4.2%, driven by a 27.6% increase in heated tobacco units and a 1.5% increase in cigarettes.
The net favorable impact of approximately 3.2 billion units reflected:
• A net favorable impact of 2.5 billion cigarettes, mainly driven by inventory movements in the second quarter of 2020 related to lower shipments to
distributors due to the pandemic; and
• A net favorable impact of 0.7 billion heated tobacco units, primarily reflecting the need to maintain inventory durations for the growing category.
Our total heated tobacco unit in-market sales volume in the quarter was 23.0 billion units, reflecting sequential growth of 8.0% compared to the first quarter
of 2021. The company believes that the current level of heated tobacco unit inventory is appropriate based on anticipated sales.
60
-- 61 of 111 --
Table of Contents
Our cigarette shipment volume by brand and heated tobacco units shipment volume are shown in the table below:
PMI Shipment Volume by Brand (Million Units)
Second-Quarter
2021 2020 Change
Cigarettes
Marlboro 58,466 54,812 6.7 %
L&M 22,096 22,385 (1.3) %
Chesterfield 14,269 12,604 13.2 %
Philip Morris 10,590 11,106 (4.6) %
Parliament 10,023 8,462 18.4 %
Sampoerna A 9,186 7,254 26.6 %
Dji Sam Soe 5,422 5,797 (6.5) %
Bond Street 4,630 6,428 (28.0) %
Lark 3,882 4,189 (7.3) %
Sampoerna Hijau 2,029 1,566 29.5 %
Others 15,545 16,756 (7.2) %
Total Cigarettes 156,138 151,359 3.2 %
Heated Tobacco Units 24,356 18,708 30.2 %
Total Cigarettes and Heated Tobacco Units 180,494 170,067 6.1 %
Note: Sampoerna A includes Sampoerna; Philip Morris includes Philip Morris/Dubliss; and Lark includes Lark Harmony
Our cigarette shipment volume of the following brands increased:
• Marlboro, mainly driven by Italy, PMI Duty Free, Spain and Turkey, partly offset by the GCC and Japan;
• Chesterfield, primarily driven by Russia, partly offset by Saudi Arabia;
• Parliament, mainly driven by Saudi Arabia and Turkey;
• Sampoerna A in Indonesia, primarily driven by premium A Mild; and
• Sampoerna Hijau in Indonesia.
Our cigarette shipment volume of the following brands decreased:
• L&M, notably due to Germany, Saudi Arabia and Turkey, partly offset by North Africa, Spain and Thailand;
• Philip Morris, primarily due to Russia;
• Dji Sam Soe in Indonesia, mainly due to Dji Sam Soe Magnum Mild;
• Bond Street, primarily due to Russia;
• Lark, mainly due to Japan; and
• "Others," primarily due to: mid-price Fortune (Philippines) and Sampoerna U (Indonesia).
The increase in our heated tobacco unit shipment volume was mainly driven by the EU (notably Italy), Eastern Europe (notably Russia and Ukraine) and
Japan.
International Share of Market (excluding China and the United States)
Our total international market share (excluding China and the United States) decreased by 0.8 points to 27.3%, reflecting:
• Total international market share for cigarettes of 23.8%, down by 1.3 points; and
• Total international market share for heated tobacco units of 3.5%, up by 0.5 points.
61
-- 62 of 111 --
Table of Contents
Our total international cigarette sales volume as a percentage of total industry cigarette sales volume was down by 1.1 points to 24.9%, mainly reflecting:
lower cigarette market share and/or an unfavorable geographic mix impact, notably in France, Germany, Japan, the Philippines and Russia, partly offset by
Indonesia, PMI Duty Free and Turkey.
Financial Summary
Financial Summary -
Quarters Ended June 30,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2021 2020 Total Excl.
Curr. Total Cur-
rency Price Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 7,594 $ 6,651 14.2 % 7.9 % $ 943 $ 420 $ 226 $ 575 $ (278)
Cost of Sales (2,353) (2,179) (8.0)% (1.9)% (174) (133) — (147) 106
Marketing, Administration and Research
Costs (2,093) (1,722) (21.5)% (12.3)% (371) (159) — — (212)
Amortization of Intangibles (19) (19) — % 5.3 % — (1) — — 1
Operating Income $ 3,129 $ 2,731 14.6 % 9.9 % $ 398 $ 127 $ 226 $ 428 $ (383)
Cost/Other variance includes a $246 million reduction in net revenues in 2021 related to the Saudi Arabia customs assessments. For more details, see Note 8.
Contingencies.
Cost/Other variance includes charges in 2021 and 2020 of $79 million and $71 million, respectively, for asset impairment and exit costs.
During the quarter, net revenues, excluding favorable currency, increased by 7.9%, mainly reflecting: favorable volume/mix, primarily driven by higher
heated tobacco unit volume (notably in the EU, particularly Italy and Poland, as well as Japan, Russia and Ukraine) and higher cigarette volume (mainly in
Indonesia, Italy, PMI Duty Free and Spain, partly offset by the GCC, Germany, Japan and the Philippines); and a favorable pricing variance (notably driven
by Germany, Japan, the Philippines, Russia and Turkey, partly offset by Indonesia); partly offset by the unfavorable impact of the Saudi Arabia customs
assessments of $246 million, shown in "Cost/Other". Excluding the unfavorable impact of the Saudi Arabia customs assessments of $246 million, net
revenues increased by 17.9%, or 11.6% excluding favorable currency of $420 million.
The favorable currency in net revenues was due primarily to the Euro, Indonesian rupiah and Mexican pesos, partially offset by the Turkish lira.
Net revenues include $2.3 billion in 2021 and $1.6 billion in 2020 related to the sale of RRPs.
Operating income, excluding favorable currency, increased by 9.9%, primarily reflecting: favorable volume/mix, primarily driven by higher heated tobacco
unit volume (reflecting the same geographies as for net revenues noted above); a favorable pricing variance; and lower manufacturing costs (driven by
productivity gains related to reduced-risk and combustible products); partly offset by the unfavorable impact of the Saudi Arabia customs assessments (as
noted above for net revenues); and higher marketing, administration and research costs.
Interest expense, net, of $161 million was essentially flat.
Our effective tax rate increased by 1.3 percentage points to 22.0%. The effective tax rate for the three months ended June 30, 2020 was favorably impacted
by the corporate income tax rate reduction in Indonesia (enacted in the second quarter of 2020). For further details, see Note 9. Income Taxes.
Net earnings attributable to PMI of $2.2 billion increased by $225 million or 11.6%. This increase was due primarily to higher operating income as
discussed above, partially offset by a higher effective tax rate. Diluted and basic EPS of $1.39 increased by 11.2%. Excluding a favorable currency impact
of $0.05, diluted EPS increased by 7.2%.
(1)
(2)
(1)
(2)
62
-- 63 of 111 --
Table of Contents
Operating Results by Business Segment
Business Environment
Taxes, Legislation, Regulation and Other Matters Regarding the Manufacture, Marketing, Sale and Use of Tobacco Products
The tobacco industry and our company face a number of challenges that may adversely affect our business, volume, results of operations, cash flows and
financial position. These challenges, which are discussed below and in “Cautionary Factors That May Affect Future Results,” include:
• regulatory restrictions on our products, including restrictions on the packaging, marketing, and sale of tobacco or other nicotine-containing
products that could reduce our competitiveness, eliminate our ability to communicate with adult consumers, or even ban certain of our products;
• fiscal challenges, such as excessive excise tax increases and discriminatory tax structures;
• illicit trade in cigarettes and other tobacco and nicotine-containing products, including counterfeit, contraband and so-called “illicit whites”;
• intense competition, including from non-tax paid volume by certain local manufacturers;
• pending and threatened litigation as discussed in Note 8. Contingencies; and
• governmental investigations.
Regulatory Restrictions: The tobacco industry operates in a highly regulated environment. The well-known risks of smoking have led regulators to impose
significant restrictions and high excise taxes on cigarettes.
Much of the regulation that shapes the business environment in which we operate is driven by the World Health Organization's (the “WHO”) Framework
Convention on Tobacco Control (the “FCTC”), which entered into force in 2005. The FCTC has as its main objective to establish a global agenda for
tobacco regulation, with the purpose of reducing tobacco use. To date, 182 countries and the European Union are Parties to the FCTC. The treaty requires
Parties to have in place various tobacco control measures and recommends others. The FCTC governing body, the Conference of the Parties (“CoP”), has
also adopted non-binding guidelines and policy recommendations related to certain articles of the FCTC that go beyond the text of the treaty. In October
2018, the CoP recognized the need for more scientific assessment and improved reporting to define policy on heated tobacco products. Similar to its
previous policy recommendations on e-cigarettes, the CoP invited countries to regulate, restrict or prohibit heated tobacco products, as appropriate under
their national laws.
In May 2021, the WHO study group on tobacco product regulation issued its Eighth Report addressing novel and emerging nicotine and tobacco products,
such as electronic nicotine delivery systems ("ENDS"), electronic non-nicotine delivery systems ("ENNDS") and heated tobacco products ("HTPs").
Although the Report presents some industry and independent research showing that heated tobacco products have the potential to reduce harm for smokers,
WHO’s overall assessment is that these products are not risk-free and should be regulated in the same manner as tobacco products and in line with the
FCTC provisions. The Report also recommends governments both to rely on independent research and data on the public health impact of use of heated
tobacco products, and to analyze tobacco industry funded data. It is not possible to predict whether or to what extent measures recommended by the WHO
study group will be implemented as the Report is not binding to the WHO Member States.
We believe that when better alternatives to cigarettes exist, the discussion should not be whether these alternatives should be made available to the more
than one billion people who smoke today, but how fast, and within what regulatory framework to maximize their adoption while minimizing unintended
use. Therefore, we advocate for regulatory frameworks that recognize a significant difference on a risk continuum between combustible tobacco on the one
hand and non-combustible tobacco and other nicotine-containing products on the other. Regulation should include measures that will accelerate switching
to non-combustible products, for example, by allowing adult consumers who would not otherwise quit to receive truthful and non-misleading information
about such products to enable them to make informed decisions and by applying uniform product standards to enable manufacturers to demonstrate the
safety of these products, as well as the absence of combustion. Regulation should also include specific rules for ingredients, labeling and consumer
communication, and should ensure that the public is informed about the health risks of all combustible and non-combustible tobacco and nicotine-
containing products. Importantly, regulation must include measures designed to prevent initiation by youth and non-smokers. We support mandated health
warnings, minimum age laws, restrictions on advertising, and public place smoking restrictions. We also support regulatory measures that help reduce illicit
trade.
63
-- 64 of 111 --
Table of Contents
Certain measures are discussed in more detail below and in the Reduced-Risk Products (RRPs) section.
Fiscal Challenges: Excessive and disruptive excise, sales and other tax increases and discriminatory tax structures are expected to continue to have an
adverse impact on our profitability, due to lower consumption and consumer down-trading to non-premium, discount, other low-price or low-taxed
combustible tobacco products such as fine cut tobacco and illicit cigarettes. In addition, in certain jurisdictions, some of our combustible products are
subject to tax structures that discriminate against premium-price products and manufactured cigarettes. We believe that such tax policies undermine public
health by encouraging consumers to turn to illicit trade, and ultimately undercut government revenue objectives, disrupt the competitive environment, and
encourage criminal activity. Other jurisdictions have imposed, or are seeking to impose, levies or other taxes specifically on tobacco companies, such as
taxes on revenues and/or profits.
World Customs Organization Developments: In 2020, the World Customs Organization (the “WCO”) amended the harmonized system nomenclature to
introduce dedicated custom codes for novel tobacco and nicotine products, including heated tobacco products, e-cigarettes and other nicotine-containing
products. The amendments will be effective as of January 1, 2022. These amendments require WCO member states to transfer products from customs
codes in the current nomenclature to the new one. These amendments are not expected to significantly impact current customs duty rates.
EU Tobacco Products Directive: In April 2014, the EU adopted a significantly revised EU Tobacco Products Directive (the “TPD”), which entered into
force in May 2016. All member states have adopted laws transposing the TPD. The TPD sets forth a comprehensive set of regulatory requirements for
tobacco products, including:
• health warnings covering 65% of the front and back panels of cigarette packs, with an option for member states to further standardize tobacco
packaging, including the introduction of plain packaging;
• a ban on characterizing flavors in some tobacco products, with a transition period for menthol that expired in May 2020;
• security features and tracking and tracing measures that became effective in May 2019; and
• a framework for the regulation of novel tobacco products and e-cigarettes, including requirements for health warnings and information leaflets, a
prohibition on product packaging text related to reduced risk, and the introduction of notification requirements or authorization procedures in
advance of commercialization.
In May 2021, the European Commission published its first report on the application of the TPD. The report identifies significant progress made due to the
implementation of the TPD and where there is still room for improvement. Most notably, it finds that the EU legislation has enhanced tobacco control,
contributed to protecting the health of EU citizens by providing Member States with strong rules to address the use of tobacco products in the EU. The TPD
reportedly achieved the 2% reduction target of the impact assessment with decreased smoking prevalence among youth. The report also concludes that
there is scope for improvement in certain areas, such as enforcement at national level, assessment of ingredients, and a better consideration for novel and
emerging products.
EU Tobacco Excise Directive: The EU Commission is preparing a legislative proposal for the revision of the 2011 EU Tobacco Excise Directive that may
include definitions and tax treatment for novel tobacco and nicotine-containing products, including heated tobacco products and e-cigarettes. The proposal
is expected to be finalized by the end of 2021. The adoption of the proposal will require unanimous agreement by all EU member states.
Plain Packaging and Other Packaging Restrictions: Plain packaging legislation bans the use of branding, logos and colors on packaging other than the
brand name and variant that may be printed only in specified locations and in a uniform font. To date, plain packaging laws have been adopted in certain
markets in all of our operating segments, including the key markets of Australia, France, Saudi Arabia and Turkey. Some countries, such as Canada, New
Zealand, Israel and Denmark, adopted plain packaging regulations that apply to all tobacco products, including RRPs. Other countries are also considering
plain packaging legislation.
Some countries have adopted, or are considering adopting, packaging restrictions that could have an impact similar to plain packaging. Examples of such
restrictions include standardizing the shape and size of packages, prohibiting certain colors or the use of certain descriptive phrases on packaging, and
requiring very large graphic health warnings that leave little space for branding.
64
-- 65 of 111 --
Table of Contents
Restrictions and Bans on the Use of Ingredients: The WHO and others in the public health community have recommended restrictions or total bans on the
use of some or all ingredients in tobacco products, including menthol. Broad restrictions and ingredient bans would require us to reformulate our American
blend tobacco products and could reduce our ability to differentiate these products in the market in the long term. In many countries, menthol bans would
eliminate the entire category of mentholated tobacco products. The European Union banned cigarettes and roll-your-own tobacco products with
characterizing flavors. Other tobacco products, including heated tobacco products, are exempted from this flavor ban. The EU Commission is required to
withdraw this exemption for a particular product category if it determines that there is a substantial change of circumstances, such as a significant increase
of EU-wide sales volumes in such product category. Other countries may follow the EU’s approach. Turkey banned menthol as of May 2020. Broader
ingredient bans have been adopted by Canada and Brazil.
Bans on Display of Tobacco Products at Retail: In a number of our markets, including, but not limited to, Australia and Russia, governments have banned
the display of tobacco products at the point of sale. Other countries are considering similar bans.
Bans and Restrictions on Advertising, Marketing, Promotions and Sponsorships: For many years, the FCTC has called for, and countries have imposed,
partial or total bans on tobacco advertising, marketing, promotions and sponsorships, including bans and restrictions on advertising on radio and television,
in print and on the Internet. The FCTC's non-binding guidelines recommend that governments prohibit all forms of communication with adult smokers.
Restrictions on Product Design: Some members of the public health community are calling for the further standardization of tobacco products by requiring,
for example, that cigarettes have a certain minimum diameter, which would amount to a ban on slim cigarettes, or requiring the use of standardized filter
and cigarette paper designs. In addition, at its meeting in November 2016, the CoP adopted non-binding guidelines recommending that countries regulate
product design features that increase the attractiveness of tobacco products, such as the diameter of cigarettes and the use of flavor capsules.
Restrictions on Public Smoking and Use of Nicotine-Containing Products in Public: The pace and scope of restrictions on the use of our products have
increased significantly in most of our markets. Many countries around the world have adopted, or are likely to adopt, regulations that restrict or ban
smoking and use of nicotine-containing products in public and/or work places, restaurants, bars and nightclubs. Some public health groups have called for,
and some countries, regional governments and municipalities have adopted or proposed, bans on smoking in outdoor places, as well as bans on smoking in
cars (typically, when minors are present) and private homes.
Other Regulatory Issues: Some regulators are considering, or in some cases have adopted, regulatory measures designed to reduce the supply of tobacco
products. These include regulations intended to reduce the number of retailers selling tobacco products by, for example, reducing the overall number of
tobacco retail licenses available or banning the sale of tobacco products within specified distances of certain public facilities. In addition, South Africa
banned the sale of tobacco products, e-cigarettes, and electronic devices that heat tobacco for several months during the COVID-19 pandemic. The ban,
which was lifted on August 17, 2020, resulted in a significant increase of illicit trade of tobacco products.
In a limited number of markets, most notably Japan, we are dependent on governmental approvals that may limit our pricing flexibility.
The EU Single-Use Plastics Directive, which will require tobacco manufacturers and importers to cover the costs of public collection systems for tobacco
product filters, under Extended Producer Responsibility ("EPR") schemes, entered into force on July 2, 2019. To date, only a few member states transposed
the Directive into national legislation. We expect remaining member states to transpose the EU Single-Use Plastics Directive into national legislation
including EPR schemes by January 2023. While we cannot predict the impact of this initiative on our business at this time, we are monitoring
developments in this area.
Illicit Trade: Illicit tobacco trade creates a cheap and unregulated supply of tobacco products, undermines efforts to reduce smoking prevalence, especially
among youth, damages legitimate businesses and intellectual property rights, stimulates organized crime, increases corruption and reduces government tax
revenue. We generally estimate that, excluding China and the U.S., illicit trade may account for as much as 12% of global cigarette consumption; this
includes counterfeit, contraband and the persistent problem of “illicit whites,” which are cigarettes legally produced in one jurisdiction for the sole purpose
of being exported and illegally sold in another jurisdiction where they have no legitimate market. Currently, we estimate that illicit trade in the European
Union accounted for approximately 8% of total cigarette consumption in 2020.
A number of jurisdictions are considering actions to prevent illicit trade. In November 2012, the FCTC adopted the Protocol to Eliminate Illicit Trade in
Tobacco Products (the “Protocol”), which includes supply chain control measures, such as licensing
65
-- 66 of 111 --
Table of Contents
of manufacturers and distributors, enforcement of these control measures in free trade zones, controls on duty free and Internet channels and the
implementation of tracking and tracing technologies. To date, 63 Parties, including the European Union, have ratified it. The Protocol came into force in
September 2018. Parties must start implementing its provisions in their national legislation. In October 2018, the first Meeting of the Parties to the Protocol
decided to produce a comprehensive report on good practices for the implementation of tracking and tracing systems and to prepare a conceptual
framework for global information sharing to combat illicit tobacco trade. We welcome this decision and expect that other Parties will ratify the Protocol.
We devote substantial resources to help prevent illicit trade in combustible tobacco products and RRPs. For example, we engage with governments, our
business partners and other stakeholders to implement effective measures to combat illicit trade and, in some instances, pursue legal remedies to protect our
intellectual property rights.
The tracking and tracing regulations for cigarettes and roll-your-own products manufactured or destined for the EU became effective on May 20, 2019. The
effective date for other tobacco-containing products, including some of our RRPs such as heated tobacco units, is May 20, 2024. While we expect that this
regulation will increase our operating expenses, we do not expect this increase to be significant.
In 2009, our Colombian subsidiaries entered into an Investment and Cooperation Agreement with the national and regional governments of Colombia to
promote investment in, and cooperation on, anti-contraband and anti-counterfeit efforts. The agreement provides $200 million in funding over a 20-year
period to address issues such as combating illegal cigarette trade and increasing the quality and quantity of locally-grown tobacco.
In May 2016, PMI launched PMI IMPACT, a global initiative that supports third-party projects dedicated to fighting illegal trade and related crimes such as
corruption, organized criminal networks and money laundering. The centerpiece of PMI IMPACT is a council of external independent experts in the fields
of law, anti-corruption and law enforcement. The experts are responsible for evaluating and approving funding proposals for PMI IMPACT grants. PMI has
pledged $100 million to fund projects within PMI IMPACT over three funding rounds.
Reduced-Risk Products (RRPs)
Our Approach to RRPs: We recognize that smoking cigarettes causes serious diseases and that the best way to avoid the harms of smoking is never to start
or to quit. Nevertheless, it is predicted that by 2025 the number of smokers will remain largely unchanged from the current estimate of 1.1 billion, despite
the considerable efforts to discourage smoking.
Cigarettes burn tobacco, which produces smoke. As a result of the combustion process, the smoker inhales various toxic substances. In contrast, RRPs do
not burn tobacco and produce an aerosol that contains significantly lower levels of harmful and potentially harmful constituents ("HPHCs") than found in
cigarette smoke.
For adult smokers who would otherwise continue to smoke, we believe that RRPs, while not risk-free, offer a much better consumer choice. Accordingly,
our key strategic priorities are: to develop and commercialize products that present less risk of harm to adult smokers who switch to those products versus
continued smoking; and to convince current adult smokers who would otherwise continue to smoke to switch to those products.
We recognize that this transformation from cigarettes to RRPs will take time and that the speed of transformation will depend in part upon factors beyond
our control, such as the willingness of governments, regulators and other policy groups to embrace RRPs as a desired alternative to continued cigarette
smoking. For as long as a significant number of adult smokers continues to smoke, responsible leadership of the category is critical. We aim to maintain our
competitive position in the cigarette market through selective investment. As a leading international cigarette manufacturer, we will continue to accelerate
this transformation by using our regulatory and commercial expertise and extensive commercial and distribution infrastructure as an effective platform for
the commercialization of our RRPs and communication with adult smokers and trade partners about the benefits of switching to our RRPs.
While seeking to remain competitive in the cigarette market, we are judiciously reallocating resources from cigarettes to RRPs and are streamlining our
cigarette portfolio.
We have a range of RRPs in various stages of development, scientific assessment and commercialization. We conduct rigorous scientific assessments of our
RRP platforms to substantiate that they reduce exposure to HPHCs and, ultimately, that these products present, are likely to present, or have the potential to
present less risk of harm to adult smokers who switch to them versus continued smoking. We draw upon a team of expert scientists and engineers from a
broad spectrum of scientific
66
-- 67 of 111 --
Table of Contents
disciplines and our extensive learnings of adult consumer preferences to develop and assess our RRPs. Our efforts are guided by the following key
objectives:
• to develop RRPs that adult smokers who would otherwise continue to smoke find to be satisfying alternatives to smoking;
• for those adult smokers, our goal is to offer RRPs with a scientifically substantiated risk-reduction profile that approaches as closely as possible
that associated with smoking cessation;
• to substantiate the reduction of risk for the individual adult smoker and the reduction of harm to the population as a whole, based on scientific
evidence of the highest standard that is made available for scrutiny and review by external independent scientists and relevant regulatory bodies;
and
• to advocate for the development of science-based regulatory frameworks for the development and commercialization of RRPs, including the
communication of scientifically substantiated information to enable adult smokers to make better consumer choices.
Our RRP Platforms: Our product development is based on the elimination of combustion via tobacco heating and other innovative systems for aerosol
generation, which we believe is the most promising path to providing a better consumer choice for those who would otherwise continue to smoke. We
recognize that no single product will appeal to all adult smokers. Therefore, we are developing a portfolio of products intended to appeal to a variety of
distinct adult consumer preferences.
Four PMI-developed RRP platforms are in various stages of development and commercialization readiness:
Platform 1 uses a precisely controlled heating device incorporating our IQOS HeatControl technology, into which a specially designed and proprietary
tobacco unit is inserted and heated to generate an aerosol. We have conducted a series of clinical studies for this platform, the results of which were
included in our submission to the U.S. Food and Drug Administration (“FDA”) described below. We completed a 6+6 month exposure response study and
shared the results with the FDA in April 2020. The study showed that for the group that switched to our Platform 1 product, the eight clinical risk endpoints
that were tested as co-primary endpoints in the first six-month term moved in the same direction as observed for smoking cessation after 12 months of use
of this product. In addition, we completed an 18-month combined chronic toxicity and carcinogenicity study in mice, which was on-going at the time of our
FDA submission. We shared the results with the FDA in August 2018.
Platform 2 uses a pressed carbon heat source which, when ignited, generates a nicotine-containing aerosol by heating tobacco. The results of our
pharmacokinetic study (that measured the nicotine pharmacokinetic profile as well as subjective effects) and of our five-day reduced exposure study
indicate that this platform could be an acceptable substitute for adult smokers who seek an alternative to cigarettes. The reduced exposure study results
showed a substantial reduction in relevant biomarkers of exposure to the measured HPHCs in those who switched to Platform 2 compared to those who
continued to smoke cigarettes over a five-day period. The sustainability of this reduction as well as changes in clinical risk markers were assessed in a
three-month reduced exposure study, which was completed in 2018.
Platform 3 provides an aerosol of nicotine salt. We have explored two routes for this platform, one with electronics and one without, and conducted
nicotine pharmacokinetic studies with both versions. The results of our pharmacokinetic study related to the version without electronics indicate this
product's potential as an acceptable alternative to continued cigarette smoking in terms of product satisfaction. In February 2020, we completed a one-
month product use and adaptation study in adult smokers for the product variant without electronics. The results of the study indicated that while during the
study period, the adult smokers did not fully switch from smoking cigarettes to this Platform 3 product, on average, they used this product on a daily basis
and significantly reduced their daily consumption of cigarettes. We are working on product modifications to enable switching by those adult smokers who
are looking for better alternatives to cigarettes.
Platform 4 covers e-vapor products, which are battery-powered devices that produce an aerosol by vaporizing a nicotine-containing liquid solution. In
2020, our e-vapor products comprised devices with the "coil and wick" technology as well as our e-vapor mesh technology designed to ensure the
consistency and quality of the generated aerosol compared to the products with the “coil and wick” technology. Recently, we discontinued the
commercialization of devices with the “coil and wick” technology. We conducted a nicotine pharmacokinetic study with respect to products with our e-
vapor mesh technology in 2017. The results of this study indicate that these products are an effective means of nicotine delivery while being a satisfying
alternative for e-cigarette users. In March 2019, a six-month pre-clinical study in mice evaluating the impact of e-cigarette vapor on the risks of pulmonary
and cardiovascular disease compared to cigarette smoke was completed; this study did
67
-- 68 of 111 --
Table of Contents
not pertain to a specific product. The study demonstrated that e-cigarette vapors induce significantly lower biological responses associated with
cardiovascular and pulmonary diseases compared with cigarette smoke.
We aim to expand our brand portfolio and market positions with additional RRPs. In addition, we are continuing to use our expertise, technology and
capabilities to explore new growth opportunities beyond our current business, including products that do not contain nicotine or tobacco.
After we receive the results of our scientific studies, including those mentioned above, in accordance with standard scientific practices, we share the
conclusions in scientific forums and submit them for inclusion in peer-reviewed publications.
Commercialization of RRPs: We are building a new product category and tailor our commercialization strategy to the characteristics of each specific
market. We focus our commercialization efforts on consumer retail experience, guided consumer trials and customer care, and increasingly, digital
communication programs and e-commerce. In order to accelerate switching to our Platform 1 products, our initial market introductions typically entail
one-to-one consumer engagement (in person or by digital means) and device discounts. These initial commercialization efforts require substantial
investment, which we believe will moderate over time and further benefit from the increased use of digital engagement capabilities. During the COVID-19
pandemic, we accelerated our investments in, and pivot to, digital consumer engagement.
In 2014, we introduced our Platform 1 product in pilot city launches in Nagoya, Japan, and in Milan, Italy. Since then, we have continuously expanded our
commercialization activities. As of June 30, 2021, PMI's smoke-free products are available for sale in 67 markets in key cities or nationwide.
We believe that only a very small percentage of adult smokers who convert to our Platform 1 product switch back to cigarettes.
We have integrated the production of our heated tobacco units into a number of our existing manufacturing facilities, are progressing with our plans to
build manufacturing capacity for our other RRP platforms, and continue to optimize our manufacturing infrastructure.
An adequate supply chain for our RRP portfolio, including the supply of electronic devices, is important to our business. We work with three electronics
manufacturing service providers for the supply of our Platform 1 and Platform 4 devices and a small number of other providers for other products in our
RRP portfolio and related accessories. Due to the COVID-19 pandemic, the operations of our two main electronic manufacturing service providers were
temporarily suspended at different times. Even though these suspensions did not materially affect our operations, if one or more of these service providers
were significantly constrained at the same time, the supply of the devices could be disrupted. Although we work closely with these service providers on
monitoring their production capability and financial health, we cannot guarantee that they will remain capable of meeting their commitments, particularly
during the COVID-19 pandemic; if they will not, the commercialization of our RRPs could be adversely affected. The production of our RRP portfolio
requires various metals, and we believe that there is an adequate supply of such metals in the world markets to satisfy our current and anticipated
production requirements. However, some components and materials necessary for the production of our RRPs, including those for the electronic devices,
are obtained from single or limited sources, and can be subject to industry-wide shortages and price fluctuations. While we were successful in maintaining
adequate supply of such components and materials so far, we may not be able to secure such supply going forward, particularly during the COVID-19
pandemic; this could negatively impact the commercialization of our RRPs. For details on the impact of COVID-19 on our production and supply chain,
see the "Executive Summary" section of this MD&A.
In addition, we are also exposed to a world-wide shortage of semiconductors, which shortage continues to put constraints on our device supplies for RRPs.
While the overall impact of this shortage remains manageable, we have adjusted our device assortments to limit the effect on consumer availability of our
RRPs.
We discuss product warranties in more detail in Note 14. Product Warranty. The significance of warranty claims is dependent on a number of factors,
including device version mix, product failure rates, logistics and service delivery costs, and warranty policies, and may increase with the number of devices
sold.
Product quality may affect consumer acceptance of our RRPs.
Our commercialization efforts for the other RRP platforms are as follows:
68
-- 69 of 111 --
Table of Contents
• We started commercializing an improved version of our IQOS MESH product in New Zealand, Italy, Finland and the Czech Republic under the
IQOS VEEV or VEEV brand names. We currently plan to launch this product in additional markets.
• With respect to TEEPS, our Platform 2 product, we are finalizing our improvements to this product and plan to conduct a consumer test in 2021.
• Following the consumer test conducted in 2020 and the results of the product use and adaptation study described above, we are incorporating our
learnings into our plans to improve our Platform 3 product.
Due to the COVID-19 pandemic, these plans may be delayed.
RRP Regulation and Taxation: RRPs contain nicotine and are not risk-free. As we describe in more detail above, we support science-based regulation and
taxation of RRPs and believe that regulation and taxation should differentiate between cigarettes and products that present, are likely to present, or have the
potential to present less risk of harm to adult smokers who switch to these products versus continued smoking and should recognize a continuum of risk for
tobacco and other nicotine-containing products. Regulation, as well as industry practices, should reflect the fact that youth should not consume nicotine in
any form.
Some governments have banned or are seeking to ban or severely restrict emerging tobacco and nicotine-containing products such as our RRPs and
communication of truthful and non-misleading information about such products.
These regulations might foreclose or unreasonably restrict adult consumer access even to products that might be shown to be a better consumer choice than
continuing to smoke. During the COVID-19 pandemic, some governments have been and may continue to be temporarily unable to focus on the
development of science-based regulatory frameworks for the development and commercialization of RRPs or on the enforcement or implementation of
regulations that are significant to our business.
We oppose blanket bans and unreasonable restrictions of products that have the potential to present less risk of harm compared to continued smoking. By
contrast, we support regulation that sets clear standards for all RRP categories and propels innovation to benefit adult smokers who would otherwise
continue to smoke.
In the United States, an established regulatory framework for assessing “Modified Risk Tobacco Products” and “New Tobacco Products” exists under the
jurisdiction of the FDA. We submitted to the FDA a Modified Risk Tobacco Product Application (“MRTPA”) for our Platform 1 product in December
2016, and a Premarket Tobacco Product Application (“PMTA”) for our Platform 1 product in March 2017.
On April 30, 2019, the FDA determined that a version of our Platform 1 product, namely, IQOS 2.4 and three related consumables, is appropriate for the
protection of public health and authorized it for sale in the United States. The FDA’s decision followed its comprehensive assessment of our PMTA. On
December 7, 2020, the FDA reached the same determination for the IQOS 3 device and authorized that version of our Platform 1 product for sale in the
United States.
On July 7, 2020, the FDA determined that the available scientific evidence demonstrates that the issuance of an exposure modification order would be
appropriate for the promotion of public health and authorized the marketing of a version of our Platform 1 product, namely, IQOS 2.4 and three related
consumables, as a "modified risk tobacco product." The FDA authorized the marketing of this product in the U.S. with the following information:
"AVAILABLE EVIDENCE TO DATE:
• the IQOS system heats tobacco but does not burn it.
• this significantly reduces the production of harmful and potentially harmful chemicals.
• scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s
exposure to harmful or potentially harmful chemicals."
We must request and receive authorization from the FDA in order to continue marketing this product with the same modified exposure information after the
present order expires in four years from the date of the orders.
On March 18, 2021, we submitted to the FDA a supplemental MRTPA ("sMRTPA") for IQOS 3 requesting authorization to market this version of the
device as a Modified Risk Tobacco Product with reduced exposure information like IQOS 2.4. In June 2021, the FDA formally accepted and filed our
sMRTPA for substantive scientific review and, already in May 2021, the
69
-- 70 of 111 --
Table of Contents
FDA opened the period for the public to provide comments on our application. The public comment period will be closed on August 2, 2021.
There are two types of MRTP orders the FDA may issue: a “risk modification” order or an “exposure modification” order. We had requested both types of
orders for IQOS 2.4 and an initial selection of 3 consumables' variants. After review, the FDA determined that the evidence did not support issuing a "risk
modification" order at this time but that it did support issuing an "exposure modification" order for the product. This determination included a finding that
issuance of the exposure modification order is expected to benefit the health of the population as a whole.
We look forward to working with the FDA to provide any additional information they may require in order to market this product with reduced risk claims.
The FDA’s PMTA and MRTP orders do not mean that the agency “approved” our Platform 1 product. These authorizations are subject to strict marketing,
reporting and other requirements and are not a guarantee that the product will remain authorized, particularly if there is a significant uptake in youth or non-
smoker initiation. The FDA will monitor the marketing of the product.
Some states and municipalities in the U.S. have introduced severe restrictions for the sale of certain e-cigarettes and tobacco products, including those
authorized by the FDA. We believe that such restrictions on FDA-authorized products will not advance public health and will unreasonably limit adult
consumer access to products that are shown to be a better alternative to continued smoking.
In March 2020, we requested a clarification from the FDA regarding the applicability of its new health warning requirements to our heated tobacco units
sold in the United States.
In the U.S., tobacco and nicotine-containing products that were not commercially marketed as of February 15, 2007 are subject to review and authorization
by the FDA. Manufacturers of all non-authorized products currently on the market were required to file a PMTA with the FDA by September 9, 2020. The
FDA announced on September 9, 2020 that it will prioritize enforcement against any tobacco and nicotine-containing product sold without a PMTA.
FDA actions may influence the regulatory approach of other governments.
Until recently, there were no countries with specific product standards for heat-not-burn products. Currently, national standards setting minimum quality
and safety requirements for such products have been adopted in several countries with technical heat-not-burn specifications and/or methods for
demonstrating the absence of combustion. They are mandatory in Egypt, Jordan, Saudi Arabia, Tunisia, the UAE and Uzbekistan, and voluntary in the
U.K., Russia, Ukraine, Kazakhstan, Kyrgyzstan, Tajikistan, Vietnam, Indonesia and Costa Rica. In Japan, a voluntary standard sets minimum safety
requirements for tobacco heating devices. We expect other governments to consider similar product standards and encourage making them mandatory.
All EU member states have transposed the EU Tobacco Products Directive, including the provisions on novel tobacco products, such as heated tobacco
units, and e-cigarettes. Most of the EU member states require a notification submitted six months before the intended placing on the market of such
products, while some require pre-market authorizations for the introduction of such products. To date, we have filed a comprehensive dossier summarizing
our scientific assessment of our Platform 1 product in over 20 member states.
In addition, in Italy, in April 2018, we submitted an application for HEETS, used with the IQOS device, requesting regulatory recognition of the reduction
of toxic substances and potential risk reduction resulting from switching to this product compared to continued cigarette smoking. In January 2019, our
application was not granted primarily on the grounds of insufficient data and questions of methodology. Due to the constraints of the review process, we
had been unable to supplement the application with all the data we subsequently filed with the FDA and to address methodological questions during the
review. We plan to submit a new application where we will clarify the concerns raised by the decision and further strengthen our application by submitting
additional evidence that became available since we submitted our first application, consistent with our FDA filings. We are confident that our evidence
supports our application.
On October 31, 2019, our Australian subsidiary, Philip Morris Limited (“PML”), submitted an application to the Scheduling Committee of the Therapeutic
Goods Administration of Australia (“TGA”) seeking to exempt heated tobacco products from being prohibited in Australia. In August 2020, the TGA
issued its decision denying the application and stating that it did not present compelling evidence to establish a public health benefit from greater access to
nicotine in heated tobacco products.
70
-- 71 of 111 --
Table of Contents
To date, several governmental agencies have published their scientific findings that analyze the harm-reduction potential of certain RRPs versus continuing
smoking, including:
In December 2017, at the request of the U.K. Department of Health and Public Health England, the U.K. Committee on Toxicity published its assessment
of the risk of heat-not-burn products relative to cigarette smoking. This assessment included analysis of scientific data for two heat-not-burn products, one
of which was our Platform 1 product. The assessment concluded that, while still harmful to health, compared with the known risks from cigarettes, heat-
not-burn products are probably less harmful. Subsequently, in February 2018, Public Health England published a report stating that the available evidence
suggests that heat-not-burn products may be considerably less harmful than cigarettes and more harmful than e-cigarettes.
In May 2018, the German Federal Institute for Risk Assessment (“BfR”) published a study on the Platform 1 aerosol relative to cigarette smoke using the
Health Canada Intense Smoking Regimen. BfR found reductions in selected HPHCs in a range of 80-99%. This publication indicates that significant
reductions in the levels of selected toxicants are likely to reduce toxicant exposure, which BfR stated might be regarded as a discrete benefit compared to
combustible cigarettes.
In May 2018, the Dutch National Institute for Public Health and Environment (“RIVM”) published a factsheet on novel tobacco products that heat rather
than burn tobacco, focusing on our Platform 1 product. RIVM analyzed the aerosol generated by our Platform 1 product and concluded that the use of this
product, while still harmful to health, is probably less harmful than continued smoking.
In June 2018, the Korean Food and Drug Administration (“KFDA”) issued a statement on products that heat rather than burn tobacco. The KFDA tested
three heat-not-burn products, one of which was our Platform 1 product. The KFDA confirmed that the levels of the nine HPHCs tested in the aerosol of
these products were on average approximately 90% lower compared to those measured in the cigarette smoke of the top five cigarette brands in South
Korea. However, the KFDA stated that it could not establish that the tested heat-not-burn products are less harmful than cigarettes. In October 2018, our
Korean subsidiary filed a request with a local court seeking information underlying KFDA’s analysis, conclusions and public statements. In May 2020, the
court ordered KFDA to produce certain records.
In August 2018, the Science & Technology Committee of the U.K. House of Commons published a report of its inquiry into e-cigarettes and heat-not-burn
products. The report concluded that e-cigarettes are significantly less harmful to health than smoking tobacco. The report also observed that for those
smokers who do not accept e-cigarettes, heat-not-burn products may offer a public health benefit despite their relative risk. The report called for a risk-
proportionate regulatory environment for both e-cigarettes and heat-not-burn products and noted that e-cigarettes should remain the least taxed, cigarettes
the most taxed, with heat-not-burn products falling between the two. The U.K. Committee on Advertising Practice announced the removal of a prohibition
of health claims in the advertising of e-cigarettes in the U.K. effective November 2018.
In November 2018, the Eurasian Economic Commission (regulatory body of the Eurasian Union consisting of Armenia, Belarus, Kazakhstan, Kyrgyzstan
and Russia) published the results of its commissioned study on novel nicotine-containing products, including our Platform 1 product. The study confirms
significantly lower levels of HPHCs in the aerosol generated by this product compared to cigarette smoke.
In January 2019, scientific media published the results of the study of the China National Tobacco Quality Supervision and Test Centre (“CNTQST”)
comparing the aerosol generated by our Platform 1 product with cigarette smoke. The CNTQST found that the former contained fewer, and lower levels of,
harmful constituents than the latter and concluded that the lower temperature of heating tobacco in our Platform 1 product contributed to the difference.
The CNTQST stated that the reduction in emissions of harmful constituents cannot be interpreted as a harm/risk reduction for smokers in the same
proportion.
In 2020, the Superior Health Council of Belgium (“SHC”) published results of its inquiry into heat-not-burn products. The SHC concluded that heat-not-
burn products, while not safe, have a more favorable toxicity profile than cigarettes. However, in light of the uncertainty of such products’ short and long-
term impacts, the toxic effects of the dual use with cigarettes, and the existence of approved smoking cessation tools, the SHC recommended that current
regulations for cigarettes should apply to heat-not-burn products.
The foregoing scientific findings of government agencies may not be indicative of the measures that the relevant government authorities could take in
regulating our products.
71
-- 72 of 111 --
Table of Contents
We make our scientific findings publicly available for scrutiny and peer review through several channels, including our websites. From time to time, adult
consumers, competitors, members of the scientific community, and others inquire into our scientific methodologies, challenge our scientific conclusions or
request further study of certain aspects of our RRPs and their health effects. We are committed to a robust and open scientific debate and believe that such
debate should be based on accurate and reliable scientific information. We seek to provide accurate and reliable scientific information about our RRPs;
nonetheless, we may not be able to prevent third-party dissemination of false, misleading or unsubstantiated information about these products. The
dissemination of scientifically unsubstantiated information or studies with a strong confirmation bias by third parties may cause confusion among adult
smokers and affect their decision to switch to better alternatives to continued smoking, such as our RRPs.
To date, we have been largely successful in demonstrating to regulators that our heated tobacco units are not cigarettes due to the absence of combustion,
and as such they are generally taxed either as a separate category or as other tobacco products, which typically yields more favorable tax rates than
cigarettes. Although we believe that this is sensible from the public health perspective, we cannot guarantee that regulators will continue this approach.
There can be no assurance that we will succeed in our efforts to replace cigarettes with RRPs or that regulation will allow us to commercialize RRPs in all
markets, to communicate about our RRPs, including making scientifically substantiated risk-reduction claims, or to treat RRPs differently from cigarettes.
Legal Challenges to RRPs: We face various administrative and legal challenges related to certain RRP activities, including allegations concerning product
classification, advertising restrictions, corporate communications, product coach activities, scientific substantiation, product liability, and unfair
competition. While we design our programs to comply with relevant regulations, we expect these or similar challenges to continue as we expand our
efforts to commercialize RRPs and to communicate publicly. The outcomes of these matters may affect our RRP commercialization and public
communication activities and performance in one or more markets.
Our RRP Business Development Initiatives: In December 2013, we established a strategic framework with Altria Group, Inc. (“Altria”) setting out terms on
how the parties would collaborate to develop and commercialize e-vapor products and commercialize two of our RRPs in the U.S. In late 2018, Altria
announced that it will participate in the e-vapor category only through another e-vapor company in which Altria acquired a minority interest. In September
2019, Altria's subsidiary, Philip Morris USA Inc. (“PM USA”), began commercialization of a version of our Platform 1 product in the U.S. PM USA is
responsible for the marketing of this product in the U.S. and communication of the reduced exposure information authorized by the FDA in its MRTP
marketing order described above.
In January 2020, we announced an agreement with KT&G, a leading tobacco and nicotine company in South Korea, for the commercialization of KT&G’s
smoke-free products outside of South Korea on an exclusive basis. For more information, see Acquisitions and Other Business Arrangements below.
Other Developments: In September 2017, we announced our support of the Foundation for a Smoke-Free World. In September 2020, our pledge agreement
with the Foundation was amended. We contributed $45 million in 2020, $40 million in 2021, and expect to contribute $35 million annually from 2022
through 2029, as specified in the amended pledge agreement. To date, we contributed a total of $249.5 million. The Foundation is an independent body and
is governed by its independent Board of Directors. The Foundation’s role, as set out in its corporate charter, includes funding research in the field of
tobacco harm reduction, encouraging measures that reduce the harm caused by smoking, and assessing the effect of reduced cigarette consumption on the
industry value chain.
Governmental Investigations
From time to time, we are subject to governmental investigations on a range of matters, including tax, customs, antitrust, advertising, and labor practices.
We describe certain matters pending in Thailand, Russia and South Korea in Note 8. Contingencies.
In November 2010, a WTO panel issued its decision in a dispute relating to facts that arose from August 2006 between the Philippines and Thailand
concerning a series of Thai customs and tax measures affecting cigarettes imported by PM Thailand into Thailand (see Note 8. Contingencies for additional
information). The WTO panel decision, which was upheld by the WTO Appellate Body, concluded that Thailand had no basis to find that PM Thailand's
declared customs values and taxes paid were too low, as alleged by the Department of Special Investigations of the government of Thailand ("DSI") in
2009. The decision
72
-- 73 of 111 --
Table of Contents
also created obligations for Thailand to revise its laws, regulations, or practices affecting the customs valuation and tax treatment of future cigarette
imports. Thailand agreed in September 2011 to fully comply with the decision by October 2012. The Philippines asserts that to date Thailand has not fully
complied with the WTO panel decision and commenced challenges at the WTO Appellate Body. The WTO Appellate Body is not operational, and the
appeals by Thailand are suspended indefinitely. In December 2020, the Philippines and Thailand agreed to pursue facilitator-assisted discussions aimed at
progressing and resolving outstanding issues. It is not possible to predict any future developments in these proceedings or the outcome of these discussions.
The Public Prosecutor’s office of Rome, Italy, notified our Italian subsidiary, Philip Morris Italia S.r.l. (“PM Italia”), as well as three former or current
employees and a former external consultant of PM Italia in July 2020 and March 2020, respectively, that it concluded a preliminary investigation against
them for alleged contravention of anti-corruption laws and related disruption of trade freedom. The Public Prosecutor alleges that the individuals involved
promised certain personal favors to government officials from January to July of 2018 in exchange for favorable treatment for PM Italia, and that PM Italia
lacked appropriate organizational controls to prevent the alleged actions by the individuals. In September 2020, the Public Prosecutor referred the matter to
trial. On May 11, 2021, a preliminary hearing judge referred all charges to trial set to begin September 22, 2021. PM Italia believes the charges brought
against it by the Public Prosecutor are without merit and will defend them vigorously.
Asset Impairment and Exit Costs
We discuss asset impairment and exit costs in Note 16. Asset Impairment and Exit Costs to our condensed consolidated financial statements.
Acquisitions and Other Business Arrangements
We discuss our acquisitions in Note 17. Acquisitions to our condensed consolidated financial statements.
Vectura
On July 9, 2021, PMI announced that it agreed with the board of Vectura Group plc (“Vectura”) on the terms of an all-cash, recommended offer to acquire
Vectura, a U.K.based company, for an enterprise value of GBP 852 million (approximately $1.2 billion, at the then-prevailing exchange rate). Under the
terms of the acquisition, Vectura shareholders would be entitled to receive 150 pence per share, a 46% premium to the ex-dividend closing price per
Vectura share of 103 pence on May 25, 2021.
Vectura is a provider of innovative inhaled drug delivery solutions that enable partners to bring their medicines to patients. The company has thirteen key
inhaled and eleven non-inhaled products marketed by major global pharmaceutical partners, as well as a diverse portfolio of partnerships for drugs in
clinical development. Upon the completion of the acquisition, Vectura will become a wholly owned subsidiary of PMI. PMI will fund the transaction with
existing cash and expects it to close in the second half of 2021, subject to a shareholder vote and approval by the appropriate regulatory authorities. PMI
expects the impact of the acquisition on its full-year 2021 results of operations to be immaterial.
Fertin Pharma
On July 1, 2021, PMI announced that it entered into an agreement to acquire Fertin Pharma A/S (“Fertin Pharma”), a leading developer and manufacturer
of innovative pharmaceutical and well-being products based on oral and intra-oral delivery systems, for an enterprise value of DKK 5.1 billion
(approximately $820 million, at the then-prevailing exchange rate).
Fertin Pharma, a Danish based company, is privately held with more than 850 employees and operations in Denmark, Canada, and India. Fertin Pharma is
currently owned by the global investment organization EQT and Bagger-Sørensen & Co. Upon the completion of the acquisition, Fertin Pharma will
become a wholly owned subsidiary of PMI. PMI will fund the transaction with existing cash and expects it to close in the fourth quarter of 2021, subject to
approval by the appropriate regulatory authorities. PMI expects the impact of the acquisition on its full-year 2021 results of operations to be immaterial.
73
-- 74 of 111 --
Table of Contents
KT&G
In January 2020, PMI announced a global collaboration agreement with the leading tobacco and nicotine company in South Korea, KT&G, to
commercialize KT&G’s smoke-free products outside of the country. The agreement will run for an initial period of three years. The two companies plan for
global collaboration with the intention to actively expand to cover many markets, based on commercial success. The agreement allows PMI to distribute
current KT&G smoke-free products, and their evolutions, on an exclusive basis, and does not restrict PMI from distributing its own or third-party products.
KT&G’s smoke-free product brand portfolio includes heat-not-burn tobacco products (e.g., LIL Mini and LIL Plus), hybrid technologies that combine heat-
not-burn tobacco and e-vapor technologies (e.g., LIL HYBRID), and e-vapor products (e.g., LIL Vapor). PMI will be responsible for the commercialization
of smoke-free products supplied under the agreement.
Products sold under the agreement are subject to careful assessment to ensure they meet the regulatory requirements in the markets where they are
launched, as well as our standards of quality and scientific substantiation to confirm the absence of combustion and significant reductions of emissions of
harmful chemicals compared to cigarettes. PMI and KT&G will seek any necessary regulatory approvals that may be required on a market-by-market basis.
There are no current plans to commercialize KT&G products in the United States.
In the third quarter of 2020, we launched commercial initiatives for licensed KT&G products in select markets.
Equity Investments
We discuss our equity investments in Note 12. Related Parties - Equity Investments and Other to our condensed consolidated financial statements.
Trade Policy
We are subject to various trade restrictions imposed by the United States of America and countries in which we do business (“Trade Sanctions”), including
the trade and economic sanctions administered by the U.S. Department of the Treasury's Office of Foreign Assets Control and the U.S. Department of
State. It is our policy to comply fully with these Trade Sanctions.
Tobacco products are agricultural products under U.S. law and are not technological or strategic in nature. From time to time we make sales in countries
subject to Trade Sanctions, either where such sanctions do not apply to our business or pursuant to exemptions or licenses.
From time to time, a subsidiary sells products to distributors that, in turn, sell those products to duty free customers that supply U.N. peacekeeping forces
around the world, including those in the U.N. peacekeeping mission located in Abyei, a special administrative territory in Sudan. We do not believe that
these sales, which are not subject to Trade Sanctions, and are de minimis in volume and value, present a material risk to our shareholders, our reputation or
the value of our shares. We have no employees, operations or assets in Sudan.
We do not sell products in Iran, North Korea and Syria. From time to time, we explore opportunities to sell our products in one or more of these countries,
as permitted by law.
We sell cigarettes in Cuba under a distribution agreement. These sales are permitted by U.S. law under a License Exception for Agricultural Commodities,
issued by the United States Department of Commerce (Bureau of Industry and Security), granted to our distributor.
Certain states within the U.S. have enacted legislation permitting or requiring state pension funds to divest or abstain from future investment in stocks of
companies that do business with certain countries that are sanctioned by the U.S. Because we do business in certain of these countries, these state pension
funds may have divested of our stock or may not invest in our stock. We do not believe such legislation has had a material effect on the price of our shares.
PMI is also subject to various Trade Sanctions imposed by the EU and other jurisdictions ("Trade Sanctions"). We comply fully with these Trade
Sanctions.
74
-- 75 of 111 --
Table of Contents
The EU imposed new sanctions regarding the Republic of Belarus ("Belarus") on June 21, 2021, including the designation of additional EU sanctions
targets (individuals and legal entities) in Belarus. On June 24, 2021, the EU council introduced new sectoral economic sanctions aimed at specific sectors
of the Belarus economy, including restrictions of trade in goods used for the production or manufacturing of tobacco products. Subsequent to the EU’s
sanctions concerning Belarus, six non-EU countries (Norway, Iceland, Liechtenstein, North Macedonia, Montenegro, and Albania) also announced that
they have “aligned themselves” with the EU individual sanctions of June 21 with immediate effect. On July 6, 2021, Switzerland amended its ordinance to
expand its sanctions against Belarusian individuals and legal entities starting from July 7, 2021, in a scope similar to the EU individual sanctions of June
21, 2021.
PMI complies with all applicable laws and regulations, including sanctions, in the markets where it operates. We have taken appropriate actions in
response to the latest sanctions to ensure full compliance with the relevant restrictions.
Operating Results – Three Months and Six Months Ended June 30, 2021
The following discussion compares operating results within each of our operating segments for the three months and six months ended June 30, 2021, with
the three months and six months ended June 30, 2020.
Unless otherwise stated, references to total industry, total market, our shipment volume and our market share performance reflect cigarettes and heated
tobacco units. Estimates for total industry volume and market share in certain geographies reflect limitations on the availability and accuracy of industry
data.
European Union:
Financial Summary -
Quarters Ended June 30,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2021 2020 Total Excl.
Curr. Total Cur-
rency Price Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 3,149 $ 2,475 27.2 % 15.6 % $ 674 $ 288 $ 35 $ 351 $ —
Operating Income $ 1,641 $ 1,178 39.3 % 24.2 % $ 463 $ 178 $ 35 $ 304 $ (54)
For the three months ended June 30, 2021, net revenues, excluding favorable currency, increased by 15.6%, reflecting: favorable volume/mix, mainly
driven by higher heated tobacco unit volume (notably in Italy and Poland), partly offset by unfavorable cigarette volume/mix (notably unfavorable
volume/mix in Germany, partly offset by higher volume in Italy and Spain); and a favorable pricing variance (driven by higher combustible pricing,
particularly in Germany).
Operating income, excluding favorable currency, increased by 24.2%, primarily reflecting: favorable volume/mix, driven by the same factors as for net
revenues noted above; lower manufacturing costs (driven mainly by combustible products); and a favorable pricing variance; partly offset by higher
marketing, administration and research costs.
Financial Summary -
Six Months Ended June 30,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2021 2020 Total Excl.
Curr. Total Cur-
rency Price Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 6,058 $ 5,010 20.9 % 10.5 % $ 1,048 $ 523 $ 72 $ 453 $ —
Operating Income $ 3,131 $ 2,336 34.0 % 19.7 % $ 795 $ 334 $ 72 $ 405 $ (16)
For the six months ended June 30, 2021, net revenues, excluding favorable currency, increased by 10.5%, reflecting: favorable volume/mix, mainly driven
by higher heated tobacco unit volume (notably in Germany, Italy and Poland), partly offset by lower cigarette volume (notably in the Czech Republic,
France and Germany) and unfavorable cigarette mix (particularly in Germany); and a favorable pricing variance (driven by higher combustible pricing,
primarily in Germany, partly offset by Poland).
75
-- 76 of 111 --
Table of Contents
Operating income, excluding favorable currency, increased by 19.7%, primarily reflecting: favorable volume/mix, driven by the same factors as for net
revenues noted above; lower manufacturing costs (driven by combustible and reduced-risk products); and a favorable pricing variance; partly offset by
higher marketing, administration and research costs.
European Union - Total Market, PMI Shipment Volume and Market Share Commentaries
Total market and market share performance are shown in the table below:
European Union Key Data Second-Quarter Six Months Year-to-Date
Change Change
2021 2020 % / pp 2021 2020 % / pp
Total Market (billion units) 121.6 116.1 4.8 % 228.1 225.5 1.1 %
PMI Market Share
Marlboro 16.7 % 17.7 % (1.0) 16.8 % 17.7 % (0.9)
L&M 5.7 % 6.5 % (0.8) 5.7 % 6.5 % (0.8)
Chesterfield 5.4 % 5.5 % (0.1) 5.4 % 5.6 % (0.2)
Philip Morris 2.2 % 2.6 % (0.4) 2.2 % 2.6 % (0.4)
HEETS 5.5 % 3.9 % 1.6 5.6 % 3.9 % 1.7
Others 3.1 % 3.0 % 0.1 3.2 % 3.0 % 0.2
Total European Union 38.6 % 39.2 % (0.6) 38.9 % 39.3 % (0.4)
Note: HEETS includes HEETS Dimensions.
In the second quarter, the estimated total market in the EU increased by 4.8% to 121.6 billion units, mainly driven by:
• Denmark, up by +100%. Excluding the net favorable impact of estimated trade inventory movements, the total estimated market was down by 16.9%,
primarily reflecting the impact of excise tax-driven price increases;
• Italy, up by 9.3%, mainly reflecting the impact on adult smoker average daily consumption of the easing of pandemic-related measures;
• Poland, up by 17.6%, primarily reflecting the impact on adult smoker average daily consumption and border sales of the easing of pandemic-related
measures, as well as a lower prevalence of illicit trade; and
• Spain, up by 8.9%, or by 5.2% excluding the net favorable impact of estimated trade inventory movements, mainly reflecting the impact on in-bound
tourism and border sales of the easing of pandemic-related measures;
partly offset by
• Germany, down by 7.2%, or by 1.9% excluding the net unfavorable impact of estimated trade inventory movements, primarily due to the impact of
price increases.
For the six months year-to-date, the estimated total market in the EU increased by 1.1% to 228.1 billion units, primarily driven by:
• Italy, up by 5.4%, mainly reflecting the same factor as in the quarter; and
• Poland, up by 8.3%, primarily reflecting the same factors as in the quarter;
partly offset by
• Czech Republic, down by 10.8%, mainly reflecting the impact, in the first quarter of 2021, of lower border sales due to pandemic-related lockdown
measures; and
• France, down by 5.1%, primarily reflecting the impact of excise tax-driven price increases and higher cross-border (non-domestic) purchases due to the
easing of pandemic-related measures.
76
-- 77 of 111 --
Table of Contents
In the second quarter, our total shipment volume increased by 8.7% to 48.4 billion units, primarily driven by:
• Italy, up by 25.8%, or by 11.4% excluding the net favorable impact of estimated distributor inventory movements, mainly reflecting the higher total
market and a higher market share driven by heated tobacco units; and
• Spain, up by 51.5%, or by 8.3% excluding the net favorable impact of estimated distributor inventory movements, mainly reflecting the higher total
market;
partly offset by
• Germany, down by 7.4%, mainly reflecting the lower total market.
Excluding the net favorable impact of estimated distributor inventory movements, our total in-market sales volume increased by 3.2%.
For the six months year-to-date, our total shipment volume increased by 2.0% to 91.6 billion units, primarily driven by:
• Italy, up by 14.4%, or by 7.3% excluding the net favorable impact of estimated distributor inventory movements, mainly reflecting the same factors as
in the quarter; and
• Spain, up by 7.0%, or by 0.5% excluding the net favorable impact of estimated distributor inventory movements, primarily reflecting the same factor
as in the quarter;
partly offset by
• Czech Republic, down by 13.8%, mainly reflecting the lower total market and a lower market share (due to cigarettes, partly offset by heated tobacco
units); and
• France, down by 7.1%, mainly reflecting the lower total market and a lower market share of cigarettes.
Excluding the net favorable impact of estimated distributor inventory movements, our total in-market sales volume increased by 0.2%.
77
-- 78 of 111 --
Table of Contents
Eastern Europe:
Financial Summary -
Quarters Ended June 30,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2021 2020 Total Excl.
Curr. Total Cur-
rency Price Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 895 $ 783 14.3 % 12.5 % $ 112 $ 14 $ 22 $ 76 $ —
Operating Income $ 314 $ 266 18.0 % 32.7 % $ 48 $ (39) $ 22 $ 56 $ 9
For the three months ended June 30, 2021, net revenues, excluding favorable currency, increased by 12.5%, reflecting: favorable volume/mix, driven by
higher heated tobacco unit volume (primarily in Russia and Ukraine), partly offset by unfavorable cigarette volume/mix (primarily in Russia); and a
favorable pricing variance, mainly driven by higher combustible pricing (primarily in Kazakhstan, Russia and Ukraine).
Operating income, excluding unfavorable currency, increased by 32.7%, primarily reflecting: favorable volume/mix, driven by the same factors as for net
revenues noted above; a favorable pricing variance; and lower manufacturing costs (primarily related to reduced-risk products, mainly in Russia).
Financial Summary -
Six Months Ended June 30,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2021 2020 Total Excl.
Curr. Total Cur-
rency Price Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 1,691 $ 1,571 7.6 % 11.5 % $ 120 $ (61) $ 46 $ 135 $ —
Operating Income $ 575 $ 365 57.5 % 66.3 % $ 210 $ (32) $ 46 $ 113 $ 83
For the six months ended June 30, 2021, net revenues, excluding unfavorable currency, increased by 11.5%, reflecting: favorable volume/mix, driven by
higher heated tobacco unit volume (mainly in Russia and Ukraine), partly offset by unfavorable cigarette volume (primarily in Russia and Ukraine); and a
favorable pricing variance, mainly driven by higher combustible pricing (primarily in Kazakhstan, Russia and Ukraine).
Operating income, excluding unfavorable currency, increased by 66.3%, primarily reflecting: favorable volume/mix, driven by the same factors as for net
revenues noted above; lower manufacturing costs (mainly related to reduced-risk products, primarily in Russia); a favorable pricing variance and lower
marketing, administration and research costs.
Eastern Europe - Total Market, PMI Shipment Volume and Market Share Commentaries
In the second quarter, the estimated total market in Eastern Europe decreased, mainly due to:
• Russia, down by 2.7%, primarily reflecting the impact of excise tax-driven price increases, partly offset by the impact on adult smoker average daily
consumption of the easing of pandemic-related measures; and
• Ukraine, down by 3.7%, mainly reflecting the impact of excise tax-driven price increases and a higher prevalence of illicit trade, partly offset by the
impact on adult smoker average daily consumption of the easing of pandemic-related measures.
For the six months year-to-date, the estimated total market in Eastern Europe decreased, notably due to:
• Ukraine, down by 9.5%, mainly reflecting the same factors as in the quarter;
partly offset by
• Russia, up by 0.6%. Excluding the net favorable impact of estimated trade inventory movements, the total estimated market was down by 1.0%,
primarily reflecting: the impact of excise tax-driven price increases, partly offset by the impact on adult smoker average daily consumption of the
easing of pandemic-related measures, as well as a lower estimated prevalence of illicit trade.
78
-- 79 of 111 --
Table of Contents
In the second quarter, our total shipment volume increased by 2.9% to 29.6 billion units, notably driven by:
• Ukraine, up by 8.8%, or by 5.0% excluding the net favorable impact of estimated distributor inventory movements, mainly reflecting a higher market
share driven by heated tobacco units, partially offset by the lower total market;
partly offset by
• Russia, down by 1.7%. Excluding the net favorable impact of estimated distributor inventory movements (primarily due to cigarettes), our in-market
sales decreased by 6.0%, mainly reflecting a lower market share due to cigarettes and the lower total market.
Excluding the net favorable impact of estimated distributor inventory movements, our total in-market sales volume decreased by 0.8%.
For the six months year-to-date, our total shipment volume increased by 1.2% to 55.2 billion units, mainly driven by:
• Russia, up by 1.0%. Excluding the net favorable impact of estimated distributor inventory movements, our total in-market sales volume was down by
3.1%, primarily reflecting a lower market share due to cigarettes.
Excluding the net favorable impact of estimated distributor inventory movements, our total in-market sales volume decreased by 1.2%.
Middle East & Africa:
Financial Summary -
Quarters Ended June 30,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2021 2020 Total Excl.
Curr. Total Cur-
rency Price Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 560 $ 704 (20.5)% (18.2)% $ (144) $ (16) $ 50 $ 100 $ (278)
Operating Income $ 16 $ 237 (93.2)% (79.7)% $ (221) $ (32) $ 50 $ 65 $ (304)
For the three months ended June 30, 2021, net revenues decreased by 20.5%, predominantly due to the unfavorable impact of the Saudi Arabia customs
assessments of $246 million, shown in "Cost/Other". Excluding the unfavorable impact of the Saudi Arabia customs assessments and unfavorable currency,
net revenues increased by 16.8%, primarily reflecting: favorable
79
-- 80 of 111 --
Table of Contents
volume/mix, mainly driven by higher cigarette volume (primarily in PMI Duty Free, South Africa and Turkey, partly offset by the GCC), as well as higher
heated tobacco unit volume (mainly in PMI Duty Free); and a favorable pricing variance (driven by combustible pricing, mainly in Turkey); partly offset
by lower fees for certain distribution rights billed to customers in certain markets, shown in "Cost/Other".
Operating income decreased by 93.2%, predominantly due to the unfavorable impact of the Saudi Arabia customs assessments, as noted above for net
revenues. Excluding the unfavorable impact of the Saudi Arabia customs assessments and unfavorable currency, operating income increased by 22.8%,
mainly reflecting: favorable volume/mix, due to the same factors as for net revenues noted above; and a favorable pricing variance; partly offset by higher
marketing, administration and research costs; and lower fees for certain distribution rights, as noted above for net revenues.
Financial Summary -
Six Months Ended June 30,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2021 2020 Total Excl.
Curr. Total Cur-
rency Price Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 1,361 $ 1,580 (13.9)% (11.4)% $ (219) $ (39) $ 127 $ (59) $ (248)
Operating Income $ 351 $ 558 (37.1)% (29.0)% $ (207) $ (45) $ 127 $ (65) $ (224)
For the six months ended June 30, 2021, net revenues decreased by 13.9%, predominantly due to the unfavorable impact of the Saudi Arabia customs
assessments of $246 million, shown in "Cost/Other". Excluding the unfavorable impact of the Saudi Arabia customs assessments and unfavorable currency,
net revenues increased by 4.2%, primarily reflecting: a favorable pricing variance, driven by combustible pricing (mainly in Egypt and Turkey); partly
offset by unfavorable volume/mix, mainly due to lower cigarette volume (primarily in Kuwait, North Africa and PMI Duty Free, partially offset by South
Africa and Turkey), partly offset by favorable cigarette mix (primarily in PMI Duty Free, Saudi Arabia and Turkey).
Operating income decreased by 37.1%, predominantly due to the unfavorable impact of the Saudi Arabia customs assessments, as noted above for net
revenues. Excluding the unfavorable impact of the Saudi Arabia customs assessments and unfavorable currency, operating income increased by 15.0%,
mainly reflecting: a favorable pricing variance; and lower manufacturing costs; partly offset by unfavorable volume/mix, due to the same factors as for net
revenues noted above.
Middle East & Africa - Total Market, PMI Shipment Volume and Market Share Commentaries
In the second quarter, the estimated total market in the Middle East & Africa increased, mainly driven by:
• Egypt, up by 43.9%, or by 35.6% excluding the net favorable impact of estimated trade inventory movements, primarily reflecting: a favorable
comparison due to pandemic-related supply-chain shortages involving competitors' products in the second quarter of 2020 and in-switching to
cigarettes from other combustible tobacco products;
• International Duty Free, up by 54.1%, reflecting the impact of reduced government travel restrictions and increased passenger traffic in certain
geographies;
• South Africa, reflecting a favorable comparison versus the second quarter of 2020, in which the total market was fully impacted by the pandemic-
related ban on all tobacco sales from March 27, 2020, through August 17, 2020; and
• Turkey, up by 7.7%, mainly reflecting the impact on adult smoker average daily consumption of the easing of pandemic-related measures.
For the six months year-to-date, the estimated total market in the Middle East & Africa increased, mainly driven by:
• Egypt, up by 22.9%, or by 17.8% excluding the net favorable impact of estimated trade inventory movements, primarily reflecting the same factors as
in the quarter;
• South Africa, up by 45.6%, primarily reflecting a favorable comparison versus the second quarter of 2020, in which the total market was fully
impacted by the pandemic-related ban on all tobacco sales from March 27, 2020, through August 17, 2020, partly offset by a higher estimated
prevalence of illicit trade stemming from the aforementioned ban; and
80
-- 81 of 111 --
Table of Contents
• Turkey, up by 2.8%, mainly reflecting the impact on adult smoker average daily consumption of the easing of pandemic-related measures, as well as a
lower estimated prevalence of illicit trade related to cut tobacco (particularly in the first quarter of 2021);
partly offset by
• International Duty Free, down by 31.7%, primarily reflecting the impact of government travel restrictions and reduced passenger traffic since the start
of the pandemic in March 2020.
In the second quarter, our total shipment volume increased by 12.7% to 30.9 billion units, notably driven by:
• Egypt, up by 13.3%, primarily reflecting the higher total market, partly offset by a lower market share (due to an unfavorable comparison following
pandemic-related supply-chain shortages involving competitors' products during the second quarter of 2020);
• PMI Duty Free, up by +100%, or by 89.3% excluding the net favorable impact of estimated distributor inventory movements, mainly reflecting the
higher total market and a higher market share; and
• Turkey, up by 16.1%, primarily reflecting a higher market share, driven by the growth of Marlboro and Parliament, as well as the higher total market;
partly offset by
• Saudi Arabia, down by 27.1%, or by 5.7% excluding the net unfavorable impact of estimated distributor inventory movements, mainly reflecting a
lower total market, partly offset by a higher market share of cigarettes (driven by Parliament) and heated tobacco units.
For the six months year-to-date, our total shipment volume increased by 1.8% to 58.9 billion units, notably driven by:
• Turkey, up by 12.2%, mainly reflecting a higher market share (driven by Marlboro and Parliament) and the higher total market;
partly offset by
• PMI Duty Free, down by 30.3%, or by 23.9% excluding the net unfavorable impact of estimated distributor inventory movements (principally due to
cigarettes), mainly reflecting the lower total market, partly offset by a higher market share.
81
-- 82 of 111 --
Table of Contents
South & Southeast Asia:
Financial Summary -
Quarters Ended June 30,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2021 2020 Total Excl.
Curr. Total Cur-
rency Price Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 1,046 $ 889 17.7 % 10.0 % $ 157 $ 68 $ 20 $ 69 $ —
Operating Income $ 331 $ 289 14.5 % 8.0 % $ 42 $ 19 $ 20 $ 33 $ (30)
For the three months ended June 30, 2021, net revenues, excluding favorable currency, increased by 10.0%, reflecting: favorable volume/mix, due to higher
cigarette volume (primarily in Indonesia, partly offset by the Philippines); and a favorable pricing variance (driven by combustible pricing mainly in the
Philippines, partly offset by Indonesia).
Operating income, excluding favorable currency, increased by 8.0%, primarily reflecting: favorable volume/mix, due to the same factors as for net revenues
noted above; and a favorable pricing variance; partly offset by higher marketing, administration and research costs (mainly related to combustible products
in Indonesia and the Philippines).
Financial Summary -
Six Months Ended June 30,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2021 2020 Total Excl.
Curr. Total Cur-
rency Price Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 2,219 $ 2,140 3.7 % (0.8)% $ 79 $ 96 $ (18) $ 1 $ —
Operating Income $ 860 $ 888 (3.2)% (6.8)% $ (28) $ 32 $ (18) $ (39) $ (3)
For the six months ended June 30, 2021, net revenues, excluding favorable currency, decreased by 0.8%, reflecting: an unfavorable pricing variance, due to
Indonesia, partially offset by the Philippines. Volume/mix was essentially stable, notably reflecting favorable cigarette mix (primarily in Indonesia and the
Philippines), partly offset by lower cigarette volume (mainly in the Philippines, partially offset by Indonesia).
Operating income, excluding favorable currency, decreased by 6.8%, primarily reflecting: unfavorable volume/mix, due mainly to lower cigarette volume
(primarily in the Philippines, partially offset by Indonesia), partly offset by favorable cigarette mix (mainly in Indonesia and the Philippines); and an
unfavorable pricing variance.
South & Southeast Asia - Total Market, PMI Shipment Volume and Market Share Commentaries
In the second quarter, the estimated total market in South & Southeast Asia increased, notably driven by:
• Bangladesh, up by 30.9%, primarily reflecting a favorable comparison versus the second quarter of 2020, during which pandemic-related restrictions
impacted tobacco product availability;
• India, up by 35.7%, mainly reflecting a favorable comparison versus the second quarter of 2020, during which pandemic-related restrictions impacted
the movement of certain products, including tobacco; and
• Indonesia, up by 12.4%, mainly reflecting the growth of the tax-advantaged 'below tier one' segment and the impact on adult smoker average daily
consumption of the easing of pandemic-related measures.
For the six months year-to-date, the estimated total market in South & Southeast Asia increased, mainly driven by:
• Bangladesh, up by 13.2%, primarily reflecting the same factor as in the quarter;
• India, up by 16.7%, mainly reflecting the same factor as in the quarter;
• Indonesia, up by 8.7%, primarily reflecting the same factors as in the quarter;
• Pakistan, up by 14.6%, or by 9.3% excluding the net favorable impact of estimated trade inventory movements, notably reflecting a lower prevalence
of illicit trade (partly due to pandemic-related supply disruptions for illicit products); and
82
-- 83 of 111 --
Table of Contents
• Vietnam, up by 7.4%, mainly reflecting a lower prevalence of illicit trade due to pandemic-related supply disruptions for illicit products;
partly offset by:
• the Philippines, down by 9.0%, primarily reflecting the impact of industry-wide price increases in the fourth quarter of 2020.
In the second quarter, our total shipment volume increased by 6.0% to 35.4 billion units, notably driven by:
• Indonesia, up by 11.5%, primarily reflecting the higher total market, partly offset by a lower market share (mainly due to adult smoker down-trading to
the 'below tier one' segment as a result of significantly lower retail prices, partly offset by share growth for our premium and hand-rolled kretek
portfolio); and
• Thailand, up by 28.0%, or by 12.6% excluding the net favorable impact of estimated distributor inventory movements, primarily due to a higher total
market and a higher market share (driven by L&M 7.1);
partly offset by
• the Philippines, down by 12.0%, mainly reflecting a lower market share (primarily due to mid-price Fortune, reflecting the impact of price increases in
the fourth quarter of 2020, partly offset by Marlboro), as well as a lower total market.
For the six months year-to-date, our total shipment volume decreased by 0.9% to 70.3 billion units, notably due to:
• the Philippines, down by 18.3%, mainly reflecting the same factors as in the quarter;
partly offset by:
• Indonesia, up by 3.9%, primarily reflecting the same factors as in the quarter;
• Pakistan, up by 12.8%, mainly reflecting the higher total market; and
• Thailand, up by 9.1%, primarily reflecting the same factors as in the quarter.
83
-- 84 of 111 --
Table of Contents
East Asia & Australia:
Financial Summary -
Quarters Ended June 30,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2021 2020 Total Excl.
Curr. Total Cur-
rency Price Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 1,514 $ 1,432 5.7 % 3.1 % $ 82 $ 37 $ 88 $ (43) $ —
Operating Income $ 715 $ 669 6.9 % 7.0 % $ 46 $ (1) $ 88 $ (40) $ (1)
For the three months ended June 30, 2021, net revenues, excluding favorable currency, increased by 3.1%, reflecting: a favorable pricing variance,
primarily driven by higher heated tobacco and combustible pricing in Japan; and unfavorable volume/mix, mainly due to lower cigarette volume (primarily
in Japan), partly offset by higher heated tobacco unit volume (predominantly in Japan).
Operating income, excluding unfavorable currency, increased by 7.0%, mainly reflecting: a favorable pricing variance; and lower manufacturing costs
(primarily related to reduced-risk products in Japan); partly offset by higher marketing, administration and research costs; and unfavorable volume/mix,
due to the same factors as for net revenues noted above.
Financial Summary -
Six Months Ended June 30,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2021 2020 Total Excl.
Curr. Total Cur-
rency Price Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 2,986 $ 2,687 11.1 % 7.1 % $ 299 $ 108 $ 193 $ (2) $ —
Operating Income $ 1,410 $ 1,155 22.1 % 20.6 % $ 255 $ 17 $ 193 $ 18 $ 27
For the six months ended June 30, 2021, net revenues, excluding favorable currency, increased by 7.1%, mainly reflecting: a favorable pricing variance,
primarily driven by higher heated tobacco and combustible pricing in Japan. Volume/mix was essentially stable, mainly reflecting: lower cigarette volume
(primarily in Japan and South Korea), unfavorable cigarette mix (mainly in Australia and Japan), lower device volume (primarily in Japan) and unfavorable
heated tobacco unit mix in Japan, partly offset by higher heated tobacco unit volume in Japan.
Operating income, excluding favorable currency, increased by 20.6%, mainly reflecting: a favorable pricing variance; lower manufacturing costs (primarily
related to reduced-risk products in Japan); and favorable volume/mix, driven by higher heated tobacco unit volume in Japan, partly offset by lower cigarette
volume (mainly in Japan and South Korea), unfavorable cigarette mix (primarily in Australia and Japan) and unfavorable heated tobacco unit mix in Japan;
partially offset by higher marketing, administration and research costs (mainly due to higher asset impairment and exit costs, primarily associated with
product distribution restructuring in South Korea).
East Asia & Australia - Total Market, PMI Shipment Volume and Market Share Commentaries
In the second quarter, the estimated total market in East Asia & Australia, excluding China, decreased, primarily due to:
• Australia, down by 7.8%, or by 12.5% excluding the net favorable impact of estimated trade inventory movements, mainly reflecting the impact of the
ending of the pandemic-related wage subsidy by the government; and
• South Korea, down by 1.6%, mainly reflecting the structural market trend.
For the six months year-to-date, the estimated total market in East Asia & Australia, excluding China, decreased, mainly due to:
• Japan, down by 4.2%, primarily reflecting the impact of excise tax-driven price increases.
84
-- 85 of 111 --
Table of Contents
In the second quarter, our total shipment volume decreased by 1.3% to 20.9 billion units, primarily due to:
• South Korea, down by 5.9%, mainly reflecting a lower market share (primarily due to the unfavorable impact of the growth of the cigarette new taste
dimension segment, in which PMI has a relatively low share) and the lower total market.
Excluding the net unfavorable impact of estimated distributor inventory movements, our total in-market sales volume was essentially stable.
For the six months year-to-date, our total shipment volume increased by 2.0% to 41.4 billion units, notably driven by:
• Japan, up by 3.9%, mainly reflecting a higher market share driven by heated tobacco units, partially offset by the lower total market;
partly offset by
• South Korea, down by 5.0%, primarily reflecting a lower market share (due to the same factor as in the quarter).
Excluding the net unfavorable impact of estimated distributor inventory movements, our total in-market sales volume was stable.
Latin America & Canada:
Financial Summary -
Quarters Ended June 30,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2021 2020 Total Excl.
Curr. Total Cur-
rency Price Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 430 $ 368 16.8 % 9.0 % $ 62 $ 29 $ 11 $ 22 $ —
Operating Income $ 112 $ 92 21.7 % 19.6 % $ 20 $ 2 $ 11 $ 10 $ (3)
For the three months ended June 30, 2021, net revenues, excluding favorable currency, increased by 9.0%, reflecting: favorable volume/mix, mainly driven
by higher cigarette volume (primarily in Mexico); and a favorable pricing variance (driven by combustible products).
85
-- 86 of 111 --
Table of Contents
Operating income, excluding favorable currency, increased by 19.6%, primarily reflecting: a favorable pricing variance; and favorable volume/mix, due to
the same factor as for net revenues noted above.
Financial Summary -
Six Months Ended June 30,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2021 2020 Total Excl.
Curr. Total Cur-
rency Price Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 864 $ 816 5.9 % 3.7 % $ 48 $ 18 $ 12 $ 16 $ 2
Operating Income $ 246 $ 218 12.8 % 9.2 % $ 28 $ 8 $ 12 $ (6) $ 14
For the six months ended June 30, 2021, net revenues, excluding favorable currency, increased by 3.7%, mainly reflecting: favorable volume/mix,
primarily driven by higher cigarette volume (mainly in Brazil and Mexico); and a favorable pricing variance, driven by higher combustible pricing (notably
in Argentina and Colombia).
Operating income, excluding favorable currency, increased by 9.2%, primarily reflecting: lower marketing, administration and research costs; and a
favorable pricing variance.
Latin America & Canada - Total Market, PMI Shipment Volume and Market Share Commentaries
In the second quarter, the estimated total market in Latin America & Canada increased, mainly driven by:
• Argentina, up by 5.1%, or by 12.2% excluding the net unfavorable impact of estimated trade inventory movements, primarily reflecting a lower
estimated prevalence of illicit trade and a favorable comparison related to retail out-of-stock in the second quarter of 2020 (due to temporary factory
shutdowns related to the pandemic), partly offset by the impact of price increases;
• Brazil, up by 8.8%, mainly reflecting a lower estimated prevalence of illicit trade due to: reduced price gaps with legal products and the impact of
border restrictions imposed as a result of the pandemic; and
• Mexico, up by 6.3%, primarily reflecting the impact on adult smoker consumption patterns of the easing of pandemic-related measures;
partly offset by
• Canada, down by 11.8%, notably reflecting the impact of price increases and out-switching from cigarettes to e-vapor products.
For the six months year-to-date, the estimated total market in Latin America & Canada increased, notably driven by:
• Argentina, up by 11.5%, primarily reflecting the same factors as in the quarter;
• Brazil, up by 8.5%, mainly reflecting the same factors as in the quarter; and
• Mexico, up by 4.2%, primarily reflecting the same factors as in the quarter;
partly offset by
• Canada, down by 5.8%, mainly reflecting the same factors as in the quarter.
86
-- 87 of 111 --
Table of Contents
In the second quarter, our total shipment volume increased by 3.2% to 15.4 billion units, mainly driven by:
• Brazil, up by 7.3%, primarily reflecting the higher total market; and
• Mexico, up by 7.9%, mainly reflecting the higher total market and a higher market share (driven by Marlboro);
partly offset by
• Argentina, down by 4.8%, mainly reflecting a lower market share (primarily due to adult smoker down-trading to ultra-low-price brands produced by
local manufacturers).
For the six months year-to-date, our total shipment volume increased by 1.0% to 30.3 billion units, primarily driven by:
• Brazil, up by 8.5%, mainly reflecting the higher total market; and
• Mexico, up by 3.9%, primarily reflecting the higher total market;
partly offset by
• Argentina, down by 2.4%, mainly reflecting a lower market share (primarily due to the same factor as in the quarter).
87
-- 88 of 111 --
Table of Contents
Financial Review
Cash Flow Highlights
For the Six Months Ended June 30,
(in millions) 2021 2020
Net cash provided by operating activities $ 4,065 $ 3,036
Net cash used in investing activities (128) (134)
Net cash used in financing activities (6,123) (5,503)
Net Cash Provided by Operating Activities
During the first six months of 2021, net cash provided by operating activities increased by $1.0 billion compared with the first six months of 2020.
Excluding favorable currency movements of $0.6 billion, net cash provided by operating activities increased by $0.4 billion, due primarily to higher net
earnings, partially offset by higher working capital requirements of $0.2 billion and higher pension plan contributions.
While the impact of the 2021 Saudi Arabia customs assessments reduced net earnings by $0.2 billion, there was no net impact on operating cash flows for
the six months, as the change in the accrued liability offset the net earnings impact. Excluding this impact, the higher working capital requirements in the
first six months of 2021 as compared with the first six months of 2020 were primarily due to the timing of excise tax-paid inventory movements and excise
tax payments, as well as lower usage of our factoring arrangements to sell trade receivables, partially offset by more cash provided by inventories primarily
due to COVID-19 pandemic related build-up of inventory levels across our supply chain in 2020. For further details on our factoring arrangements to sell
trade receivables, see Note 13. Sale of Accounts Receivable.
Net Cash Used in Investing Activities
During the first six months of 2021, net cash used in investing activities was essentially flat as compared to the first six months of 2020.
In May 2021, PMI acquired 100% of AG Snus Aktieselskab ("AG Snus"), a Danish based company, and its Swedish subsidiary Tobacco House of Sweden
AB fully owned by AG Snus, which operates in the oral tobacco (i.e. Snus) and modern oral (i.e. Nicotine Pouches) product categories. The purchase price
was $27 million in cash, net of cash acquired. For further details, see Note 17. Acquisitions.
88
-- 89 of 111 --
Table of Contents
Capital expenditures during the first six months of 2021 was essentially flat as compared with the first six months of 2020. The 2021 capital expenditures
were primarily related to our ongoing investments in RRPs. We expect total capital expenditures in 2021 to be approximately $0.8 billion.
Net Cash Used in Financing Activities
During the first six months of 2021, net cash used in financing activities increased by $0.6 billion compared to the first six months of 2020. The change
was due to the proceeds we received in 2020 from long-term U.S. dollar debt issuances ($2.2 billion), partially offset by lower long-term debt repayments
of $1.6 billion ($2.0 billion in 2021 compared with $3.6 billion in 2020).
Debt and Liquidity
We define cash and cash equivalents as short-term, highly liquid investments, readily convertible to known amounts of cash that mature within a maximum
of three months and have an insignificant risk of change in value due to interest rate or credit risk changes. As a policy, we do not hold any investments in
structured or equity-linked products. Our cash and cash equivalents are predominantly held with institutions that have investment-grade long-term credit
rating. As part of our cash management strategy and in order to manage counterparty exposure, we also enter into reverse repurchase agreements. Such
agreements are collateralized with government or corporate securities held by a custodial bank and, at maturity, cash is paid back to PMI, and the collateral
is returned to the bank. For the six months ended June 30, 2021 and the full-year 2020, the activities for such reverse repurchase agreements were not
material.
As previously disclosed in the “Acquisitions and Other Business Arrangements” section of this MD&A, on July 9, 2021, PMI announced that it agreed with
the board of Vectura Group plc (“Vectura”) on the terms of an all-cash, recommended offer to acquire Vectura, a U.K. based company, for an enterprise
value of GBP 852 million (approximately $1.2 billion, at the then-prevailing exchange rate). PMI will fund the transaction with existing cash. In July 2021,
in anticipation of this acquisition, PMI deposited $1.5 billion of existing cash (including a reserve for foreign exchange volatility) to a designated account
operated solely for the purpose of funding this transaction. This restricted cash of $1.5 billion will be included in other current assets in our consolidated
balance sheets starting in July 2021 until the closing.
We utilize long-term and short-term debt financing, including a commercial paper program that is regularly used to finance ongoing liquidity requirements,
as part of our overall cash management strategy. Our ability to access the capital and credit markets as well as overall dynamics of these markets may
impact borrowing costs. We expect that the combination of our long-term and short-term debt financing, the commercial paper program and the committed
credit facilities, coupled with our operating cash flows, will enable us to meet our liquidity requirements.
Credit Ratings – The cost and terms of our financing arrangements as well as our access to commercial paper markets may be affected by applicable credit
ratings. At June 30, 2021, our credit ratings and outlook by major credit rating agencies were as follows:
Short-term Long-term Outlook
Moody’s P-1 A2 Stable
Standard & Poor’s A-1 A Stable
Fitch F1 A Stable
89
-- 90 of 111 --
Table of Contents
Credit Facilities – On January 29, 2021, we entered into an agreement to amend and extend the term of our 364-day revolving credit facility from February
2, 2021, to February 1, 2022 in the amount of $1.75 billion.
At June 30, 2021, our committed credit facilities were as follows:
(in billions)
Type
Committed
Credit
Facilities
364-day revolving credit, expiring February 1, 2022 $ 1.75
Multi-year revolving credit, expiring October 1, 2022 3.50
Multi-year revolving credit, expiring February 10, 2025 2.00
Total facilities $ 7.25
On January 29, 2021, we entered into an agreement, effective February 10, 2021, to amend and extend the term of our multi-year revolving credit facility, for an
additional year covering the period February 11, 2025 to February 10, 2026, in the amount of $1.86 billion. Effective July 2, 2021, the total facility amount for this
additional year is $1.95 billion.
At June 30, 2021, there were no borrowings under the committed credit facilities, and the entire committed amounts were available for borrowing.
All banks participating in our committed credit facilities have an investment-grade long-term credit rating from the credit rating agencies. We continuously
monitor the credit quality of our banking group, and at this time we are not aware of any potential non-performing credit provider.
These facilities do not include any credit rating triggers, material adverse change clauses or any provisions that could require us to post collateral. The $3.5
billion multi-year revolving credit facility in the table above requires us to maintain a ratio of consolidated earnings before interest, taxes, depreciation and
amortization (“consolidated EBITDA”) to consolidated interest expense of not less than 3.5 to 1.0 on a rolling four-quarter basis. At June 30, 2021, our
ratio calculated in accordance with the agreement was 14.3 to 1.0. We expect to continue to meet our covenants. The terms “consolidated EBITDA” and
“consolidated interest expense,” both of which include certain adjustments, are defined in the facility agreement previously filed with the U.S. Securities
and Exchange Commission.
In addition to the committed credit facilities discussed above, certain of our subsidiaries maintain short-term credit arrangements to meet their respective
working capital needs. These credit arrangements, which amounted to approximately $2.4 billion at June 30, 2021 and $2.7 billion at December 31, 2020,
are for the sole use of our subsidiaries. Borrowings under these arrangements and other bank loans amounted to $136 million at June 30, 2021, and $244
million at December 31, 2020.
Commercial Paper Program – We continue to have access to liquidity in the commercial paper market through programs in place in the U.S. and in Europe
having an aggregate issuance capacity of $8.0 billion. At June 30, 2021 and December 31, 2020, we had no commercial paper outstanding. The average
commercial paper balance outstanding during the first six months of 2021 was $1.1 billion. The average commercial paper balance outstanding during 2020
was $1.2 billion.
Sale of Accounts Receivable – To mitigate credit risk and enhance cash and liquidity management, we sell trade receivables to unaffiliated financial
institutions. These arrangements allow us to sell, on an ongoing basis, certain trade receivables without recourse. The trade receivables sold are generally
short-term in nature and are removed from the condensed consolidated balance sheets. We sell trade receivables under two types of arrangements, servicing
and nonservicing.
Our operating cash flows were positively impacted by the amount of the trade receivables sold and derecognized from the condensed consolidated balance
sheets, which remained outstanding with the unaffiliated financial institutions. The trade receivables sold that remained outstanding under these
arrangements as of June 30, 2021, and June 30, 2020 were $0.7 billion and $0.6 billion, respectively. The net proceeds received are included in cash
provided by operating activities in the condensed consolidated statements of cash flows.
For further details, see Note 13. Sale of Accounts Receivable to our condensed consolidated financial statements.
Debt – Our total debt was $29.2 billion at June 30, 2021 and $31.5 billion at December 31, 2020.
(a)
(a)
90
-- 91 of 111 --
Table of Contents
On February 11, 2020, we filed a shelf registration statement with the U.S. Securities and Exchange Commission, under which we may from time to time
sell debt securities and/or warrants to purchase debt securities over a three-year period.
Guarantees – At June 30, 2021, we were contingently liable for guarantees of our own performance, of which $0.3 billion were related to our obligations
under indemnity agreements to enable appeals of customs assessments against our distributors. In July 2021, our obligations under those indemnity
agreements were reduced to $0.1 billion. In October 2020, we guaranteed an obligation for an equity method investee. For further details, see Note 8.
Contingencies to our condensed consolidated financial statements. Additionally, we have other guarantees of our own performance, which are primarily
related to excise taxes on the shipment of our products. There is no liability in the condensed consolidated financial statements associated with these
guarantees. These guarantees have not had, and are not expected to have, a significant impact on PMI’s liquidity.
Equity and Dividends
We discuss our stock awards as of June 30, 2021 in Note 2. Stock Plans to our condensed consolidated financial statements.
During 2020 and the first six months of 2021, we did not repurchase any shares under a share repurchase program. On June 11, 2021, our Board of
Directors authorized a new share repurchase program of up to $7 billion, with target spending of $5 billion to $7 billion over a three-year period that will
commence in the third quarter of 2021.
Dividends paid in the first six months of 2021 were $3.8 billion. During the third quarter of 2020, our Board of Directors approved a 2.6% increase in the
quarterly dividend to $1.20 per common share. As a result, the present annualized dividend rate is $4.80 per common share.
Market Risk
Counterparty Risk - We predominantly work with financial institutions with strong short- and long-term credit ratings as assigned by Standard & Poor’s
and Moody’s. These banks are also part of a defined group of relationship banks. Non-investment grade institutions are only used in certain emerging
markets to the extent required by local business needs. We have a conservative approach when it comes to choosing financial counterparties and financial
instruments. As such, we do not invest or hold investments in any structured or equity-linked products. The majority of our cash and cash equivalents is
currently invested with maturities of less than 30 days.
We continuously monitor and assess the credit worthiness of all our counterparties.
Derivative Financial Instruments - We operate in markets outside of the United States of America, with manufacturing and sales facilities in various
locations throughout the world. Consequently, we use certain financial instruments to manage our foreign currency and interest rate exposure. We use
derivative financial instruments principally to reduce our exposure to market risks resulting from fluctuations in foreign exchange and interest rates by
creating offsetting exposures. We are not a party to leveraged derivatives and, by policy, do not use derivative financial instruments for speculative
purposes.
See Note 5. Financial Instruments to our condensed consolidated financial statements for further details on our derivative financial instruments and the
related collateral arrangements.
Contingencies
See Note 8. Contingencies to our condensed consolidated financial statements for a discussion of contingencies.
Cautionary Factors That May Affect Future Results
Forward-Looking and Cautionary Statements
We may from time to time make written or oral forward-looking statements, including statements contained in filings with the SEC, in reports to
stockholders and in press releases and investor webcasts. You can identify these forward-looking statements by use of words such as "strategy," "expects,"
"continues," "plans," "anticipates," "believes," "will," "aspires," "estimates," "intends," "projects," "aims," "goals," "targets," "forecasts" and other words of
similar meaning. You can also identify them by the fact that they do not relate strictly to historical or current facts.
91
-- 92 of 111 --
Table of Contents
We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans and assumptions. Our
RRPs constitute a new product category in its early stages that is less predictable than our mature cigarette business. Achievement of future results is
subject to risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions
prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. Investors should bear this in mind as they consider
forward-looking statements and whether to invest in or remain invested in our securities. In connection with the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995, we are identifying important factors that, individually or in the aggregate, could cause actual results and
outcomes to differ materially from those contained in any forward-looking statements made by us; any such statement is qualified by reference to the
following cautionary statements. We elaborate on these and other risks we face throughout this document, particularly in the "Business Environment"
section. You should understand that it is not possible to predict or identify all risk factors. Consequently, you should not consider the following to be a
complete discussion of all potential risks or uncertainties. We do not undertake to update any forward-looking statement that we may make from time to
time, except in the normal course of our public disclosure obligations.
Overall Business Risks
Consumption of tax-paid cigarettes continues to decline in many of our markets.
This decline is due to multiple factors, including increased taxes and pricing, governmental actions, the diminishing social acceptance of smoking and
health concerns, continuing economic and geopolitical uncertainty, and the continuing prevalence of illicit products. These factors and their potential
consequences are discussed more fully below and in the "Business Environment" section.
Cigarettes are subject to substantial taxes. Significant increases in cigarette-related taxes have been proposed or enacted and are likely to continue to be
proposed or enacted in numerous jurisdictions. These tax increases may disproportionately affect our profitability and make us less competitive versus
certain of our competitors.
Tax regimes, including excise taxes, sales taxes and import duties, can disproportionately affect the retail price of cigarettes versus other combustible
tobacco products, or disproportionately affect the relative retail price of our cigarette brands versus cigarette brands manufactured by certain of our
competitors. Because our portfolio is weighted toward the premium-price cigarette category, tax regimes based on sales price can place us at a competitive
disadvantage in certain markets. As a result, our volume and profitability may be adversely affected in these markets.
Increases in cigarette taxes are expected to continue to have an adverse impact on our sales of cigarettes, due to resulting lower consumption levels, a shift
in sales from manufactured cigarettes to other combustible tobacco products and from the premium-price to the mid-price or low-price cigarette categories,
where we may be under-represented, from local sales to legal cross-border purchases of lower price products, or to illicit products such as contraband,
counterfeit and "illicit whites."
Our business faces significant governmental action aimed at increasing regulatory requirements with the goal of reducing or preventing the use of tobacco
products.
Governmental actions, combined with the diminishing social acceptance of smoking and private actions to restrict smoking, have resulted in reduced
industry volumes in many of our markets, and we expect that such factors will continue to reduce consumption levels and will increase down-trading and
the risk of counterfeiting, contraband, "illicit whites" and legal cross-border purchases. Significant regulatory developments will continue to take place over
the next few years in most of our markets, driven principally by the World Health Organization's Framework Convention on Tobacco Control (the
"FCTC"). Since it came into force in 2005, the FCTC has led to increased efforts by tobacco control advocates and public health organizations to promote
increasingly restrictive regulatory measures on the marketing and sale of tobacco products to adult smokers. Regulatory initiatives that have been proposed,
introduced or enacted include:
• restrictions on or licensing of outlets permitted to sell cigarettes;
• the levying of substantial and increasing tax and duty charges;
• restrictions or bans on advertising, marketing and sponsorship;
• the display of larger health warnings, graphic health warnings and other labeling requirements;
92
-- 93 of 111 --
Table of Contents
• restrictions on packaging design, including the use of colors, and mandating plain packaging;
• restrictions on packaging and cigarette formats and dimensions;
• restrictions or bans on the display of tobacco product packaging at the point of sale and restrictions or bans on vending machines;
• requirements regarding testing, disclosure and performance standards for tar, nicotine, carbon monoxide and other smoke constituents;
• disclosure, restrictions, or bans of tobacco product ingredients, including bans on the flavors of certain tobacco products;
• increased restrictions on smoking and use of tobacco and nicotine-containing products in public and work places and, in some instances, in
private places and outdoors;
• restrictions or prohibitions of novel tobacco or nicotine-containing products;
• elimination of duty free sales and duty free allowances for travelers;
• encouraging litigation against tobacco companies; and
• excluding tobacco companies from transparent public dialogue regarding public health and other policy matters.
Our financial results could be materially affected by regulatory initiatives resulting in a significant decrease in demand for our brands. More specifically,
requirements that lead to a commoditization of tobacco products or impede adult consumers' ability to convert to our RRPs, as well as any significant
increase in the cost of complying with new regulatory requirements could have a material adverse effect on our financial results.
Changes in the earnings mix and changes in tax laws may result in significant variability in our effective tax rates. Our ability to receive payments from
foreign subsidiaries or to repatriate royalties and dividends could be restricted by local country currency exchange controls and other regulations.
We are subject to income tax laws in the United States and numerous foreign jurisdictions. The results of the 2020 U.S. presidential and congressional
elections could lead to changes in the U.S. tax system, including significant increases in the U.S. corporate income tax rate and the minimum tax rate on
certain earnings of foreign subsidiaries. If ultimately enacted into law, such changes could have a material adverse impact on our effective tax rate thereby
reducing our net earnings. Further changes in the tax laws of foreign jurisdictions could arise as a result of the base erosion and profit shifting project
undertaken by the Organisation for Economic Co-operation and Development, which recommended changes to numerous long-standing tax principles. If
implemented, such changes, as well as changes in taxing jurisdictions’ administrative interpretations, decisions, policies, or positions, could also have a
material adverse impact on our effective tax rate thereby reducing our net earnings. In future periods, our ability to recover deferred tax assets could be
subject to additional uncertainty as a result of such developments. Furthermore, changes in the earnings mix or applicable foreign tax laws may result in
significant variability in our effective tax rates.
Because we are a U.S. holding company, our most significant source of funds is distributions from our non-U.S. subsidiaries. Certain countries in which we
operate have adopted or could institute currency exchange controls and other regulations that limit or prohibit our local subsidiaries' ability to convert local
currency into U.S. dollars or to make payments outside the country. This could subject us to the risks of local currency devaluation and business disruption.
Risks Related to our International Operations
Because we have operations in numerous countries, our results may be adversely impacted by economic, regulatory and political developments, natural
disasters, pandemics or conflicts.
Some of the countries in which we operate face the threat of civil unrest and can be subject to regime changes. In others, nationalization, terrorism, conflict
and the threat of war may have a significant impact on the business environment. Natural disasters, pandemics, economic, political, regulatory or other
developments could disrupt our supply chain, manufacturing capabilities or distribution capabilities. In addition, such developments could increase costs of
our materials and operations and lead to loss of property or equipment that are critical to our business in certain markets and difficulty in staffing and
managing our operations, all of which could reduce our volumes, revenues and net earnings. We discuss risks associated with the COVID-19 pandemic
below.
In certain markets, we are dependent on governmental approvals of various actions such as price changes, and failure to obtain such approvals could impair
growth of our profitability.
93
-- 94 of 111 --
Table of Contents
In addition, despite our high ethical standards and rigorous control and compliance procedures aimed at preventing and detecting unlawful conduct, given
the breadth and scope of our international operations, we may not be able to detect all potential improper or unlawful conduct by our employees and
partners. Such improper or unlawful conduct (actual or alleged) could lead to litigation and regulatory action, cause damage to our reputation and that of
our brands and result in substantial costs.
Our reported results could be adversely affected by unfavorable currency exchange rates, and currency devaluations could impair our competitiveness.
We conduct our business primarily in local currency and, for purposes of financial reporting, the local currency results are translated into U.S. dollars based
on average exchange rates prevailing during a reporting period. During times of a strengthening U.S. dollar, our reported net revenues, operating income
and EPS will be reduced because the local currency translates into fewer U.S. dollars. During periods of economic crises, such as during the ongoing
COVID-19 pandemic, foreign currencies may be devalued significantly against the U.S. dollar, reducing our margins. Actions to recover margins may
result in lower volume and a weaker competitive position.
Risks Related to Legal Challenges and Investigations
Litigation related to tobacco use and exposure to environmental tobacco smoke could substantially reduce our profitability and could severely impair our
liquidity.
There is litigation related to tobacco products pending in certain jurisdictions in which we operate. Damages claimed in some tobacco-related litigation are
significant and, in certain cases in Brazil, Canada, and Nigeria, range into the billions of U.S. dollars. We anticipate that new cases will continue to be filed.
The FCTC encourages litigation against tobacco product manufacturers. It is possible that our consolidated results of operations, cash flows or financial
position could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation. See
Note 8. Contingencies to our condensed consolidated financial statements for a discussion of pending litigation and "Business Environment—Reduced-
Risk Products (RRPs)—Legal Challenges to RRPs."
From time to time, we are subject to governmental investigations on a range of matters.
Investigations include allegations of contraband shipments of cigarettes, allegations of unlawful pricing activities within certain markets, allegations of
underpayment of income taxes, customs duties and/or excise taxes, allegations of false and misleading usage of descriptors, allegations of unlawful
advertising, and allegations of unlawful labor practices. We cannot predict the outcome of those investigations or whether additional investigations may be
commenced, and it is possible that our business could be materially affected by an unfavorable outcome of pending or future investigations. See Note 8.
Contingencies—Other Litigation and “Management's Discussion and Analysis of Financial Condition and Results of Operations—Operating Results by
Business Segment—Business Environment—Governmental Investigations” for a description of certain governmental investigations to which we are
subject.
We may be unable to adequately protect our intellectual property rights, and disputes relating to intellectual property rights could harm our business.
Our intellectual property rights are valuable assets, and their protection is important to our business. If the steps we take to protect our intellectual property
rights globally, including through a combination of trademark, design, patent and other intellectual property rights, are inadequate, or if others infringe or
misappropriate our intellectual property rights, notwithstanding legal protection, our business could be adversely impacted. Intellectual property rights of
third parties may limit our ability to commercialize our products or improve product quality in one or more markets. Competitors or other third parties may
claim that we infringe their intellectual property rights. Any such claims, regardless of merit, could divert management’s attention, be costly, disruptive,
time-consuming and unpredictable and expose us to litigation costs and damages, and impede our ability to manufacture, commercialize and improve our
products. If, as a result, we are unable to manufacture or sell our RRPs or improve their quality in one or more markets, our ability to convert adult smokers
to our RRPs in such markets would be adversely affected. See Note 8. Contingencies— Other Litigation to our condensed consolidated financial statements
for a description of certain intellectual property proceedings.
94
-- 95 of 111 --
Table of Contents
Risks Related to our Competitive Environment
We face intense competition, and our failure to compete effectively could have a material adverse effect on our profitability and results of operations.
We are subject to highly competitive conditions in all aspects of our business. We compete primarily on the basis of product quality, brand recognition,
brand loyalty, taste, R&D, innovation, packaging, customer service, marketing, advertising and retail price and, increasingly, adult smoker willingness to
convert to our RRPs. The competitive environment and our competitive position can be significantly influenced by weak economic conditions, erosion of
consumer confidence, competitors' introduction of lower-price products or innovative products, higher tobacco product taxes, higher absolute prices and
larger gaps between retail price categories, and product regulation that diminishes the ability to differentiate tobacco products and restricts adult consumer
access to truthful and non-misleading information about our RRPs. Competitors include three large international tobacco companies, new market entrants,
particularly with respect to innovative products, several regional and local tobacco companies and, in some instances, state-owned tobacco enterprises,
principally in Algeria, Egypt, the PRC, Taiwan, Thailand and Vietnam. Industry consolidation and privatizations of state-owned enterprises have led to an
overall increase in competitive pressures. Some competitors have different profit, volume and regulatory objectives, and some international competitors are
susceptible to changes in different currency exchange rates. Certain new market entrants may alienate consumers from innovative products through
inappropriate marketing campaigns, messaging and inferior product satisfaction, while not relying on scientific substantiation based on appropriate R&D
protocols and standards. The growing use of digital media could increase the speed and extent of the dissemination of inaccurate and misleading
information about our RRPs.
We may be unable to anticipate changes in adult consumer preferences.
Our business is subject to changes in adult consumer preferences, which may be influenced by local economic conditions.
To be successful, we must:
• promote brand equity successfully;
• anticipate and respond to new adult consumer trends;
• develop new products and markets and broaden brand portfolios;
• improve productivity;
• convince adult smokers to convert to our RRPs;
• ensure effective adult consumer engagement, including communication about product characteristics and usage of RRPs;
• provide excellent customer care;
• ensure adequate production capacity to meet demand for our products; and
• be able to protect or enhance margins through price increases.
In periods of economic uncertainty, adult consumers may tend to purchase lower-price brands, and the volume of our premium-price and mid-price brands
and our profitability could be materially adversely impacted as a result. Such down-trading trends may be reinforced by regulation that limits branding,
communication and product differentiation.
Our ability to grow profitability may be limited by our inability to introduce new products, enter new markets or improve our margins through higher
pricing and improvements in our brand and geographic mix.
Our profit growth may be adversely impacted if we are unable to introduce new products or enter new markets successfully, to raise prices or to improve
the proportion of our sales of higher margin products and in higher margin geographies.
We may be unable to expand our brand portfolio through successful acquisitions or the development of strategic business relationships, and the intended
benefits from our investments may not materialize.
One element of our growth strategy is to expand our brand portfolio and market positions through selective acquisitions and the development of strategic
business relationships. Acquisition and strategic business development opportunities are limited and present risks of failing to achieve efficient and
effective integration, strategic objectives and/or anticipated revenue improvements and cost savings. There is no assurance that we will be able to acquire
attractive businesses or enter into strategic business relationships on favorable terms ahead of our competitors, or that such acquisitions or strategic
business development relationships will be accretive to earnings or improve our competitive position. In addition, we may not have a controlling
95
-- 96 of 111 --
Table of Contents
position in certain strategic investments or relationships, which could impact the extent to which the intended financial growth and other benefits from
these investments or relationships may ultimately materialize.
Our ability to achieve our strategic goals may be impaired if we fail to attract, motivate and retain the best global talent and effectively align our
organizational design with the goals of our transformation.
To be successful, we must continue transforming our culture and ways of working, align our talent and organizational design with our increasingly complex
business needs, and innovate and transform to a consumer-centric business. We compete for talent, including in areas that are new to us, such as digital and
technical solutions, with companies in the consumer products, technology and other sectors that enjoy greater societal acceptance. As a result, we may be
unable to attract, motivate and retain the best global talent with the right degree of diversity, experience and skills to achieve our strategic goals.
Risks Related to the Impact of COVID-19 on our Business
Our business, results of operations, cash flows and financial position will be adversely impacted during the continuation of the COVID-19 pandemic.
The COVID-19 pandemic has created significant societal and economic disruption, and resulted in closures of stores, factories and offices, and restrictions
on manufacturing, distribution and travel, all of which have and will continue to adversely impact our business, results of operations, cash flows and
financial position while the pandemic continues. Our business continuity plans and other safeguards may not be effective to mitigate the impact of the
pandemic.
Currently, significant risks include our diminished ability to convert adult smokers to our RRPs, significant volume declines in our duty-free business and
certain other key markets, disruptions or delays in our manufacturing and supply chain, increased currency volatility, and delays in certain cost saving,
transformation and restructuring initiatives. Our business could also be adversely impacted if key personnel or a significant number of employees or
business partners become unavailable due to the COVID-19 outbreak. The significant adverse impact of COVID-19 on the economic or political conditions
in markets in which we operate could result in changes to the preferences of our adult consumers and lower demand for our products, particularly for our
mid-price or premium-price brands. Continuation of the pandemic could disrupt our access to the credit markets or increase our borrowing costs.
Governments may temporarily be unable to focus on the development of science-based regulatory frameworks for the development and commercialization
of RRPs or on the enforcement or implementation of regulations that are significant to our business. In addition, messaging about the potential negative
impacts of the use of our products on COVID-19 risks may lead to increasingly restrictive regulatory measures on the sale and use of our products,
negatively impact demand for our products and the willingness of adult consumers to switch to our RRPs, and adversely impact our efforts to advocate for
the development of science-based regulatory frameworks for the development and commercialization of RRPs.
The impact of these risks also depends on factors beyond our knowledge or control, including the duration and severity of the COVID-19 pandemic in
general and specifically in the jurisdictions in which we operate, its recurrence in our key markets, actions taken to contain its spread and to mitigate its
public health effects, and the ultimate economic consequences thereof.
Risks Related to Sourcing of Materials, Products and Services
Use of third-party resources may negatively impact quality of our products and services, and we may be required to replace third-party contract
manufacturers or service providers with our own resources.
We increasingly rely on third-party resources to manufacture some of our products and product parts (particularly, the electronic devices and accessories)
and to provide services, including to support our finance and information technology processes. While many of these arrangements improve efficiencies
and decrease our operating costs, they also diminish our direct control. Such diminished control may have an adverse effect on the quality of products or
services, our supply chain, and the speed and flexibility in our response to changing market conditions and adult consumer preferences, all of which may
place us at a competitive disadvantage. In addition, we may be unable to renew these agreements on satisfactory terms for numerous reasons, including
government regulations, and our costs may increase significantly if we must replace such third parties with our own resources.
96
-- 97 of 111 --
Table of Contents
Government mandated prices, production control programs, shifts in crops driven by economic conditions and the impact of climate change may increase
the cost or reduce the quality of the tobacco and other agricultural products used to manufacture our products.
As with other agricultural commodities, the price of tobacco leaf and cloves can be influenced by imbalances in supply and demand and the impacts of
natural disasters and pandemics such as COVID-19. Furthermore, crop quality may be influenced by variations in weather patterns, including those caused
by climate change. Tobacco production in certain countries is subject to a variety of controls, including government mandated prices and production control
programs. Changes in the patterns of demand for agricultural products could cause farmers to produce less tobacco or cloves. Any significant change in
tobacco leaf and clove prices, quality and quantity could affect our profitability and our business.
Risks Related to the Success of our Reduced-Risk Products
The financial and business performance of our reduced-risk products is less predictable than our cigarette business.
Our RRPs are novel products in a new category, and the pace at which adult smokers adopt them may vary, depending on the competitive, regulatory, fiscal
and cultural environment, and other factors in a specific market. There may be periods of accelerated growth and periods of slower growth for these
products, the timing and drivers of which may be more difficult for us to predict versus our mature cigarette business. The impact of this lower
predictability on our projected results for a specific period may be significant, particularly during the early stages of this new product category and during
the COVID-19 pandemic.
We may be unsuccessful in our attempts to introduce reduced-risk products, and regulators may not permit the commercialization of these products or the
communication of scientifically substantiated information and claims.
Our key strategic priorities are: to develop and commercialize products that present less risk of harm to adult smokers who switch to those products versus
continued smoking; and to convince current adult smokers who would otherwise continue to smoke to switch to those RRPs. For our efforts to be
successful, we must:
• develop RRPs that such adult smokers find acceptable alternatives to smoking;
• conduct rigorous scientific studies to substantiate that they reduce exposure to harmful and potentially harmful constituents in smoke and,
ultimately, that these products present, are likely to present, or have the potential to present less risk of harm to adult smokers who switch to
them versus continued smoking; and
• effectively advocate for the development of science-based regulatory frameworks for the development and commercialization of RRPs,
including communication of scientifically substantiated information to enable adult smokers to make better consumer choices.
We might not succeed in our efforts. If we do not succeed, but others do, or if heat-not-burn products are inequitably regulated compared to other RRP
categories without regard to the totality of the scientific evidence available for such products, we may be at a competitive disadvantage. In addition, actions
of some market entrants, such as the inappropriate marketing of e-vapor products to youth, as well as alleged health consequences associated with the use
of certain e-vapor products, may unfavorably impact public opinion and/or mischaracterize all e-vapor products or other RRPs to consumers, regulators
and policy makers without regard to the totality of scientific evidence for specific products. This may impede our efforts to advocate for the development
of science-based regulatory frameworks for the development and commercialization of RRPs. We cannot predict whether regulators will permit the sale
and/or marketing of RRPs with scientifically substantiated information and claims. Such restrictions could limit the success of our RRPs.
The WHO study group on tobacco product regulation ("TobReg") published their eighth report on the scientific basis of tobacco product regulation in May
2021. The report is based on a review of scientific evidence related to novel and emerging nicotine and tobacco products, such as electronic nicotine
delivery systems ("ENDS"), electronic non-nicotine delivery systems ("ENNDS") and heated tobacco products ("HTPs") on a number of scientific topics.
The report concludes by making a number of policy recommendations on HTPs and ENDS that, if implemented, could restrict both the availability of these
products, and the access to accurate information about them.
Our RRPs and commercial activities for these products are designed for, and directed toward, current adult smokers and users of nicotine-containing
products, and not for non-smokers or youth. If nonetheless there is a significant usage of our products or competitive products among youth or non-
smokers, even in situations over which we have no control, our credibility may suffer, and our efforts to advocate for the development of science-based
regulatory frameworks for the commercialization of RRPs may be significantly impacted.
97
-- 98 of 111 --
Table of Contents
Moreover, the FDA’s premarket tobacco product and modified risk tobacco product authorizations of a version of our Platform 1 product are subject to
strict marketing, reporting and other requirements. Although we have received these product authorizations from the FDA, there is no guarantee that the
product will remain authorized, particularly if there is a significant uptake in youth or non-smoker initiation.
We may be unsuccessful in our efforts to differentiate reduced-risk products and cigarettes with respect to taxation.
To date, we have been largely successful in demonstrating to regulators that our RRPs are not cigarettes due to the absence of combustion, and as such they
are generally taxed either as a separate category or as other tobacco products, which typically yields more favorable tax rates than cigarettes. If we cease to
be successful in these efforts, RRP unit margins may be adversely affected.
Risks Related to Illicit Trade
We lose revenues as a result of counterfeiting, contraband, cross-border purchases, "illicit whites," non-tax-paid volume produced by local manufacturers,
and counterfeiting of our Platform 1 device and heated tobacco units.
Large quantities of counterfeit cigarettes are sold in the international market. We believe that Marlboro is the most heavily counterfeited international
cigarette brand, although we cannot quantify the revenues we lose as a result of this activity. In addition, our revenues are reduced by contraband, legal
cross-border purchases, "illicit whites" and non-tax-paid volume produced by local manufacturers. Our revenues and consumer satisfaction with our
Platform 1 device and heated tobacco units may be adversely affected by counterfeit products that do not meet our product quality standards and scientific
validation procedures.
Risks Related to Cybersecurity and Data Governance
The failure of our information systems to function as intended or their penetration with the intent to corrupt them or our failure to adhere to strict data
governance and cybersecurity protocols and to comply with privacy laws and regulations could result in business disruption, loss of reputation, litigation
and regulatory action, and loss of revenue, assets or personal or other confidential data.
We use information systems to help manage business processes, collect and interpret data and communicate internally and externally with employees,
suppliers, consumers, customers and others. Some of these information systems are managed by third-party service providers. We are continuously
evolving our approach to business continuity planning and backups to provide appropriate business resilience, particularly in light of the increasing cyber
threat landscape. Nevertheless, failure of these systems to function as intended, or penetration of these systems by parties intent on extracting or corrupting
information or otherwise disrupting business processes, could place us at a competitive disadvantage, result in a loss of revenue, assets or personal or other
sensitive data, litigation and regulatory action, cause damage to our reputation and that of our brands and result in significant remediation and other costs.
Failure to protect personal data, respect the rights of data subjects, and adhere to strict data governance and cybersecurity protocols could subject us to
substantial fines and other legal challenges under regulations such as the EU General Data Protection Regulation. As we are increasingly relying on digital
platforms in our business, and as privacy laws in the jurisdictions in which we do business become more stringent, the magnitude of these risks is likely to
increase.
Risks Related to the Pending Acquisitions of Fertin Pharma and Vectura
The proposed acquisitions of Fertin Pharma and Vectura may not be completed on the anticipated terms and there are uncertainties and risks to
consummating these acquisitions.
As previously disclosed in this Form 10-Q, we are acquiring Fertin Pharma and Vectura (with the Fertin Pharma acquisition and the Vectura acquisition
being collectively referred to in these Risk Factors as the “Acquisitions”).
Our obligations to consummate these Acquisitions are subject to satisfaction or waiver, to the extent permitted under applicable law, of a number of
conditions. For example, each Acquisition is subject to antitrust and other regulatory approvals in certain jurisdictions. We cannot provide any assurance
that all required antitrust clearances and other regulatory approvals will be obtained, the cost, scope or impact of the actions that may be required to obtain
antitrust and other regulatory approvals, which could have the effect of delaying or preventing completion of the proposed Acquisitions, respectively. In
addition, the Vectura acquisition is subject to shareholder approval by the Vectura shareholders. There can be no assurance that the number of shareholders
required to vote in favor of our proposed offer will do so to enable us to effect the Vectura acquisition.
98
-- 99 of 111 --
Table of Contents
Failure to complete the Acquisitions could impact our future business and financial results.
If the proposed Acquisitions are not completed, we may experience negative reactions from our investors and the financial markets. We also may be subject
to litigation related to any failure to complete either of these proposed Acquisitions or to enforcement proceedings commenced against us to perform our
obligations under either acquisition agreement. If the respective Acquisitions are not completed, these risks may materialize, and may adversely affect our
business, financial results and financial condition, as well as the price of our common stock.
We may be unable to successfully integrate the businesses that we acquire and unable to realize the anticipated benefits from such Acquisitions.
If the Acquisitions are completed, the successful integration of the acquired businesses and their operations into those of our own, and our ability to realize
the benefits of the Acquisitions, are subject to a number of risks and uncertainties, many of which are outside of our control. The risks and uncertainties
relating to integrating the businesses acquired include, among other things: (i) the challenge of integrating complex organizations, systems, operating
procedures, compliance programs, technology, networks and other assets of the businesses that we acquire, and the costs related to such integration efforts;
(ii) the possibility that we are unable to gain access to differentiated proprietary technology and pharmaceutical development expertise as anticipated by
these Acquisitions, and thus fail to realize our desired entry into additional smoke-free and beyond nicotine platforms; and (iii) the challenge of integrating
the cultures and business practices of each of Fertin Pharma and Vectura to our culture and business practices, which if not managed correctly, could lead to
difficulties in retaining key management and other key employees. In addition, even if we are able to successfully integrate, the anticipated benefits of the
proposed Acquisitions may not be realized fully, or at all, or may take longer to realize than expected.
The businesses that we acquire in the Acquisitions may have liabilities that are not known to us.
The businesses that we acquire in the Acquisitions may have liabilities that we were unable to identify, or were unable to discover, in the course of
performing our due diligence investigations thereof. We cannot assure you that the indemnification available to us under the respective acquisition
agreements that we have negotiated or will negotiate, as applicable, will be sufficient in amount, scope or duration to fully offset the possible liabilities
associated with the respective business or property that we will assume upon consummation of each acquisition. Any such liabilities, individually or in the
aggregate, could have a material adverse effect on our business, financial condition and results of operations.
Acquisition accounting adjustments related to the Acquisitions could adversely affect our financial results.
We will account for the completion of the Acquisitions using the acquisition method of accounting. Differences between preliminary estimates and the final
acquisition accounting may occur, and these differences could have a material impact on the consolidated financial statements and our future results of
operations and financial position in combination with the businesses acquired. Furthermore, given the nature of the assets being acquired in the
Acquisitions, we may not be able to avoid future impairments of those assets, which may also have a material impact on our future results of operation and
financial position.
While the Acquisitions are pending, PMI, Fertin Pharma and Vectura will be subject to business uncertainties that could adversely affect our respective
businesses, and adversely affect the financial results of our combined businesses after the consummation of the Acquisitions.
Our success following these Acquisitions will depend in part upon our ability, and the ability of Fertin Pharma and Vectura, respectively, to maintain
respective business relationships. Uncertainty about the effect of the Fertin Pharma Acquisition and the Vectura acquisition on customers, suppliers,
employees and other constituencies of each of Fertin Pharma and Vectura, may have a material adverse effect on us and/or the businesses that we will
acquire with the proposed Acquisitions. Customers, suppliers and others who do business with Fertin Pharma or Vectura may delay or defer business
decisions, decide to terminate, modify or renegotiate their relationships, or take other actions as a result of our proposed acquisitions of Fertin Pharma and
Vectura, respectively, which could negatively affect the revenues, earnings and cash flows of our company or the businesses we acquire upon the respective
consummation of the Acquisitions. If we are unable to maintain these business and operational relationships after the consummation of each Acquisition,
our financial position, results of operations or cash flows upon combining with these companies could be adversely affected.
99
-- 100 of 111 --
Table of Contents
Item 4. Controls and Procedures.
PMI carried out an evaluation, with the participation of PMI’s management, including PMI’s Chief Executive Officer and Chief Financial Officer, of the
effectiveness of PMI’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of the
end of the period covered by this report. Based upon that evaluation, PMI’s Chief Executive Officer and Chief Financial Officer concluded that PMI’s
disclosure controls and procedures are effective. There have been no changes in PMI’s internal control over financial reporting during the most recent fiscal
quarter that have materially affected, or are reasonably likely to materially affect, PMI’s internal control over financial reporting.
100
-- 101 of 111 --
Table of Contents
Part II - OTHER INFORMATION
Item 1. Legal Proceedings.
See Note 8. Contingencies of the Notes to the Condensed Consolidated Financial Statements included in Part I – Item 1 of this report for a discussion of
legal proceedings pending against Philip Morris International Inc. and its subsidiaries.
Item 1A. Risk Factors.
Information regarding Risk Factors appears in “MD&A – Cautionary Factors That May Affect Future Results,” in Part I – Item 2 of this Form 10-Q and in
Part I – Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2020.
101
-- 102 of 111 --
Table of Contents
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Our share repurchase activity for each of the three months in the quarter ended June 30, 2021 was as follows:
Period
Total Number
of Shares
Repurchased
Average
Price Paid
Per Share
Total Number of
Shares Purchased as
Part of Publicly
Announced Plans or
Programs
Approximate Dollar
Value of Shares that
May Yet be Purchased
Under the Plans or
Programs
April 1, 2021 –
April 30, 2021 (1) — $ — — $ —
May 1, 2021 –
May 31, 2021 (1) — $ — — $ —
June 1, 2021 –
June 30, 2021 (1) — $ — — $ —
Pursuant to Publicly
Announced Plans
or Programs — $ —
April 1, 2021 –
April 30, 2021 (2) 6,144 $ 88.88
May 1, 2021 –
May 31, 2021 (2) 814 $ 94.97
June 1, 2021 –
June 30, 2021 (2) 3,838 $ 97.06
For the Quarter Ended June
30, 2021 10,796 $ 92.24
(1) During this reporting period, we did not repurchase any shares under a share repurchase program. On June 11, 2021, our Board of Directors
authorized a new share repurchase program of up to $7 billion, with target spending of $5 billion to $7 billion over a three-year period that will
commence in the third quarter of 2021.
(2) Shares repurchased represent shares tendered to us by employees who vested in restricted and performance share unit awards and used shares to
pay all, or a portion of, the related taxes.
102
-- 103 of 111 --
Table of Contents
Item 6. Exhibits.
2.1 Share Sale and Purchase Agreement by and among Claudio Topco B.V., Bagger-Sorenson & Co. A/S and PMI Global Services, Inc.,
dated June 30, 2021 (incorporated by reference to Exhibit 2.1 the Current Report on Form 8-K filed July 7, 2021).
10.1 Supplemental letter to the Employment Agreement with André Calantzopoulos, effective May 5, 2021.
10.2 Supplemental letter to the Employment Agreement with Jacek Olczak, effective May 5, 2021.
31.1 Certification of the Registrant's Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934,
as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification of the Registrant's Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934,
as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 Certification of the Registrant's Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
32.2 Certification of the Registrant's Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded
within the Inline XBRL document.
101.SCH XBRL Taxonomy Extension Schema.
101.CAL XBRL Taxonomy Extension Calculation Linkbase.
101.DEF XBRL Taxonomy Extension Definition Linkbase.
101.LAB XBRL Taxonomy Extension Label Linkbase.
101.PRE XBRL Taxonomy Extension Presentation Linkbase.
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
103
-- 104 of 111 --
Table of Contents
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
PHILIP MORRIS INTERNATIONAL INC.
/s/ EMMANUEL BABEAU
Emmanuel Babeau
Chief Financial Officer
July 27, 2021
104
-- 105 of 111 --
Exhibit 10.1
PERSONAL AND CONFIDENTIAL
HAND DELIVERY
To: André Calantzopoulos Lausanne, April 28, 2021
Dear André,
We are pleased to confirm your appointment, effective May 5, 2021, to the position of Executive Chairman.
Your gross base salary will be: CHF 1,000,000.-- annually CHF 76,923.08 monthly
You will be removed from the Company’s salary grade structure.
You will no longer be eligible to participate in the Incentive Compensation Award Program.
You will continue to be eligible to participate in the Equity Award Program, which is administered at the sole discretion of the Compensation and Leadership
Development Committee of the Board of Directors of Philip Morris International Inc. pursuant and subject to the terms of the 2017 Performance Incentive
Plan (or any similar plan adopted from time to time).
Your annual Equity Award target will be as follows:
Target %
Equity Award 300% of annual base salary (40% in the form of Restricted Stock Units and 60% in the form of
Performance Share Units)
It is agreed and understood that this letter will for all purposes be regarded as a continuation of your employment with Philip Morris Products S.A.
All other conditions relating to your employment with Philip Morris Products S.A. remain as stated in your employment contract and, if applicable, in any
subsequent amendments.
We would like to take this opportunity to wish you continued success and satisfaction.
Yours sincerely,
PHILIP MORRIS PRODUCTS S.A.
/s/ CHARLES BENDOTTI /s/ CONSTANTIN ROMANOV
Charles Bendotti Constantin Romanov
Global Head of People & Culture Global Head of Total Rewards
Read and approved: /s/ ANDRÉ CALANTZOPOULOS Date: ______________
(André Calantzopoulos)
The Equity Award Program is discretionary and does not obligate the Company to make an award nor entitles employees to receive an award. Eligibility to
participate in the Program does not guarantee receipt of an award and receiving an annual award does not guarantee receipt of an award in the future. Any
awards that are made may be higher or lower than the target mentioned above. Targets may be amended at the discretion of the Compensation and
Leadership Development Committee of the Board of Directors at any time without prior notice.
(1)
(1)
Philip Morris Products S.A., Avenue de Rhodanie 50, 1007 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
-- 106 of 111 --
Exhibit 10.2
PERSONAL AND CONFIDENTIAL
HAND DELIVERY
To: Jacek Olczak Lausanne, April 28, 2021
Dear Jacek,
We are pleased to confirm your promotion, effective May 5, 2021, to the position of Chief Executive Officer.
Your gross base salary will be: CHF 1,350,000.-- annually CHF 103,846.15 monthly
Your new grade will be 28.
You will continue to be eligible to participate in the Incentive Compensation (“IC”) and Equity Award Programs, which are administered at the sole discretion
of the Compensation and Leadership Development Committee of the Board of Directors of Philip Morris International Inc. pursuant and subject to the terms
of the 2017 Performance Incentive Plan (or any similar plan adopted from time to time).
Your annual IC and Equity Award targets that assume 100 individual performance ratings and a PMI company performance rating of 100 for the IC award will
be increased as follows:
Target %
Incentive Compensation Award to 200% of annual base salary
Equity Award to 600% of annual base salary (40% in the form of Restricted Stock Units and 60% in the form of
Performance Share Units)
It is agreed and understood that this letter will for all purposes be regarded as a continuation of your employment with Philip Morris Products S.A.
All other conditions relating to your employment with Philip Morris Products S.A. remain as stated in your employment contract and, if applicable, in any
subsequent amendments.
We would like to take this opportunity to wish you continued success and satisfaction.
Yours sincerely,
PHILIP MORRIS PRODUCTS S.A.
/s/ CHARLES BENDOTTI /s/ ANDRÉ CALANTZOPOULOS
Charles Bendotti André Calantzopoulos
Global Head of People & Culture Chief Executive Officer
Read and approved: /s/ JACEK OLCZAK Date: 5/5/2021
(Jacek Olczak)
The Incentive Compensation and Equity Award Programs are discretionary and do not obligate the Company to make an award nor entitle employees to
receive an award. Eligibility to participate in the Programs does not guarantee receipt of an award and receiving an annual award does not guarantee receipt
of an award in the future. Any awards that are made may be higher or lower than the targets mentioned above. Targets may be amended at the discretion of
the Compensation and Leadership Development Committee of the Board of Directors at any time without prior notice.
(1)
(1)
Philip Morris Products S.A., Avenue de Rhodanie 50, 1007 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
-- 107 of 111 --
Exhibit 31.1
Certifications
I, Jacek Olczak, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Philip Morris International Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
Date: July 27, 2021
/s/ JACEK OLCZAK
Jacek Olczak
Chief Executive Officer
-1-
-- 108 of 111 --
Exhibit 31.2
Certifications
I, Emmanuel Babeau, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Philip Morris International Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
Date: July 27, 2021
/s/ EMMANUEL BABEAU
Emmanuel Babeau
Chief Financial Officer
- 1 -
-- 109 of 111 --
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Philip Morris International Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2021 as filed with
the Securities and Exchange Commission on the date hereof (the “Report”), I, Jacek Olczak, Chief Executive Officer of the Company, certify, pursuant to
18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.
/s/ JACEK OLCZAK
Jacek Olczak
Chief Executive Officer
July 27, 2021
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature
that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Philip Morris International
Inc. and will be retained by Philip Morris International Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
-1-
-- 110 of 111 --
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Philip Morris International Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2021 as filed with
the Securities and Exchange Commission on the date hereof (the “Report”), I, Emmanuel Babeau, Chief Financial Officer of the Company, certify, pursuant
to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.
/s/ EMMANUEL BABEAU
Emmanuel Babeau
Chief Financial Officer
July 27, 2021
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature
that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Philip Morris International
Inc. and will be retained by Philip Morris International Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
-1-
-- 111 of 111 --